EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 86

Results Generated From:
Embase <1980 to 2025 Week 01>
Embase Weekly Updates (updates since 2024-12-27)

<1>
Accession Number
2032655344
Title
Effect of transcutaneous electro-stimulation in postoperative
rehabilitation pain treatment in thoracic surgery: a randomized clinical
trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 839. Date of
Publication: December 2024.
Author
Alamo-Arce D.D.; Lopez-Fernandez D.; Medina-Ramirez R.; Vilchez-Barrera
M.; Etopa-Bitata P.; del Pino Quintana-Montesdeoca M.; Baez-Suarez A.;
Freixinet J.L.
Institution
(Alamo-Arce, Lopez-Fernandez, Medina-Ramirez, Vilchez-Barrera,
Baez-Suarez) Physical Therapy, University of Las Palmas de Gran Canaria,
Las Palmas, Spain
(Etopa-Bitata, del Pino Quintana-Montesdeoca, Freixinet) University of Las
Palmas de Gran Canaria, Las Palmas, Spain
Publisher
BioMed Central Ltd
Abstract
Background: Chest pain is one of the most difficult problems to solve
after thoracic surgery. Its correct control is often quite difficult,
which can cause complications due to an ineffective cough and superficial
respiratory movements. <br/>Method(s): This study has been designed with
the purpose of studying the value of transcutaneous electrical stimulation
(TENS) in the postoperative pain rehabilitation of thoracotomy. A
prospective and randomized study has been developed. The patients (n =
109) have been treated after hospital discharge with physiotherapy for 3
weeks. Three groups have been established: experimental (n = 37), control
(n = 35), and placebo (n = 37), experimental and placebo including the
application of TENS during the physiotherapy protocol. Postoperative pain
(McGill test) and spirometry have been studied before and after treatment.
<br/>Result(s): The largest between-group discrepancy occurred between the
experimental and control groups, 16.77 points (p < 0.001). Spirometry has
shown an improvement in FVC (27.11%) and FEV1 (28.68%) (p < 0.001) in the
experimental group, which was statistically significant compared to the
other groups. <br/>Conclusion(s): The use of TENS, as an adjunctive
treatment to physiotherapy, leads to an improvement in pain control and
spirometry values in patients after thoracic surgery, without producing
side effects with the technique. These findings provide physiological
evidence for the use of TENS in post-pulmonary surgery and may form the
basis for the development of pain managed-based programs in clinics and
hospitals. Trial registration: NCT04964973 (ClinicalTrials.gov). First
registration: July 16, 2021. Protocol:
https://clinicaltrials.gov/study/NCT04964973.<br/>Copyright &#xa9; The
Author(s) 2024.

<2>
Accession Number
2031677261
Title
Multicentre, randomized, double-blind, prospective study on the effects of
ImmunoAdSorptiOn on cardiac function in patients with Dilated
CardioMyopathy (IASO-DCM): Rationale and design.
Source
European Journal of Heart Failure. 26(11) (pp 2464-2473), 2024. Date of
Publication: November 2024.
Author
Dorr M.; Bohm M.; Erdmann E.; Gross S.; Mahabadi A.-A.; Nauck M.;
Nickening G.; Schultheiss H.-P.; Staudt A.; Werdan K.; Waagstein F.;
Hjalmarson A.; Felix S.B.
Institution
(Dorr, Gros, Felix) Department of Internal Medicine B, University
Medicine, Greifswald, Germany
(Dorr, Gros, Nauck, Felix) DZHK (German Center for Cardiovascular
Research), Partner site Greifswald, Greifswald, Germany
(Bohm) Department of Internal Medicine III, Saarland University, Homburg,
Germany
(Erdmann) Department of Internal Medicine III, University of Cologne,
Cologne, Germany
(Mahabadi) Department of Cardiology and Vascular Medicine, West German
Heart and Vascular Center Essen, University Hospital Essen, Essen, Germany
(Nauck) Institute of Clinical Chemistry and Laboratory Medicine,
University Medicine, Greifswald, Germany
(Nickening) Department of Internal Medicine II - Pneumology/Cardiology,
University Hospital Bonn, Bonn, Germany
(Schultheiss) Institute of Cardiac Diagnostics and Therapy, IKDT GmbH,
Berlin, Germany
(Staudt) Helios-Kliniken Schwerin, Department of Cardiology and Angiology,
Schwerin, Germany
(Werdan) Department of Internal Medicine III - Cardiology, Angiology and
Internal Intensive Care Medicine, Mid-German Heart Center, University
Hospital Halle (Saale), Halle, Germany
(Waagstein, Hjalmarson) Wallenberg Laboratory, Sahlgrenska University
Hospital, Goteborg, Sweden
Publisher
John Wiley and Sons Ltd
Abstract
Aims: Pilot studies indicate that immunoadsorption with subsequent IgG
substitution (IA/IgG) induces beneficial effects in patients with dilated
cardiomyopathy (DCM) and heart failure. This placebo-controlled study
investigates whether IA/IgG treatment enhances left ventricular (LV)
systolic function as compared to a control group receiving
pseudo-treatment. <br/>Method(s): This multicentre, randomized,
double-blind, parallel-group trial aims to include 200 patients with heart
failure due to DCM (LV ejection fraction [LVEF] <40%) on optimized
guideline-directed heart failure medication. Participants are randomly
assigned in a 1:1 ratio to IA/IgG using protein-A columns, or to
pseudo-immunoadsorption followed by an intravenous infusion without IgG.
Follow-up visits take place by telephone after 1 and 3 months and at the
study centres after 6, 12 and 24 months. The primary efficacy endpoint is
the change in LVEF from baseline to 6 months determined by contrast
echocardiography, analysed at a core lab. In addition, LV end-diastolic
and end-systolic volumes will be analysed as secondary endpoints over the
entire study period to assess whether IA/IgG affects LV remodelling. As
main secondary outcome, a composite of all-cause death, cardiac
resuscitation, hospitalization for heart failure, and need for cardiac
surgery to improve myocardial pump function will be evaluated after 24
months. In addition, exploratory outcomes as well as safety endpoints
related to the treatment will be assessed throughout the whole study
period. <br/>Conclusion(s): IASO-DCM is a randomized study which will
provide comprehensive insights into the effects of immunoadsorption with
subsequent IgG substitution in patients with DCM.<br/>Copyright &#xa9;
2024 The Author(s). European Journal of Heart Failure published by John
Wiley & Sons Ltd on behalf of European Society of Cardiology.

<3>
Accession Number
2032665712
Title
Using artificial intelligence to predict post-operative outcomes in
congenital heart surgeries: a systematic review.
Source
BMC Cardiovascular Disorders. 24(1) (no pagination), 2024. Article Number:
718. Date of Publication: December 2024.
Author
Mohammadi I.; Rajai Firouzabadi S.; Hosseinpour M.; Akhlaghpasand M.;
Hajikarimloo B.; Zeraatian-Nejad S.; Sardari Nia P.
Institution
(Mohammadi, Rajai Firouzabadi, Hosseinpour, Akhlaghpasand, Hajikarimloo,
Zeraatian-Nejad) Cardiovascular Surgery Research and Development
Committee, Iran University of Medical Sciences (IUMS), PO box 14665-354,
Tehran, Iran, Islamic Republic of
(Rajai Firouzabadi) Student Research Committee, School of Medicine, Shahid
Beheshti University of Medical Sciences, Teheran, Iran, Islamic Republic
of
(Akhlaghpasand, Zeraatian-Nejad) Department of Surgery, Surgery Research
Center, School of Medicine, Rasool-E Akram Hospital, Iran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Sardari Nia) Department of Cardiothoracic Surgery, Maastricht University
Medical Centre, Maastricht, Netherlands
(Sardari Nia) Foundation Heart Team Academy, Maastricht, Netherlands
Publisher
BioMed Central Ltd
Abstract
Introduction: Congenital heart disease (CHD) represents the most common
group of congenital anomalies, constitutes a significant contributor to
the burden of non-communicable diseases, highlighting the critical need
for improved risk assessment tools. Artificial intelligence (AI) holds
promise in enhancing outcome predictions for congenital cardiac surgery.
This study aims to systematically review the utilization of AI in
predicting post-operative outcomes in this population. <br/>Method(s):
Following PRISMA guidelines, a comprehensive search of Pubmed, Scopus, and
Web of Science databases was conducted. Two independent reviewers screened
articles based on predefined criteria. Included studies focused on AI
models predicting various post-operative outcomes in congenital heart
surgery. <br/>Result(s): The review included 35 articles, primarily
published within the last four years, indicating growing interest in AI
applications. Models predominantly targeted mortality and survival (n =
16), prolonged length of hospital or ICU stay (n = 7), postoperative
complications (n = 6), prolonged mechanical ventilatory support time (n =
4), with additional focus on specific outcomes such as peri-ventricular
leucomalacia (n = 2) and malnutrition (n = 1). Performance metrics, such
as area under the curve (AUC), ranged from 0.52 to 0.997. Notably, these
AI models consistently outperformed traditional risk stratification
categories. For instance, in assessing the risk of morbidity and
mortality, the AI models demonstrated superior performance compared to
conventional methods. <br/>Conclusion(s): AI-driven prediction models show
significant promise in improving outcome predictions for congenital heart
surgery. They surpass traditional risk prediction tools not only in
immediate postoperative risks but also in long-term outcomes such as
1-year survival and malnutrition. Further studies with robust external
validation are necessary to assess the practical applicability of these
models in clinical settings. The protocol of this review was prospectively
registered on PROSPERO (CRD42024550942).<br/>Copyright &#xa9; The
Author(s) 2024.

<4>
Accession Number
2032665095
Title
Rationale and design of a large trial of perioperative ketamine for
prevention of chronic post-surgical pain.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 840. Date of
Publication: December 2024.
Author
Peyton P.J.; Braat S.; De Silva A.; Story D.; Evered L.; Myles P.S.; Chan
M.; Schug S.; Hogg M.; Holmes A.; Sidiropoulos S.; Leslie K.
Institution
(Peyton, Story, Evered, Hogg, Sidiropoulos, Leslie) Department of Critical
Care, Melbourne Medicine School, Faculty of Medicine, Dentistry and Health
Sciences, University of Melbourne, Melbourne, VIC, Australia
(Peyton, Story, Sidiropoulos) Department of Anaesthesia, Austin Health,
Studley Rd., Heidelberg, VIC 3084, Australia
(Hogg, Holmes, Leslie) Department of Anaesthesia & Pain Management, Royal
Melbourne Hospital, Parkville, VIC, Australia
(Braat, De Silva) Centre for Epidemiology and Biostatistics, Melbourne
School of Population and Global Health, University of Melbourne,
Melbourne, VIC, Australia
(Braat, De Silva) Methods & Implementation Support for Clinical and Health
(MISCH) research Hub, Faculty of Medicine, Dentistry and Health Sciences,
University of Melbourne, Melbourne, VIC, Australia
(Myles, Leslie) School of Translational Medicine, Faculty of Medicine,
Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia
(Chan) Department of Anaesthesia and Intensive Care, The Chinese
University of Hong Kong, Hong Kong
(Evered) Department of Anesthesiology, Weill Cornell Medicine, New York,
NY, United States
(Schug) Department of Anaesthesiology, University of Western Australia,
Perth, Australia
(Evered) Department of Anaesthesia, St Vincent's Hospital, Melbourne, VIC,
Australia
(Myles) Department of Anaesthesiology and Perioperative Medicine, Alfred
Health, Melbourne, VIC, Australia
Publisher
BioMed Central Ltd
Abstract
Background: Chronic post-surgical pain (CPSP) is recognised as one of the
most common and debilitating complications of major surgery. Progression
from acute to chronic pain after surgery involves sensitisation of central
nervous system pathways with the N-methyl-D-aspartate (NMDA) receptor
having a central role. Ketamine is a potent, non-selective NMDA antagonist
commonly used for management of acute postoperative pain. Inconsistent but
largely supportive evidence from small trials of a preventative effect of
perioperative ketamine on CPSP risk suggests that a confirmative large
trial is needed. <br/>Method(s): The ROCKet (Reduction Of Chronic
Post-surgical Pain with Ketamine) Trial is a multicentre, double-blind,
placebo-controlled, individually randomised superiority trial conducted in
36 hospitals across Australia, New Zealand, and Hong Kong. The trial aims
to recruit 4884 patients undergoing abdominal, thoracic, or major
orthopaedic surgery. Eligible participants are randomised equally to
perioperative intravenous ketamine or placebo for up to 72 h. Incidence of
pain in the area of the index surgery is measured by structured telephone
interview at 3 months (primary trial endpoint) and 12 months. Pain
severity, nature, and associated psychological and quality of life indices
are measured using the modified Brief Pain Inventory short form,
Neuropathic Pain Questionnaire, Kessler K-10 Psychological Distress Scale,
Pain Catastrophising Scale, EQ-5D-3L, and measures of healthcare
utilisation and costs. The trial is being conducted by the Department of
Critical Care, University of Melbourne, and the Australian and New Zealand
College of Anaesthetists Clinical Trials Network. The trial is funded by
the Australian National Health and Medical Research Council.
<br/>Discussion(s): The ROCKet trial will clarify the effectiveness of
ketamine in primary prevention of CPSP. In addition, it will provide
high-quality, prospective data on the epidemiology of CPSP which will
better inform further research into prevention and management of CPSP.
Trial registration: Australian New Zealand Clinical Trials Registry
(ACTRN12617001619336) on the date of 12/11/2017.<br/>Copyright &#xa9; The
Author(s) 2024.

<5>
Accession Number
2035741529
Title
Skin cancer after heart transplantation: a systematic review.
Source
Anais Brasileiros de Dermatologia. 100(1) (pp 63-86), 2025. Date of
Publication: 01 Jan 2025.
Author
Aguzzoli N.H.G.; Bueno A.L.; Halezeroglu Y.; Bonamigo R.R.
Institution
(Aguzzoli, Bueno, Bonamigo) Dermatology Department, Universidade Federal
de Ciencias da Saude de Porto Alegre, RS, Porto Alegre, Brazil
(Halezeroglu) Medical School Department, University of California, San
Francisco, CA, United States
(Halezeroglu) Medical School Department, University of California Berkeley
School of Public Health and University of California San Francisco School
of Medicine, Berkely, CA, United States
(Bonamigo) Dermatology Department, Universidade Federal do Rio Grande do
Sul, RS, Porto Alegre, Brazil
Publisher
Elsevier Espana S.L.U
Abstract
Background: Cancer is an important cause of morbidity and mortality after
solid organ transplants. Skin cancer is the most prevalent non-lymphoid
malignancy occurring during heart transplantation follow-up. Due to the
complexity of immunosuppressive therapy and the high prevalence and
incidence of skin cancer in this population, dermatologists play an
important role in the short and long-term follow-up of heart transplant
recipients. <br/>Objective(s): The goal of this study is to present data
from a systematic literature review focusing on the occurrence of skin
cancer in patients who have undergone heart transplantation.
<br/>Method(s): The authors conducted a systematic review of the
literature in the EMBASE and PubMed databases from August to September
2021 to investigate the incidence of skin cancer in heart transplant
patients. The authors selected retrospective and prospective cohort
studies presenting data on the frequency of skin cancer in patients
following heart transplantation. Exclusion criteria included articles that
did not stratify the organ transplant type and studies that did not
evaluate the frequency of skin cancer in the specific population.
<br/>Result(s): Based on the search strategy, the authors found 2589
studies, out of which 37 were eligible for inclusion in this study.
Provided data are from 20 different countries, over the period 1974 to
2015. Incidence of non-melanoma skin cancer (NMSC) ranges from 0.97% to
52.8%. The incidence of squamous cell carcinoma (SCC) ranges from 1.19% to
89% and the incidence of basal cell carcinoma (BCC) ranges from 2% to 63%.
Malignant Melanoma (MM) incidence ranges from 0.94% to 4.6% Study
limitations: The analysis involved an exclusive focus on heart transplant
patients, and the statistical analysis of the sample may have been
hampered. The significant heterogeneity among the studies emerged as a
challenge during the analysis of the results. Furthermore, the study is
limited by variations in follow-up periods among the included studies.
<br/>Conclusion(s): Although gathering methodologically heterogeneous
data, this systematic review was able to show the epidemiological
importance of skin cancer in heart transplant patients. This study
reinforces the important role dermatologists play in the short and
long-term follow-up of heart transplant patients.<br/>Copyright &#xa9;
2024

<6>
Accession Number
2035498393
Title
Biomarkers of PUFA and cardiovascular risk factors and events in healthy
Asian populations: a systematic review.
Source
British Journal of Nutrition. 132(11) (pp 1474-1489), 2024. Date of
Publication: 14 Dec 2024.
Author
Lee Y.Q.; Tan K.H.; Chong M.F.-F.
Institution
(Lee, Tan, Chong) Saw Swee Hock School of Public Health, National
University of Singapore, Singapore
(Chong) Institute for Human Development and Potential, Agency for Science,
Technology, and Research, Singapore
Publisher
Cambridge University Press
Abstract
The associations between circulating PUFA and cardiovascular risk factors
and events in healthy Asian populations have been less examined robustly
compared with Western populations. This systematic review aimed to
summarise current evidence on the associations between n-3 and n-6 PUFA
biomarkers and cardiovascular risk factors and events in healthy Asian
populations. Four databases were searched for observational studies from
2010 until 2024. Twenty-three studies were eligible, which covered six
Asian countries and included events (n 7), traditional risk factors such
as blood pressure and lipids (n 4), physical signs such as arterial
stiffness (n 4), non-traditional lipid markers (n 1), markers of
inflammation (n 4), markers of thrombosis (n 2) and non-invasive
imaging-based markers (n 5). Biological sample types included plasma (n
6), serum (n 14) and erythrocyte (n 3). Higher circulating total n-3 PUFA
appeared to be associated with lower hypertension risk and specifically
EPA and DHA to be associated with lower myocardial infarction risk,
reduction in TAG and inflammation. Higher circulating linoleic acid was
associated with improved lipid profiles and lower inflammation. Limited
evidence led to inconclusive associations between circulating n-6 PUFA
biomarkers and CVD events and blood pressure. No consistent associations
with arterial stiffness, obesity, thrombosis and imaging-based biomarkers
were observed for circulating PUFA biomarkers in Asian populations.
Limited studies exist for each outcome; hence, results should be
interpreted with caution. More high-quality and prospective studies in
Asian populations are warranted. Several recommendations such as sample
size justification and reporting of non-respondents rate are proposed for
future studies.<br/>Copyright &#xa9; The Author(s), 2024. Published by
Cambridge.

<7>
Accession Number
2032040496
Title
Drug-coated balloons in high-risk patients and diabetes mellitus: A
meta-analysis of 10 studies.
Source
Catheterization and Cardiovascular Interventions. 104(7) (pp 1423-1433),
2024. Date of Publication: December 2024.
Author
Verdoia M.; Nardin M.; Rognoni A.; Cortese B.
Institution
(Verdoia, Rognoni) Division of Cardiology, ASL, Biella, Italy
(Nardin) Department of Internal Medicine, Spedali Civili, Brescia, Italy
(Cortese) Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy
(Cortese) DCB Academy, Milano, Italy
Publisher
John Wiley and Sons Inc
Abstract
Background: Despite the improvements in drug eluting stents (DES)
technology, suboptimal results have been observed in certain higher-risk
subsets of patients, as in diabetes mellitus (DM). Drug-coated balloons
(DCB) could represent an alternative to DES in complex populations and
anatomies, as in DM. <br/>Aim(s): The present meta-analysis aimed at
assessing the role of DCBs in patients with diabetes mellitus.
<br/>Method(s): Studies comparing DCB versus percutaneous coronary
revascularization (PCI) with/without DES for PCI in high-risk populations
(>30% DM) were included. The primary efficacy endpoint was overall
mortality, secondary endpoints were myocardial infarction, target lesion
revascularization (TLR), and major adverse cardiovascular events (MACE).
<br/>Result(s): We included 10 studies, comprising 2026 patients. Among
them, 1002 patients (49.5%) were treated with DCB and 1024 with DES
implantation. Among the included studies, 6 only enrolled diabetic
patients and 2 had a prevalence of diabetes of 50%. At a mean follow-up of
15.3 months, mortality rate was 3.8% (82 patients), significantly lower
with DCB (3.2% vs. 4.9% with DES; odds ratio [OR] [95% confidence interval
{CI}] = 0.61 [0.38, 0.97], p = 0.04 p<inf>het</inf> = 0.34. A similar
reduction in favor of DCB was observed for MACE (13.6% vs. 17.6%; OR [95%
CI] = 0.79 [0.61, 1.04], p = 0.09, p<inf>het</inf> = 0.25), while TLR was
significantly reduced only in the diabetic-restricted sub-analysis.
<br/>Conclusion(s): In the present meta-analysis, we showed a significant
survival benefit and an absolute reduction in MACE and TLR with a
DCB-based strategy as compared to DES in high-risk patients, mostly with
DM. Future large-scale randomized trials, dedicated to this population,
are deserved to confirm our findings. What is Known: Complex coronary
anatomies and diabetes mellitus (DM) represent the pitfall of drug eluting
stents (DES), mainly due to inflammatory and thrombotic complications,
which should be reduced with drug-coated balloons (DCB). What is New: We
confirmed a significant advantage of DCB versus DES in the treatment of de
novo lesions in high-risk patients and mainly in DM, reducing overall
mortality, MACE and target lesion revascularization.<br/>Copyright &#xa9;
2024 Wiley Periodicals LLC.

<8>
Accession Number
2032709185
Title
Effect of individualized versus conventional perioperative blood pressure
management on postoperative major complications in high-risk patients
undergoing noncardiac surgery: study protocol for the SPROUT-4 multicenter
randomized controlled trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 850. Date of
Publication: December 2024.
Author
Chung J.; Koo C.-H.; Park J.; Kim H.-B.; Bae J.; Ju J.-W.; Lee S.; Oh
A.R.; Kim H.S.; Park S.J.; Jeon Y.; Nam K.
Institution
(Chung, Ju, Jeon, Nam) Department of Anesthesiology and Pain Medicine,
Seoul National University Hospital, Seoul National University College of
Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul 03080, South Korea
(Koo, Lee) Department of Anesthesiology and Pain Medicine, Seoul National
University Bundang Hospital, Gyeonggi Province, Seongnam, South Korea
(Park, Oh) Department of Anesthesiology and Pain Medicine, Samsung Medical
Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
(Kim, Kim) Department of Anesthesiology and Pain Medicine, Korea
University Guro Hospital, Korea University College of Medicine, Seoul,
South Korea
(Bae, Park) Department of Anesthesiology and Pain Medicine, Ajou
University Medical Center, Ajou University of College of Medicine,
Gyeonggi Province, Suwon, South Korea
Publisher
BioMed Central Ltd
Abstract
Background: Intraoperative hypotension is very common during surgery and
is linked to major organ dysfunction and mortality. Current perioperative
blood pressure management is largely based on universal blood pressure
thresholds ranging from a mean arterial pressure of 60-70 mmHg. However,
the effectiveness of this conventional management remains unproven in
prospective randomized trials. Therefore, we will conduct this study to
test if individualized perioperative blood pressure management decreases
the incidence of postoperative major adverse outcomes. <br/>Method(s):
This multicenter, randomized controlled superiority trial will enroll 1896
high-risk patients undergoing major noncardiac surgery from five tertiary
university hospitals in South Korea. In the control group, mean arterial
pressure will be maintained at >= 65 mmHg and systolic blood pressure >=
90 mmHg during surgery. In the intervention group, mean arterial pressure
and systolic blood pressure will be maintained at no less than 20% of
their baseline values. The baseline values are calculated as the average
of all values measured from the day before surgery until the morning of
surgery. These targets will be maintained until the patient is discharged
from the post-anesthesia care unit or, for those who are transferred to
the intensive care unit after surgery, until the end of the surgery. No
specific restrictions, except for these blood pressure targets, will be
applied to perioperative management. The primary composite outcome
consists of all-cause death, stroke, myocardial infarction, new or
worsening congestive heart failure, unplanned coronary revascularization,
and acute kidney injury within 7 days after noncardiac surgery or until
hospital discharge, whichever occurs first. <br/>Discussion(s): This study
will reveal if individualized perioperative blood pressure management
decreases the risk of major adverse outcomes in patients at high-risk
undergoing noncardiac surgery. Trial registration: ClinicalTrials.gov
NCT06225453. Registered on January 26, 2024.<br/>Copyright &#xa9; The
Author(s) 2024.

<9>
Accession Number
2036588969
Title
Effects of fluid therapy with ringer's vs. ringer lactate solution on
acid-base balance and serum electrolytes in patients undergoing coronary
artery bypass graft surgery.
Source
Journal of Cardiovascular and Thoracic Research. 16(4) (pp 258-263), 2024.
Date of Publication: 2024.
Author
Hadipourzadeh F.; Azarfarin R.; Ziyaeifard M.; Jamalian J.; Ghadimi M.;
Chaibakhsh Y.
Institution
(Hadipourzadeh, Azarfarin, Ziyaeifard, Jamalian, Ghadimi, Chaibakhsh)
Rajaie Cardiovascular Medical and Research institute, Iran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Tabriz University of Medical Sciences
Abstract
Introduction: Preventing acid-base and electrolyte disturbance is crucial
in coronary artery bypass graft surgery (CABG), since any of these
conditions can affect outcome. The type of crystalloid solution used
during and after the surgery can affect these disturbances.
<br/>Method(s): In this study, 90 patients who candidates for CABG surgery
were randomly allocated to either ringer's lactate (RL) or ringer's group.
In order to provide essential blood volume before and after the start of
CPB fluid administration with either ringer's or RL solution was started
during operation and continued for 18 hours after the patient was
transferred to ICU. ABG, serum electrolytes and Lactate level were
measured before and at the end of CPB, upon arrival to the ICU, and 6, 12
and 18 hours after ICU admission and compared between the two groups.
<br/>Result(s): Blood PH level was significantly different between the two
groups upon arrival to ICU, 6 and 18 hours after ICU admission (P< 0.05)
which was clinically closer to the normal range in the RL group. Serum
bicarbonate level showed a significantly difference between the two groups
(P< 0.05). There were no significantly differences between the two groups
in terms of lactate level, serum electrolytes, blood loss, intake and
output of fluids and blood products transfusion. <br/>Conclusion(s): In
this study, ringer's lactate solution creates a more favorable acid-base
balance without a significant increase in blood lactate level which is
attributed to the buffering effect of existing lactate, and can be used as
an appropriate alternative to ringer's solution during and after
CABG.<br/>Copyright &#xa9; 2024 The Author(s).

<10>
Accession Number
2032687865
Title
Identifying Paediatric Populations with Increased Risk for Oropharyngeal
Dysphagia in Acute and Critical Care Settings: A Scoping Review.
Source
Dysphagia. (no pagination), 2024. Date of Publication: 2024.
Author
Grunke C.; Marshall J.; Miles A.; Carrigg B.; Ward E.C.
Institution
(Grunke, Marshall, Ward) School of Health and Rehabilitation Sciences, The
University of Queensland, Brisbane, Australia
(Marshall) Queensland Children's Hospital, Children's Health Queensland
Hospital and Health Service, Brisbane, Australia
(Miles) Speech Science, School of Psychology, The University of Auckland,
Auckland, New Zealand
(Carrigg) The Royal Children's Hospital, Melbourne, Australia
(Ward) Centre for Functioning and Health Research (CFAHR), Metro South
Hospital and Health Service, Brisbane, Australia
Publisher
Springer
Abstract
Dysphagia is common in hospitalised children. Clarity regarding its
prevalence is required to direct service needs. This review reports
oropharyngeal dysphagia prevalence in children admitted to acute and/or
critical care, following acute illness, medical or surgical intervention.
It also explores patient characteristics significantly associated with
oropharyngeal dysphagia in these settings. Five electronic databases
(EMBASE, CINAHL, Cochrane, PubMed, Scopus) were searched. Studies
identified for inclusion involved children (0-16 years), in acute or
critical care settings, where prevalence data for new-onset or worsening
oropharyngeal dysphagia was reported. Peer reviewed journal articles,
including systematic reviews were included. Data was extracted and
synthesised using a purpose designed extraction tool. A total of 7,522
studies were screened and 67 studies met criteria. The most researched
populations included congenital heart disease surgeries, posterior fossa
tumour resections, stroke and post-extubation dysphagia. Populations with
the highest documented dysphagia prevalence were children after posterior
fossa tumour resection with a new tracheostomy, children using nasal
continuous positive airway pressure, and children following ischemic
stroke. Characteristics significantly associated with oropharyngeal
dysphagia were younger age, lower weight, longer intubation, upper/middle
airway dysfunction (e.g., vocal paresis), and presence of additional
comorbidities. This review presents synthesised prevalence data for
children in acute and critical care settings with new-onset or worsening
oropharyngeal dysphagia. It highlights the broad nature of oropharyngeal
dysphagia in hospitalised children and the need for more rigorous research
into characteristics associated with increased risk to better support
screening and early identification of oropharyngeal dysphagia in these
settings.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<11>
Accession Number
2036604226
Title
The effect of stand-alone and additional preoperative video education on
patients' knowledge of anaesthesia: A randomised controlled trial.
Source
European Journal of Anaesthesiology. (no pagination), 2024. Article
Number: 10.1097/EJA.0000000000002109. Date of Publication: 2024.
Author
Van Den Heuvel S.F.; Jonker P.; Hoeks S.E.; Ismail S.Y.; Stolker R.J.;
Korstanje J.-W.H.
Institution
(Van Den Heuvel, Jonker, Hoeks, Stolker, Korstanje) Department of
Anaesthesiology, Erasmus MC University, Medical Centre Rotterdam, CA,
Rotterdam, Netherlands
(Ismail) The Department of Psychiatry, Erasmus MC University, Medical
Centre Rotterdam, Rotterdam, Netherlands
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND Fully digital preoperative information could save valuable time
and resources. However, compared with face to face consultations,
equivalent levels of safety, patient satisfaction and participation need
to be maintained when using other methods to inform patients. This trial
compared knowledge retention between preoperative stand-alone video
education and face-to-face education by an anaesthesiologist. OBJECTIVES
To assess if video education, alone or combined with face-to-face
education, leads to better knowledge retention more than conventional
face-to-face education. DESIGN A randomised controlled trial with four
arms: Video, Anaesthesiologist, Video & Anaesthesiologist, and Reference
for baseline measurements and exploration of a test-enhanced learning
effect. SETTING A Dutch tertiary care centre from February 2022 to
February 2023. PATIENTS A total of 767 adult patients undergoing
preoperative consultation for elective non-cardiothoracic surgery, with
677 included in the complete case analysis. INTERVENTION(S) Stand-alone
preoperative video education and video education in combination with
face-to-face education in the preoperative outpatient clinic. MAIN OUTCOME
MEASURES Primary outcome, measured by the Rotterdam Anaesthesia Knowledge
Questionnaire, was knowledge retention on day 0. Secondary outcomes
included knowledge retention at 14 and 42 days, preoperative anxiety, and
the need for additional information using the Amsterdam Preoperative
Anxiety and Information Scale. Other outcomes were satisfaction,
self-assessed knowledge, and test-enhanced learning effect. RESULTS
Stand-alone video education led to higher Rotterdam Anaesthesia Knowledge
Questionnaire scores than face-to-face education on day 0: median [IQR],
87.5 [81.3 to 93.8] vs. 81.3 [68.8 to 87.5], P < 0.001. Combined education
in the "Video & Anaesthesiologist"group led to better knowledge retention
compared with both the "Anaesthesiologist"group and the Video group: 93.8
[87.5 to 93.8] vs. 81.3 [68.8 to 87.5], P < 0.001; 93.8 [87.5 to 93.8] vs.
87.5 [81.3 to 93.8], P = 0.01, respectively. No differences in the
patients' preoperative anxiety and satisfaction levels were found.
CONCLUSION Compared with face-to-face education by an anaesthesiologist,
stand-alone video and combined video education improve short-term
knowledge retention, without increasing patient anxiety. TRIAL
REGISTRATION ClinicalTrials.gov Identifier: NCT05188547
(https://clinicaltrials.gov/ct2/show/NCT05188547). <br/>Copyright &#xa9;
2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of
the European Society of Anaesthesiology.

<12>
Accession Number
646112784
Title
Evaluating the impact of Benson's relaxation technique on anxiety and
delirium among coronary artery bypass graft surgery patients.
Source
Journal of cardiothoracic surgery. 19(1) (pp 657), 2024. Date of
Publication: 19 Dec 2024.
Author
Golchoubi A.; Miri K.; Vagheei S.; Hajiabadi F.; Kahrom M.; Behnam Vashani
H.R.
Institution
(Golchoubi) Department of Medical- Surgical Nursing, School of Nursing and
Midwifery (MSC Student), Mashhad University of Medical Sciences, Mashhad,
Iran, Islamic Republic of
(Miri) Department of Nursing, School of Nursing and Midwifery, Torbat
Heydariyeh University of Medical Sciences, Iran, Islamic Republic of
(Vagheei, Hajiabadi) Nursing and Midwifery Care Research Center, Mashhad
University of Medical Sciences, Mashhad, Iran, Islamic Republic of
(Hajiabadi) Department of Medical Surgical Nursing, School of Nursing and
Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic
Republic of
(Kahrom) Department of Cardiovascular Surgery, Faculty of Medicine,
Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of
(Behnam Vashani) Nursing and Midwifery Care Research Centre, Mashhad
University of Medical Sciences, Mashhad, Iran, Islamic Republic of
Abstract
BACKGROUND: Anxiety and delirium are prevalent complications in cardiac
patients undergoing invasive procedures like coronary artery bypass
surgery, with untreated symptoms potentially leading to enduring physical
and psychological consequences. Benson's relaxation technique, a method of
attention focusing, has demonstrated efficacy in alleviating various
symptoms, although findings are conflicting. Thus, this study aimed to
assess the influence of Benson's relaxation on anxiety and delirium
severity in open-heart surgery candidates. <br/>METHOD(S): Conducted in
2022 at Qaem Hospital in Mashhad, this randomized controlled trial
involved 60 patients. The intervention group received Benson's relaxation
training pre-surgery and practiced it twice daily for 72 h post-admission.
Standard care was provided to controls. Anxiety and delirium were assessed
using standardized scales before and after the intervention.
<br/>RESULT(S): The demographic characteristics of both groups were
comparable with no significant differences. Benson's relaxation
significantly reduced delirium scores on the first and second days
post-surgery (P<0.001). However, the difference in delirium scores between
the groups was not significant on the third day (P=0.129). While the
intervention led to a significant reduction in anxiety within the
intervention group, no significant difference in anxiety reduction was
observed between the intervention and control groups (P=0.579).
<br/>CONCLUSION(S): Incorporating Benson's relaxation technique, which
showed significant effects in reducing early postoperative delirium, into
postoperative care plans for open-heart surgery patients warrants
consideration. However, given the lack of a significant effect on anxiety
reduction compared to routine care, further research is necessary to
evaluate its long-term effectiveness and broader impact on psychological
outcomes. TRIAL REGISTRATION: This study was registered in the Iranian
Registry of Clinical Trials (no. c IRCT20210903052365N1) on
2022-01-28.<br/>Copyright &#xa9; 2024. The Author(s).

<13>
Accession Number
646121324
Title
Transcatheter tricuspid valve intervention versus medical therapy for
symptomatic tricuspid regurgitation: a meta-analysis of reconstructed
time-to-event data.
Source
International journal of surgery (London, England). 110(10) (pp
6800-6809), 2024. Date of Publication: 01 Oct 2024.
Author
Fu G.; Zhu J.; Song W.; Bagaber G.; Wang C.; Chen J.; Wei L.
Institution
(Fu, Song, Wang, Chen, Wei) Department of Cardiovascular Surgery,
Zhongshan Hospital, Fudan University, Shanghai, China
(Zhu) Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital,
Fudan University, Shanghai, China
(Bagaber) Shanghai Medical College, Fudan University, Shanghai, China
(Wang, Chen, Wei) Department of Cardiovascular Surgery, Shanghai Geriatric
Medical Center, Shanghai, China
Abstract
BACKGROUND: Transcatheter tricuspid valve intervention (TTVI) has
demonstrated safety and efficacy in treating high-risk patients with
tricuspid regurgitation (TR). The authors aimed to perform a meta-analysis
based on reconstructed time-to-event data to compare the clinical benefit
of TTVI with medical therapy (MED). <br/>METHOD(S): A systematic
literature search was conducted in major databases, including PubMed,
Embase, and the Cochrane Library, until 20 October 2023. All studies
comparing the outcomes between TTVI and MED were included. The primary
outcome was all-cause mortality. The secondary outcomes included heart
failure (HF) hospitalization and the composite outcome of all-cause
mortality and HF hospitalization. <br/>RESULT(S): Five studies covering
3826 patients (1146 received TTVI and 2680 received MED) were identified.
At 1-year follow-up, TTVI significantly reduced the risk of all-cause
mortality compared with MED [hazard ratio (HR) 0.54, 95% CI: 0.39-0.74,
P=0.0001]. There was a trend in favor of TTVI in HF hospitalization,
although without significant difference (HR 0.70, 95% CI: 0.42-1.18,
P=0.18). TTVI was also associated with a decreased risk of composite
outcome (HR 0.57, 95% CI: 0.38-0.86, P=0.007). Reconstructed Kaplan-Meier
curves illustrated a 1-year overall survival rate of 83.1% in the TTVI
group and 68.8% in the MED group. The subgroup analysis of device types
yielded consistent results. <br/>CONCLUSION(S): Compared with MED, TTVI
was associated with greater 1-year benefits for patients with symptomatic
moderate or greater TR from the aspects of all-cause mortality and HF
hospitalization.<br/>Copyright &#xa9; 2024 The Author(s). Published by
Wolters Kluwer Health, Inc.

<14>
Accession Number
2036759845
Title
Routine stress testing in diabetic patients after coronary intervention: a
systematic review and meta-analysis.
Source
Current Problems in Cardiology. 50(3) (no pagination), 2025. Article
Number: 102972. Date of Publication: March 2025.
Author
de Oliveira J.P.; da Rocha F.R.; Huntermann R.; de Oliveira R.P.; Bacca
C.O.F.
Institution
(de Oliveira, da Rocha, Huntermann, de Oliveira, Bacca) Medical Sciences
Research Center, University Center for the Development of Alto Vale - Rio
do Sul -, Brazil
(Bacca) Regional Hospital of Alto Vale - HRAV, Rio do Sul, Santa Catarina,
Brazil
Publisher
Elsevier Inc.
Abstract
Background: Stress testing is a widely used non-invasive tool in patients
with angina, but its role in diabetic patients after coronary intervention
remains uncertain. This review evaluates its impact in this population.
Goals: We aimed to perform a systematic review and meta-analysis of
studies assessing death, MACE, ischemia and repeated revascularization in
diabetic patients post-coronary intervention. <br/>Method(s): We searched
PubMed, Embase, and Cochrane for RCTs and cohort studies on diabetic
patients post-revascularization reporting MI and cardiovascular death,
ischemia, repeat revascularization, and pooled hazard ratios for mortality
or MI. Statistical analysis used RStudio and RevMan, with heterogeneity
assessed via I2 statistics. <br/>Result(s): We included 14,461 patients
from 15 studies (14 observational cohorts, 1 RCT), all with diabetes and
prior revascularization. Follow-up ranged from 1 to 5.2 years, with a mean
age of 60.8 +/- 9.5 years, and 75 % male. MI and cardiovascular death
occurred in 11.24 % (95 % CI: 7.35-15.79 %; p < 0.01, Figure 2), ischemia
in 36.07 % (95 % CI: 30.26-42.08 %; p < 0.01, Figure 3), and repeated
revascularization in 15.65 % (95 % CI: 6.65-27.64 %; p < 0.01, Figure 4).
For mortality or MI, the pooled hazard ratio was 1.28 (95 % CI: 1.02-1.61,
Figure 5), suggesting a modest benefit of standard care over routine
stress testing. <br/>Conclusion(s): Routine stress testing in diabetic
patients after coronary intervention may not significantly impact
outcomes. Further controlled studies are needed to clarify its clinical
benefit.<br/>Copyright &#xa9; 2024

<15>
Accession Number
2035403478
Title
Ultrasound-Guided Continuous Rhomboid Intercostal and Sub-Serratus Plane
Block Comparison of Thoracoscopic Intercostal Nerve Block After
Thoracoscopic Surgery: A Prospective Randomized Controlled Study.
Source
Journal of Pain Research. 17 (pp 4471-4481), 2024. Date of Publication:
2024.
Author
Wang S.; Wang H.; Chen X.; Li M.; Xu D.
Institution
(Wang, Wang, Chen, Li, Xu) Department of Anesthesiology, Affiliated
Hospital of Chifeng University, Chifeng 024000, China
Publisher
Dove Medical Press Ltd
Abstract
Purpose: Thoracic surgery is among the most painful surgeries,
postoperative pain can lead to a poor prognosis. This study aimed to
explore the analgesic effect of ultrasound-guided continuous rhomboid
intercostal and sub-serratus (RISS) plane block Comparison of
thoracoscopic intercostal nerve block (ICNB) on postoperative pain
management and recovery in patients who underwent Video-Assisted Thoracic
Surgery (VATS) Lobectomy. <br/>Method(s): This prospective randomized
controlled study enrolled patients after VATS Lobectomy who received
ultrasound-guided continuous RISS plane block (RISS group) or ICNB
(Control group) for postoperative pain. The primary outcome was the visual
analogue scale (VAS) score. The secondary outcomes included non-invasive
blood pressure (NIBP), heart rate (HR), the time to ambulation after
surgery, the timing of drain removal, and the duration of postoperative
hospitalization. <br/>Result(s): A total of 98 participants were collected
(53.08 +/- 13.63; 43 (43.88%) males); each group included 49 patients. The
RISS group displayed significantly lower visual analogue scale (VAS)
scores during rest and when coughing at postoperative 12, 24, and 48h
compared to the Control group (P < 0.001). The total consumption of
sufentanil and remifentanil was smaller in the RISS group than in the
control group. The NIBP,HR in the RISS group were significantly lower than
in the Control group at immediately after skin incision (T1), upon
entering the thoracic cavity (T2), 5 min after entering the thoracic
cavity (T3) (P < 0.001). The patients in the RISS group were more likely
to exhibit a shorter time to the first postoperative ambulation compared
to the Control group (8.84 +/- 2.87,15.43 +/- 4.50, P < 0.001).
<br/>Conclusion(s): Continuous RISS may be a safe and effective strategy
for postoperative pain management after thoracoscopic
surgery.<br/>Copyright &#xa9; 2024 Wang et al.

<16>
Accession Number
2032796689
Title
Efficacy of preoperative prophylactic application of betamethasone on
postoperative nausea and vomiting in patients undergoing total knee
arthroplasty: a prospective randomized controlled trial.
Source
Frontiers in Medicine. 11 (no pagination), 2024. Article Number: 1487818.
Date of Publication: 2024.
Author
Sun X.; Dou Q.; Li B.; Bai G.; Qin K.; Ma J.; Yao F.; Huang Y.
Institution
(Sun, Li, Bai, Qin, Ma, Huang) Department of Knee Joint Surgery, Honghui
Hospital, Xi'an Jiaotong University, Shaanxi, Xi'an, China
(Sun, Dou, Bai, Qin) The First Clinical Medical College, Shaanxi
University of Chinese Medicine, Xianyang, China
(Yao) Department of Orthopedics, Baoji Central Hospital, Shaanxi, Baoji,
China
Publisher
Frontiers Media SA
Abstract
Background: The demand for total knee arthroplasty (TKA) is increasing,
yet postoperative nausea and vomiting (PONV) significantly hinder patient
recovery. Preoperative prophylactic administration of glucocorticoids can
alleviate PONV, with betamethasone showing promising results in breast and
cardiac surgeries. However, its efficacy in TKA patients remains unclear.
This study evaluates the efficacy and safety of preoperative betamethasone
for PONV in TKA patients through a prospective randomized controlled trial
(RCT). <br/>Material(s) and Method(s): In this trial, 124 patients were
randomly assigned to receive either 2 mL of normal saline (control group)
or 2 mL of betamethasone sodium phosphate (10.52 mg total dose;
experimental group) 10 min before anesthesia induction. Primary outcomes
included nausea severity, vomiting frequency, and antiemetic use, while
secondary outcomes were pain scores, knee range of motion, blood glucose,
IL-6, CRP, ESR, and adverse reactions. <br/>Result(s): Results showed the
experimental group had significantly lower nausea severity at 2, 4, 6, 12,
and 24 h post-surgery compared to controls. The average frequency of
vomiting in the experimental group (0.060 +/- 0.307) was lower than that
in the control group (0.390 +/- 0.662), with a statistical difference (P <
0.001). The postoperative use of metoclopramide in the experimental group
(0.480 +/- 2.163) was lower than that in the control group (4.520 +/-
6.447), and there was a statistical difference between the two groups (P <
0.001). CRP in the experimental group on the second day after surgery
(45.741 +/- 47.044) was lower than that in the control group (65.235 +/-
50.970), with a statistical difference (P = 0.014). IL-6 in the
experimental group was lower on the first (51.853 +/- 67.202) and second
postoperative days (25.143 +/- 31.912) than that in the control group on
the first (79.477 +/- 97.441) and second postoperative days (38.618 +/-
36.282), with statistical differences (P = 0.039, P = 0.006). There was no
significant difference in postoperative knee pain, knee range of motion,
blood glucose, ESR, and adverse reactions between the two groups.
<br/>Conclusion(s): Our prospective RCT demonstrates that preoperative
betamethasone is effective and safe for reducing PONV in TKA patients,
suggesting a new clinical approach for prophylactic treatment of PONV
post-TKA.<br/>Copyright &#xa9; 2024 Sun, Dou, Li, Bai, Qin, Ma, Yao and
Huang.

<17>
Accession Number
2032775895
Title
Contemporary Review of Minimally Invasive Mitral Valve Surgery: Current
Considerations and Innovations.
Source
Journal of Cardiovascular Development and Disease. 11(12) (no pagination),
2024. Article Number: 404. Date of Publication: December 2024.
Author
Alsheebani S.; Goubran D.; de Varennes B.; Chan V.
Institution
(Alsheebani, de Varennes) Department of Surgery, McGill University,
Montreal, QC H3A 0G4, Canada
(Goubran, Chan) Department of Surgery, University of Ottawa Heart
Institute, Ottawa, ON K1Y 4W7, Canada
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Minimally invasive mitral valve surgery (MIMVS) has become a
well-established alternative to traditional median sternotomy at
high-volume surgical centers. Advancements in surgical instruments have
led to further refinement of MIMVS. However, MIMVS remains limited to
select patients in select settings. In this review, we provide a brief
overview of the evolution of MIMVS, as well as a technical description of
the most relevant aspects of minimally invasive mitral valve
surgery.<br/>Copyright &#xa9; 2024 by the authors.

<18>
Accession Number
2032772704
Title
Benefits from Implementing Low- to High-Intensity Inspiratory Muscle
Training in Patients Undergoing Cardiac Surgery: A Systematic Review.
Source
Journal of Cardiovascular Development and Disease. 11(12) (no pagination),
2024. Article Number: 380. Date of Publication: December 2024.
Author
Evangelodimou A.; Patsaki I.; Andrikopoulos A.; Chatzivasiloglou F.;
Dimopoulos S.
Institution
(Evangelodimou, Patsaki) Laboratory of Advanced Physiotherapy,
Physiotherapy Department, School of Health & Care Sciences, University of
West Attica, Athens 12243, Greece
(Andrikopoulos, Dimopoulos) Clinical Ergospirometry, Exercise and
Rehabilitation Laboratory, 1st Critical Care Department, Evangelismos
Hospital, School of Medicine, National and Kapodistrian University of
Athens, Athens 10675, Greece
(Chatzivasiloglou) Intensive Care Unit, Bristol Royal Infirmary University
Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS2 8HW, United
Kingdom
(Dimopoulos) Cardiac Surgery ICU, Onassis Cardiac Surgery Center, Athens,
Kallithea 17674, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Cardiac surgery procedures are among the main treatments for people with
cardiovascular disease, with physiotherapy playing a vital part.
Respiratory complications are common and associated with prolonged
Intensive Care Unit (ICU) and hospital stay, as well as increased
mortality. Inspiratory muscle training has been found to be beneficial in
improving respiratory muscle function in critically ill patients and
patients with heart failure. The purpose of this review is to present the
results of implementing inspiratory muscle training (IMT) programs in
patients before and/or after cardiac surgery. The PubMed, Embase and
Science Direct databases were searched from January 2012 to August 2023.
In the present review, randomized controlled clinical trials (RCTs),
clinical trials and quasi-experimental studies conducted in adult patients
pre and/or post cardiac surgery were included. Fifteen studies were
considered eligible for inclusion in the review. The results revealed that
the IMT programs varied in intensity, repetitions, and duration in all
included studies. Most studies implemented the IMT after the surgery.
Statistical significance between groups was noted in Maximal Inspiratory
Pressure and the 6-Minute Walk Distance Test. Preoperative and
postoperative programs could improve inspiratory muscle strength,
pulmonary function, and functional capacity as well as decrease the length
of hospital stay in patients undergoing cardiac surgery. No clear evidence
emerged favoring low or higher IMT intensities. The combination of IMT
with other forms of exercise might be beneficial in patients undergoing
cardiac surgery. However, further RCTs are required to provide confirming
evidence.<br/>Copyright &#xa9; 2024 by the authors.

<19>
Accession Number
2036791908
Title
The Prognostic Relevance of a New Bundle Branch Block After Transcatheter
Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Source
Structural Heart. (no pagination), 2025. Article Number: 100392. Date of
Publication: 2025.
Author
Rao K.; Ahmed M.; Brieger D.; Baer A.; Hansen P.; Bhindi R.
Institution
(Rao, Brieger, Hansen, Bhindi) Royal North Shore Hospital, Sydney,
Australia
(Rao, Baer, Hansen, Bhindi) North Shore Private Hospital, Sydney,
Australia
(Rao, Ahmed, Bhindi) University of Sydney, Australia
Publisher
Cardiovascular Research Foundation
Abstract
Background: Interference with the cardiac conduction system is common
after transcatheter aortic valve implantation (TAVI), manifesting as
atrioventricular block, or more commonly, new-onset persistent left bundle
branch block (NOP-LBBB). Bundle branch block results in ventricular
dyssynchrony and reduced cardiac output and may be associated with a
poorer prognosis. This systematic review and meta-analysis evaluates the
prognostic impact of a left or right bundle branch block after TAVI.
<br/>Method(s): A systematic review was performed of the following online
databases: PubMed, Medline, Scopus, and Web of Science, including English
language studies from 2014 to 2024. Two separate searches for conducted
for NOP-LBBB and new-onset persistent right bundle branch block
(NOP-RBBB). The Newcastle-Ottawa Scale was used to evaluate risk of bias.
<br/>Result(s): Twenty-three studies totaling 18875 patients were included
for NOP-LBBB, whilst 5 studies with a total of 3525 patients were included
for NOP-RBBB. NOP-LBBB was associated with higher all-cause mortality at 1
year (risk ratio [RR] 1.41 [95% CI 1.12-1.78], I² = 49%, p <
0.01), cardiovascular mortality (RR 1.34 [95% CI 1.02-1.75], I²
= 60%, p = 0.02), heart failure-related rehospitalization (RR 1.56 [95% CI
1.31-1.84], I² = 47%, p < 0.01), and permanent pacemaker
implantation at 1 year (RR 3.05 [95% CI 2.39-3.89], I² = 14%, p
< 0.01). NOP-RBBB was not associated with higher all-cause mortality at 1
year (RR 1.74 [95% CI 0.88-3.46], I² = 93%, p = 0.11), however
increased the risk of pacemaker implantation at 1 year (RR 4.68 [95% CI
3.60-6.08], I² = 67%, p < 0.01). <br/>Conclusion(s): NOP-LBBB
is associated with higher mortality and heart failure rehospitalization
after TAVI, whilst both NOP-LBBB and NOP-RBBB increase the risk of
permanent pacemaker implantation at 1 year after TAVI.<br/>Copyright
&#xa9; 2024 The Authors

<20>
Accession Number
2036791379
Title
Sex Differences in Patients Undergoing FFR-Guided PCI or CABG in the FAME
3 Trial.
Source
JACC: Cardiovascular Interventions. (no pagination), 2025. Date of
Publication: 2025.
Author
Takahashi K.; Otsuki H.; Zimmermann F.M.; Ding V.Y.; Oldroyd K.G.; Wendler
O.; Reardon M.J.; Woo Y.J.; Yeung A.C.; Pijls N.H.J.; De Bruyne B.; Fearon
W.F.
Institution
(Takahashi, Otsuki, Ding, Yeung, Fearon) Stanford University School of
Medicine and Stanford Cardiovascular Institute, Stanford University,
Stanford, CA, United States
(Zimmermann, Pijls) Department of Cardiology, Catharina Hospital,
Eindhoven, Netherlands
(Zimmermann) St. Antonius Hospital, Nieuwegein, Netherlands
(Oldroyd) Golden Jubilee National Hospital, Glasgow, United Kingdom
(Wendler) Cleveland Clinic London, London, United Kingdom
(Reardon) Houston Methodist Debakey Heart & Vascular Center, Houston, TX,
United States
(Woo) Department of Cardiothoracic Surgery, Division of Cardiovascular
Medicine and Stanford Cardiovascular Institute, Stanford University,
Stanford, CA, United States
(De Bruyne) Cardiovascular Center Aalst, Belgium
(Fearon) VA Palo Alto Medical Systems, Palo Alto, CA, United States
Publisher
Elsevier Inc.
Abstract
Background: Outcomes in women after fractional flow reserve (FFR)-guided
percutaneous coronary intervention (PCI) using current-generation
drug-eluting stents (DES) compared with coronary artery bypass grafting
(CABG) are unknown. <br/>Objective(s): This study sought to evaluate
differences in clinical outcomes according to sex after FFR-guided PCI
with current generation DES compared with CABG. <br/>Method(s): The FAME 3
trial was an investigator-initiated, randomized controlled trial,
comparing FFR-guided PCI with current generation DES or CABG in patients
with 3-vessel coronary artery disease. This prespecified subgroup analysis
compared the incidence of major adverse cardiac and cerebrovascular events
(MACCE) according to sex, defined as the composite of all-cause death,
myocardial infarction, stroke, or repeat revascularization at 3 years.
<br/>Result(s): Of 1,500 patients included in the FAME 3 trial, 265
(17.7%) were women. Women had a significantly higher risk of MACCE at 3
years compared with men after CABG (18.1% vs 11.7%; adjusted HR: 2.07; 95%
CI: 1.19-3.60), whereas women had a similar risk of MACCE at 3 years
compared with men after PCI (18.2% vs 19.1%; adjusted HR: 1.27; 95% CI:
0.79-2.03). Regarding treatment effects by sex, women undergoing PCI had a
similar risk of MACCE at 3 years compared with CABG (adjusted HR: 1.15;
95% CI: 0.62-2.11). By contrast, men undergoing PCI had a higher risk of
MACCE at 3 years compared with CABG (adjusted HR: 1.68; 95% CI: 1.25-2.25;
P<inf>interaction</inf> = 0.142), which was mainly driven by a higher risk
of myocardial infarction (adjusted HR: 2.11; 95% CI: 1.26-3.56;
P<inf>interaction</inf> = 0.102) and repeat revascularization (adjusted
HR: 2.26; 95% CI: 1.47-3.47; P<inf>interaction</inf> = 0.071).
<br/>Conclusion(s): In the FAME 3 trial, at 3 years, women had similar
outcomes with FFR-guided PCI compared with CABG, whereas men had improved
outcomes with CABG. (A Comparison of Fractional Flow Reserve-Guided
Percutaneous Coronary Intervention and Coronary Artery Bypass Graft
Surgery in Patients With Multivessel Coronary Artery Disease [FAME 3];
NCT02100722)<br/>Copyright &#xa9; 2024 American College of Cardiology
Foundation

<21>
Accession Number
646118414
Title
Effects of continuous pecto-intercostal fascial block for management of
post-sternotomy pain in patients undergoing cardiac surgery: a randomized
controlled trial.
Source
International journal of surgery (London, England). (no pagination),
2024. Date of Publication: 20 Dec 2024.
Author
Zhao Y.; He D.; Zhou W.; Chen C.; Liu Z.; Xia P.; Ye Z.; Li C.
Institution
(Zhao, He, Zhou, Chen, Liu, Xia, Ye, Li) Department of Anesthesiology,
Xiangya Hospital of Central South University, Hunan Province, Changsha,
China
(Liu, Xia, Ye, Li) National Clinical Research Center for Geriatric
Disorders, Central South University, Hunan Province, Changsha, China
Abstract
BACKGROUND: Managing postoperative pain following median sternotomy has
long been a notable challenge for anesthesiologists. The administration of
postoperative analgesia traditionally relies on intravenous pumps for the
delivery of opioids. With the development of regional block techniques and
postoperative multimodal analgesia, pecto-intercostal fascial block (PIFB)
has gained widespread utilization due to its distinctive advantages.
However, its application is limited to a single block. This study aimed to
indicate whether continuous PIFB analgesia in cardiac surgery via
sternotomy could possess clinical advantages compared with intravenous
analgesia in terms of postoperative pain management. If continuous PIFB
analgesia was the priority, the secondary objective would involve
determining the most effective administration method, making it a critical
area of exploration. <br/>METHOD(S): Totally, 114 patients were randomly
allocated to three groups: the PCIA group, receiving intravenous opioid
infusion exclusively via pump, and the C-PIFB and I-PIFB groups, where
ultrasound-guided PIFB with a nerve blocking pump was administered. The
C-PIFB group received a constant basal infusion, while programmed
intermittent boluses were administered in the I-PIFB group. The primary
endpoint was postoperative visual analogue scale (VAS) scores, and
secondary outcomes included intraoperative sufentanil consumption, time to
extubation, mobilization, length of stay in intensive care unit (ICU) and
hospital, and the incidence of postoperative complications.
<br/>RESULT(S): The VAS scores at rest and during coughing were noticeably
diminished in the two block groups relative to the intravenous pump group
at 12, 24, 48, and 72 h postoperatively. Notably, intraoperative
sufentanil consumption was significantly reduced in the C-PIFB group (3.12
[0.93] ug.kg-1) and the I-PIFB group (3.42 [0.77] ug.kg-1) compared with
the PCIA group (4.66 [1.02] ug.kg-1, P < 0.001). Time to extubation,
mobilization, length of stay in ICU and hospital, and use of rescue
analgesics did not exhibit statistically significant differences among the
three groups. However, the postoperative complication rates were markedly
lower in the C-PIFB group (42.11%) and I-PIFB group (36.84%) relative to
the PCIA group (81.58%, P < 0.001). There were no significant differences
between C-PIFB and I-PIFB groups regarding VAS score, secondary outcomes,
and postoperative complications. <br/>CONCLUSION(S): Continuous PIFB can
provide satisfactory postoperative analgesia while reducing perioperative
opioid consumption, diminishing the risk of postoperative complications,
and accelerating postoperative recovery for patients undergoing median
sternotomy in cardiac surgery. The constant basal infusion method may be
the optimal approach for administering continuous PIFB.<br/>Copyright
&#xa9; 2024. Published by Wolters Kluwer Health, Inc.

<22>
Accession Number
646115897
Title
Comparison of thoracoscopic-guided intercostal nerve block and
ultrasound-guided intercostal nerve block in postoperative analgesia of
uniportal video-assisted lobectomy: a pilot randomized controlled trial.
Source
International journal of surgery (London, England). (no pagination),
2024. Date of Publication: 20 Dec 2024.
Author
Li Y.; Wei L.; Du J.-H.; He J.-X.; Xu X.; Hu L.-H.
Institution
(Li, Wei, Du, Xu, Hu) Department of Anesthesiology
(He) Department of Thoracic Surgery, affiliated Lihuili Hospital of Ningbo
University, Ningbo, China
Abstract
BACKGROUND: Ultrasound-guided intercostal nerve block (UINB) and
thoracoscopic-guided intercostal nerve block (TINB) are often used for
analgesia after thoracic surgery. Herein, we compared the application of
TINB and UINB for analgesia after uniportal video-assisted lobectomy.
<br/>METHOD(S): Sixty patients were randomly allocated into two groups:
UINB and TINB. The surgical time of intercostal nerve block (INB), the
success rate of the first needle, visual analog scale (VAS) scores, the
time of the first patient-controlled intravenous analgesia (PCIA) press,
the time for removing the thoracic drainage tube, consumption of
sufentanil and the number of PCIA presses within 24 hours postoperatively,
and adverse reactions (ARs) were compared between the two groups.
<br/>RESULT(S): The surgical time of INB was significantly shorter in the
TINB group than in the UINB group (P < 0.001). The time of the first press
of PCIA was significantly earlier in the TINB group than in the UINB group
(P < 0.001). The success rate of the first needle was significantly higher
in the TINB group than in the UINB group (P < 0.001). No significant
differences were observed between the two groups regarding VAS scores,
time for removing the thoracic drainage tube, the consumption of
sufentanil, the number of PCIA presses within 24 hours postoperatively,
and ARs. <br/>CONCLUSION(S): TINB and UINB have similar analgesic effects
after uniportal video-assisted lobectomy. However, TINB demonstrates
shorter surgical time and a higher success rate than UINB.<br/>Copyright
&#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

<23>
Accession Number
646115432
Title
Efficacy of the intravenous formulation of fentanyl citrate administered
orally as premedication in paediatric patients undergoing open cardiac
surgery.
Source
Journal of perioperative practice. (pp 17504589241301311), 2024. Date of
Publication: 19 Dec 2024.
Author
Elbardan I.M.; Shehab A.S.; Yacout A.G.; Mabrouk I.M.
Institution
(Elbardan, Shehab, Yacout, Mabrouk) Department of Anesthesia and Surgical
Intensive Care, Alexandria Faculty of Medicine, Alexandria, Egypt
Abstract
BACKGROUND: Recently, fentanyl has become prevalent as a sedative
premedication. <br/>METHOD(S): A non-inferiority parallel design
quadruple-blinded randomised controlled trial of 1- to 7-year-old children
scheduled for elective cardiac surgery was conducted. Participants were
assigned a 1:1 allocation ratio to a control group (n=50) given a
parenteral formulation of midazolam 0.5mg/kg and an intervention group
(n=50) given a parenteral formulation of fentanyl 10 mug/kg 30min before
admission to the operating room. <br/>RESULT(S): Fentanyl was shown to be
inferior when compared to midazolam during inhalational induction but not
in the 'after premedication' and 'during separation' periods. A lower
percentage of children disliked the medication in the fentanyl group.
<br/>CONCLUSION(S): A parenteral formulation of fentanyl can be a
satisfactory alternative when given orally as a sedative pre-anaesthetic
medication in paediatric cardiac surgery before admission to the operating
room.

<24>
Accession Number
646115381
Title
Efficacy of Cerebral Oxygen Saturation Monitoring for Perioperative
Neurocognitive Disorder in Adult Non-cardiac Surgical Patients: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Source
World neurosurgery. (pp 123570), 2024. Date of Publication: 17 Dec 2024.
Author
Qiu L.; Ma Y.; Ge L.; Zhou H.; Jia W.
Institution
(Qiu, Ma, Ge, Zhou, Jia) Department of Anesthesiology, Gansu Provincial
Hospital, Gansu Province, Lanzhou, China
Abstract
BACKGROUND: Perioperative neurocognitive disorders (PND) are common
perioperative complications associated with various poor outcomes.
Regional cerebral oxygen saturation (rSO2) monitoring is a non-invasive
technique based on near-infrared spectroscopy detection. Due to the
considerable controversy among currently published studies on the
application of intraoperative rSO2 monitoring in adult patients undergoing
elective non-cardiac surgery, this study aims to conduct a systematic
review and meta-analysis to provide more comprehensive and robust evidence
to support clinical decision-making. MATERIALS AND METHODS: This study
conducted a systematic literature search of databases including PubMed,
Embase, CENTRAL, and Web of Science, from their inception to May 1, 2024.
The eligible randomized controlled trials included adult patients
undergoing elective non-cardiac surgery under general anesthesia who
received optimized anesthesia management guided by rSO2 monitoring and
those in the control group who received routine anesthesia management
under standard monitoring or blinded rSO2 monitoring. The primary outcomes
were the incidence of PND, including postoperative delirium (POD) and
postoperative cognitive dysfunction (POCD), and Mini-Mental State
Examination (MMSE) scores. Secondary outcomes included the incidence of
intraoperative cerebral desaturation and length of hospital stay (LOS).
<br/>RESULT(S): The pooled results showed that compared to the control
group, optimized anesthesia management guided by intraoperative rSO2
monitoring significantly reduced the incidence of POCD within 7 days
postoperatively and may reduce the incidence of POCD at 3 months and
longer periods postoperatively. However, it may not reduce the incidence
of POD within 7 days or longer periods postoperatively, improve MMSE
scores, reduce the incidence of intraoperative cerebral desaturation, or
shorten LOS. Given the substantial heterogeneity in the pooled results for
MMSE scores within 7 days postoperatively and LOS, and the limited number
of studies reporting the incidence of POD, POCD, and MMSE scores after 7
days postoperatively, the related results should be interpreted with
caution. <br/>CONCLUSION(S): Despite the presence of heterogeneity and the
inclusion of a limited number of studies for some outcomes, it is still
recommended that clinical anesthesiologists routinely perform
intraoperative rSO2 monitoring and optimize intraoperative anesthesia
management based on the monitoring results to maximize rSO2 and improve
cerebral perfusion, thereby improving patients' neurocognitive outcomes.
Further large-scale high-quality studies are needed to confirm the
conclusions of this study.<br/>Copyright &#xa9; 2024. Published by
Elsevier Inc.

<25>
Accession Number
646114766
Title
A Systematic Review of Multimodal Analgesic Effectiveness on Acute
Postoperative Pain After Adult Cardiac Surgery.
Source
Journal of advanced nursing. (no pagination), 2024. Date of Publication:
20 Dec 2024.
Author
Wynne R.; Jedwab R.M.; Gjeilo K.H.; Fredericks S.; Magboo R.; Phillips
E.K.; Goudarzi Rad M.; O'Keefe-Mccarthy S.; Keeping-Burke L.; Murfin J.;
Killackey T.; Bruneau J.; Matthews S.; Bowden T.; Sanders J.; Lie I.
Institution
(Wynne, Matthews) School of Nursing & Midwifery, Centre for Quality &
Patient Safety in the Institute for Health Transformation, Deakin
University, Geelong, VIC, Australia
(Wynne) Western Health, St Albans, VIC, Australia
(Jedwab) EMR & Informatics Program, Monash Health, Clayton, VIC, Australia
(Gjeilo) Department of Public Health and Nursing, Faculty of Medicine and
Health, NTNU - Norwegian University of Science and Technology, Trondheim,
Norway
(Gjeilo) Department of Cardiology, St. Olav's Hospital, Trondheim, Norway
(Fredericks) Daphne Cockwell School of Nursing, Ryerson University,
Toronto, Canada
(Magboo) Adult Critical Care Unit, St. Bartholomew's Hospital, London,
United Kingdom
(Magboo) Queen Mary University of London, London, United Kingdom
(Phillips) Cardiac Sciences, Winnipeg Regional Health Authority, Winnipeg,
MB, Canada
(Phillips) Applied Health Sciences, University of Manitoba, Winnipeg, MB,
Canada
(Goudarzi Rad, Killackey) Lawrence S Bloomberg Faculty of Nursing,
University of Toronto, Toronto, ON, Canada
(Goudarzi Rad, Killackey) Peter Munk Cardiac Centre, University Health
Network, Toronto, ON, Canada
(O'Keefe-Mccarthy) Department of Nursing, Brock University, St.
Catharines, ON, Canada
(Keeping-Burke) Department of Nursing & Health Sciences, University of New
Brunswick, Saint John, New Brunswick, Canada
(Murfin) Cardiac Surgery, University of Southampton NHS Foundation Trust,
Southampton, United Kingdom
(Bruneau) Memorial University of Newfoundland, St John's ,Newfoundland and
Labrador, Canada
(Matthews) Heart Foundation, Global Cardiovascular Research Funders Forum,
Melbourne, VIC, Australia
(Bowden) School of Health & Psychological Sciences, Nursing Department,
University of London, London, United Kingdom
(Sanders) Faculty of Nursing, King's College London, London, United
Kingdom
(Sanders) Barts Health NHS Trust, St Bartholomew's Hospital, London,
United Kingdom
(Sanders) William Harvey Research Institute, London, United Kingdom
(Lie) Centre for Patient-Centred Heart & Lung Research, Department of
Cardiothoracic Surgery, Division of Cardiovascular & Pulmonary Disease,
Oslo University Hospital, Oslo, Norway
(Lie) Department of Health Sciences in Gjovik, Faculty of Medicine &
Health Sciences, Norwegian University of Science & Technology, Norway
Abstract
AIM: To synthesise the best available empirical evidence about the
effectiveness of multimodal analgesics on pain after adult cardiac
surgery. DESIGN: A systematic review with meta-analysis. <br/>METHOD(S):
Indexed full-text papers or abstracts, in any language, of randomised
controlled trials of adult patients undergoing cardiac surgery
investigating multimodal postoperative analgesic regimen effect on mean
level of patient-reported pain intensity at rest. DATA SOURCES: Eight
databases, via two platforms and three trial registries were searched from
1 January 1995 to 1 June 2024 returning 3823 citations. <br/>RESULT(S): Of
the 123 full-text papers assessed, 29 were eligible for inclusion. Data
were independently extracted by a minimum of two reviewers in Covidence.
There were 2195 participants, aged 60.4+/-6.6 (range 40-79) years, who
were primarily male (n=1522, 76.1%), randomised in the included studies.
Risk of bias was high and reporting quality was poor. Patient-reported
pain was measured at rest in 28 (96.6%) trials. Data were suitable for
pooled analysis from 10 (34.5%) of these trials with an average rest pain
intensity of 3.3 (SD 1.5) in the control and 2.7 (SD 1.9) in the
intervention groups, respectively. No trials compared combinations of
nonopioid, opioid-agonist-antagonist, partial opioid agonists or full
opioid agonists. Most trials (n=11, 37.9%) compared two different full
opioid options for less than 72h (n=24, 82.7%). <br/>CONCLUSION(S): Robust
trials are needed to determine which multimodal analgesic combination will
optimise patient recovery after adult cardiac surgery. There is an urgent
need to test and refine high-quality end-point measures. IMPLICATIONS FOR
PATIENT CARE: Adequate assessment precedes ideal pain treatment. The
findings from this review reveal neither are sufficient, and the impact of
suboptimal pain management on postoperative recovery is grossly
underinvestigated. IMPACT: The optimal combination of multimodal
analgesics is unknown despite being recommended in best practice
guidelines for enhanced recovery after cardiac surgery. Almost 30% of
adults continue to experience ongoing pain up to a year after cardiac
surgery, and findings from this review reveal a dearth of robust empirical
evidence for optimal pain management, and heterogeneity in the way pain is
assessed, measured and managed. This review provides a premise for robust
trials focused on acute postoperative recovery in cardiac surgery and
beyond. REPORTING METHOD: This review was conducted in accordance with the
PRISMA-P statement. PATIENT OR PUBLIC CONTRIBUTION: There was no patient
or public contribution. PROTOCOL REGISTRATION: PROSPERO:
CRD42022355834.<br/>Copyright &#xa9; 2024 John Wiley & Sons Ltd.

<26>
Accession Number
646114597
Title
Safety and efficacy of cerebral embolic protection systems in
transcatheter aortic valve replacement: a systematic review and
meta-analysis.
Source
Expert review of cardiovascular therapy. (no pagination), 2024. Date of
Publication: 20 Dec 2024.
Author
Kheyrbek M.; Alsabti S.; Niroula S.; Ahmad E.; Choucair M.; Bhatia U.;
Wernette A.; Chhabra K.; Strubchevska K.; Hanson I.; Halalau A.
Institution
(Kheyrbek, Alsabti, Niroula, Ahmad, Choucair, Bhatia, Wernette, Chhabra,
Strubchevska, Halalau) Department of Internal Medicine, Corewell Health
William Beaumont University Hospital, Royal Oak, MI, United States
(Hanson) Department of Cardiovascular Medicine, Corewell Health William
Beaumont University Hospital, Royal Oak, MI, United States
(Hanson, Halalau) Oakland University William Beaumont School of Medicine,
Rochester, MI, United States
Abstract
BACKGROUND: Stroke is a potentialcomplication of Transcatheter Aortic
Valve Replacement (TAVR). Recent trials evaluating Cerebral Embolic
ProtectionSystems(CEPS) to reduce the incidence of stroke after TAVR have
been conflicting. <br/>METHOD(S): Multiple databaseswere searched for
studies comparing TAVR with or without CEPS and that reportedon the
primary outcome of periprocedural stroke. Two authors individuallyscreened
the titles, the abstracts and the full texts using Covidence. Risk ofbias
was assessed using Cochrane's ROB-2 and ROBINS-I tools. <br/>RESULT(S): 15
studies (3 randomized controlled trials, 7 national registries, and
5cohort studies) met the eligibility criteria and were included in our
review. CEPS was associatedwith lower rates of periprocedural stroke [OR
0.71 (95% CI 0.55, 0.93)p=0.012], as well as lower rates of mortality [OR
0.60 (95% CI 0.49, 0.74)p<0.001]. There was no significant difference
between the two groups in theincidence of acute kidney injury [OR 0.91
(95% CI 0.82, 1.01) p=0.087], majorvascular complications [OR 0.97 (95% CI
0.83, 1.14) p=0.734], and major life-threateningbleeding [OR 0.89 (95% CI
0.73, 1.07) p=0.222]. <br/>CONCLUSION(S): Our findings suggest that the
use of CEPS in TAVR is associated with alower risk of periprocedural
stroke and mortality. REGISTRATION: The PROSPERO identification number is
CRD42022374055.

<27>
Accession Number
2032760265
Title
Advancements and Challenges in the Management of Prosthetic Valve
Endocarditis: A Review.
Source
Pathogens. 13(12) (no pagination), 2024. Article Number: 1039. Date of
Publication: December 2024.
Author
Nappi F.
Institution
(Nappi) Department of Cardiac Surgery, Centre Cardiologique du Nord,
Saint-Denis 93200, France
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Prosthetic valve endocarditis (PVE) is the medical term used to describe a
focus of infection involving a valvular substitute within the heart. It is
a significant concern in the field of cardiology, and the epidemiology of
PVE has seen notable developments over the last five decades. The disease
currently affects an older demographic and is becoming increasingly
prevalent in patients with transcatheter-implanted valves. It is
imperative that we urgently address the significant challenges posed by
PVE. It is a disease that has a wide range of potential aetiologies,
clinical presentations, and courses. In developed countries,
Staphylococcus aureus is now the predominant causative organism, resulting
in an aggressive form of disease that frequently afflicts vulnerable or
elderly populations. However, it is clear that Enterococcus species
present a significant challenge in the context of PVE following TAVR
procedures, given their elevated prevalence. The 2023 Duke/International
Society for Cardiovascular Infectious Diseases infective endocarditis
diagnostic criteria now include significant developments in
microbiological and image-based techniques for diagnostic purposes,
specifically the incorporation of fluorine-18 fluorodeoxyglucose positron
emission tomography and computed tomography. These developments
unequivocally enhance the diagnostic sensitivity for PVE, while
maintaining the specificity. They do so in accordance with the results of
studies conducted specifically for the purpose of validation. The lack of
rigorous scientific studies and a shortage of funding and resources for
research have led to a significant gap in our understanding. Randomized
controlled trials could provide invaluable insight and guidance for
clinical practice, but they are missing, which represents a major gap. It
is clear that there is an urgent need for more research. PVE is a
life-threatening condition that must be handled by a multidisciplinary
endocarditis team at a cardiac centre in order to improve outcomes. The
emergence of innovative surgical techniques has empowered clinicians to
steer more patients away from surgical procedures, despite the presence of
clear indications for them. A select group of patients can now complete
parenteral or oral antimicrobial treatment at home. Additionally,
antibiotic prophylaxis is the best option for individuals with prosthetic
valves who are going to have invasive dental procedures. These individuals
should be given antibiotics beforehand.<br/>Copyright &#xa9; 2024 by the
author.

<28>
Accession Number
2032772516
Title
Bioprosthetic Aortic Valve Degeneration After TAVR and SAVR: Incidence,
Diagnosis, Predictors, and Management.
Source
Journal of Cardiovascular Development and Disease. 11(12) (no pagination),
2024. Article Number: 384. Date of Publication: December 2024.
Author
Bismee N.N.; Javadi N.; Khedr A.; Omar F.; Awad K.; Abbas M.T.; Scalia
I.G.; Pereyra M.; Bcharah G.; Farina J.M.; Ayoub C.; Sell-Dottin K.A.;
Arsanjani R.
Institution
(Bismee, Javadi, Awad, Abbas, Scalia, Pereyra, Farina, Ayoub, Arsanjani)
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054,
United States
(Khedr, Sell-Dottin) Department of Cardiovascular Surgery, Mayo Clinic,
Phoenix, AZ 85054, United States
(Omar, Bcharah) Mayo Clinic Alix School of Medicine, Phoenix, AZ 85054,
United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Bioprosthetic aortic valve degeneration (BAVD) is a significant clinical
concern following both transcatheter aortic valve replacement (TAVR) and
surgical aortic valve replacement (SAVR). The increasing use of
bioprosthetic valves in aortic valve replacement in younger patients and
the subsequent rise in cases of BAVD are acknowledged in this review which
aims to provide a comprehensive overview of the incidence, diagnosis,
predictors, and management of BAVD. Based on a thorough review of the
existing literature, this article provides an updated overview of the
biological mechanisms underlying valve degeneration, including
calcification, structural deterioration, and inflammatory processes and
addresses the various risk factors contributing to BAVD, such as patient
demographics, comorbidities, and procedural variables. The difficulties in
early detection and accurate diagnosis of BAVD are discussed with an
emphasis on the need for improved imaging techniques. The incidence and
progression of BAVD in patients undergoing TAVR versus SAVR are compared,
providing insights into the differences and similarities between the two
procedures and procedural impacts on valve longevity. The current
strategies for managing BAVD, including re-intervention options of redo
surgery and valve-in-valve TAVR, along with emerging treatments are
discussed. The controversies in the existing literature are highlighted to
offer directions for future investigations to enhance the understanding
and management of BAVD.<br/>Copyright &#xa9; 2024 by the authors.

<29>
Accession Number
2036650768
Title
Traditional vs. modified Ringer lactate-based del Nido cardioplegia
impacts on clinical outcomes in patients undergoing coronary artery bypass
grafting: Results from a prospective, randomized, blinded trial.
Source
Journal of Extra-Corporeal Technology. 56(4) (pp 159-166), 2024. Date of
Publication: 01 Dec 2024.
Author
Kachoueian N.; Janghorban S.; Torkashvand M.; Mahjoob M.P.; Aslani H.;
Mehrabanian M.; Gorjipour F.
Institution
(Kachoueian, Janghorban, Mahjoob) Shahid Beheshti University of Medical
Sciences, Tehran 1516745811, Iran, Islamic Republic of
(Gorjipour) Rajaie Cardiovascular, Medical and Research Center, Tehran
1995614331, Iran, Islamic Republic of
(Gorjipour) Iranian Scientific Society of Extra-Corporeal Technology,
Tehran 1995614331, Iran, Islamic Republic of
(Torkashvand, Aslani, Mehrabanian) Tehran University Medical Sciences,
Tehran 1416634793, Iran, Islamic Republic of
(Gorjipour) Physiology Research Center, Iran University of Medical
Sciences, Tehran 1449614535, Iran, Islamic Republic of
Publisher
EDP Sciences
Abstract
Introduction: Myocardial protection with cardioplegia is a crucial
approach to mitigate myocardial damage during coronary bypass grafting
surgery (CABG) with cardiopulmonary bypass (CPB). The major component of
the del Nido cardioplegia solution, Plasma-Lyte A, is difficult to obtain
in Iran due to high cost. The objective of the current study was to study
if the lactated Ringer's solution as the base for del Nido solution (LR
DN) usage is a viable option as a substitute for Plasma-Lyte A in adult
patients presenting for CABG surgery. Study design and methods: The
present prospective, randomized, blinded study was performed on
18-75-year-old patients ejection fraction (EF) > 35% undergoing CABG with
CPB. Patients were randomly allocated to LR DN (modified del Nido
cardioplegia) and PL DN (standard del Nido cardioplegia solution) groups.
Serum level of cardiac troponin I (cTnI), the type and dosage of inotrope
agents, EF, rate of arrhythmia after clamp removal and lactate level were
measured and compared between patients of LR DN and PL DN groups.
<br/>Result(s): 109 patients were recruited. There were no statistically
significant differences between groups for cardiopulmonary bypass times,
cardiac enzymes, transfusion requirements, and arterial blood gases. There
was no mortality for study patients. Postoperative serum levels of cTnI
among patients in the LR DN group was significantly higher than patients
of the PL DN group after ICU admission and 24 h post-ICU. Also, more
patients needed epinephrine administration in the operating room in the LR
DN group (29.8% vs. 11.5%; p: 0.019 vs. PL DN group). <br/>Conclusion(s):
We concluded that the standard del Nido cardioplegia solution offers
better myocardial protection compared with Ringer's lactate-based del Nido
cardioplegia in adult patients undergoing CABG with CPB. We recommend
using standard del Nido cardioplegia with a PL base for patients
presenting for CABG surgery. <br/>Copyright &#xa9; The Author(s),
published by EDP Sciences, 2024.

<30>
Accession Number
2036724535
Title
Surgical treatment of thoracic aortic pseudoaneurysm: a systematic review
of the literature.
Source
Intervencni a Akutni Kardiologie. 23(2-3) (pp 90-95), 2024. Date of
Publication: 2024.
Author
Recicarova S.; Lawrie K.; Jonak M.; Netuka I.
Institution
(Recicarova, Jonak, Netuka) Department of Cardiovascular Surgery,
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia
(Recicarova) First Faculty of Medicine, Charles University, Prague,
Czechia
(Lawrie) Department of Transplantation Surgery, Institute for Clinical and
Experimental Medicine (IKEM), Prague, Czechia
(Lawrie) Third Faculty of Medicine, Charles University, Prague, Czechia
Publisher
SOLEN s.r.o.
Abstract
Introduction: Thoracic aortic false aneurysm is a rare complication of
cardiac surgery or procedures on the thoracic aorta. We present the
results of a systematic review of the literature. Our aim was to determine
the best treatment options and surgical techniques. <br/>Method(s): We
performed a literature search regarding thoracic aortic pseudoaneurysm and
its surgical treatment in English, limited by the dates 1^st
January 1979 to 31^st December 2022. We searched the PubMed and
EMBASE databases for the following medical terms: thoracic aortic false
aneurysm, pseudoaneurysm, and surgical treatment. <br/>Result(s): Our
search screened 4,046 articles. Only nine articles were eligible. The
other articles were single case reports or small series of case reports
with fewer than nine patients. All the studies were retrospective. Ninety
percent of the cases underwent prior aortic or cardiac surgery. The
surgical treatment strategies were chosen according to the location of the
pseudoaneurysm and were overall inconclusive. <br/>Conclusion(s):
According to the current literature, there are no clear guidelines or
recommendations; therefore, the operation should be tailored to each
patient individually. Regular checkups involving imaging techniques after
cardiac surgeries are recommended. Despite significant advancements in
endovascular treatment, it is often not suitable, making open surgery the
treatment of choice.<br/>Copyright &#xa9; 2024 SOLEN s.r.o.. All rights
reserved.

<31>
Accession Number
2036623094
Title
Outcomes of Concomitant Mitral Intervention in Hypertrophic Obstructive
Cardiomyopathy Surgery? A Systematic Review and Meta-Analysis of
Contemporary Evidence.
Source
Cardiology in Review. (no pagination), 2024. Article Number:
10.1097/CRD.0000000000000819. Date of Publication: 2024.
Author
Domondon I.A.A.; de Guzman R.M.; Bruno C.J.P.; Jaffar-Karballai M.;
Alroobi A.; Siddique M.; Bitar M.; Enaya H.H.; Al-Tawil M.; Haneya A.
Institution
(Domondon, de Guzman) The Emergency Department, Portsmouth Hospitals
University NHS Trust, Portsmouth, United Kingdom
(Bruno) Department of Medicine for Older People, Stockport NHS Foundation
Trust, Stockport, United Kingdom
(Jaffar-Karballai) Medical Department, Chelsea and Westminster Hospital
NHS Trust, London, United Kingdom
(Alroobi, Enaya) Faculty of Medicine, Islamic University of Gaza, Gaza,
Palestine
(Siddique, Bitar) Department of Internal Medicine, Jamaica Hospital
Medical Center, Queens, NY, United States
(Al-Tawil, Haneya) Department of Cardiac and Thoracic Surgery, Trier Heart
Centre, Trier, Germany
Publisher
Lippincott Williams and Wilkins
Abstract
The 2020 American Heart Association Guidelines advise not to perform
mitral valve replacement (MVR) during septal myectomy (SM) to alleviate
outflow obstruction.This study aims to review outcomes after concomitant
mitral valve (MV) intervention versus SM alone.We conducted a
comprehensive literature search across Embase, PubMed, and Scopus.Studies
published up to June 15, 2024 were considered.We included studies that
compared SM alone to concomitant MV repair or replacement.Subgroup
analyses based on MV intervention were performed.Seven studies met our
criteria, including 1 randomized and 6 observational studies.The total
sample size was 17, 565 patients with hypertrophic cardiomyopathy (11, 849
SM, 2303 SM + MVR, and 3390 SM + MV repair).Patients who underwent SM + MV
intervention had more pronounced preoperative MV regurgitation.SM + MVR
was associated with significantly higher early mortality [risk ratio (RR):
2.85, 95% confidence interval (CI): 2.37-3.43, P < 0.00001, I²
= 0%].However, there was no difference in early mortality in patients who
underwent SM + MV repair compared with SM alone (RR: 1.14, 95% CI:
0.88-1.49, P = 0.33, I² = 0%).Thirty days systolic anterior
motion was significantly lower in patients who underwent SM + MV repair
compared with SM alone (RR: 0.15, 95%CI: 0.05-0.45, P = 0.0007).Peak
pressure left ventricular outflow tract gradient was significantly lower
in the SM + MV repair group compared with SM alone (mean difference:
-3.47, 95% CI: -5.55 to -1.39, P = 0.001).Current observational evidence
suggests an increased risk of in-patient mortality in patients who
underwent SM + MVR.SM + MV repair did not affect early mortality but was
linked to improved outcomes.Future comprehensive and matched studies are
warranted.<br/>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc.All rights
reserved.

<32>
Accession Number
2035550661
Title
Three-Year <inf>(<75 Years)</inf>Outcomes <inf>Low-Surgical-Risk</inf>
Following<inf>Severe</inf> TAVR in<inf>Aortic</inf> Younger Stenosis
Patients.
Source
Circulation: Cardiovascular Interventions. 17(11) (pp e014018), 2024. Date
of Publication: 01 Nov 2024.
Author
Modine T.; Tchetche D.; Van Mieghem N.M.; Michael Deeb G.; Chetcuti S.J.;
Yakubov S.J.; Sorajja P.; Gada H.; Mumtaz M.; Ramlawi B.; Bajwa T.; Crouch
J.; Teirstein P.S.; Kleiman N.S.; Iskander A.; Bagur R.; Chu M.W.A.;
Berthoumieu P.; Sudre A.; Adrichem R.; Ito S.; Huang J.; Popma J.J.;
Forrest J.K.; Reardon M.J.
Institution
(Modine) Centre Hospitalier Universitaire de Bordeaux, L'Unite
Medico-Chirurgicale des Valvulopathies, Chirurgie Cardiaque, Universite de
Bordeaux, France
(Tchetche, Berthoumieu) Clinique Pasteur, Toulouse, France
(Van Mieghem, Adrichem) Department of Interventional Cardiology,
Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands
(Michael Deeb) Department of Cardiac Surgery, Division of Interventional
Cardiology, United States
(Chetcuti) Department of Internal Medicine, Division of Cardiovascular
Medicine, United States
(Yakubov) Michigan Medicine Health Systems, University Hospital, Ann
Arbor, MI, United States
(Yakubov) Department of Cardiology, Ohio Health Riverside Methodist
Hospital, Columbus, United States
(Sorajja) Minneapolis Heart Institute Foundation, Abbott Northwestern
Hospital, Mongolia
(Gada, Mumtaz) Department of Interventional Cardiology and Cardiothoracic
Surgery, University of Pittsburgh Medical Center, Moffitt Heart/Pinnacle
Health, Harrisburg, PA, United States
(Ramlawi) Cardiothoracic Surgery, Lankenau Heart Institute, Wynnewood, PA,
United States
(Bajwa, Crouch) Department of Interventional Cardiology and Cardiothoracic
Surgery, Aurora Health Care, Aurora St. Luke's Medical Center, Milwaukee,
WI, United States
(Teirstein) Department of Interventional Cardiology, Scripps Clinic,
Scripps Prebys Cardiovascular Institute, La Jolla, CA, United States
(Kleiman, Reardon) Department of Interventional Cardiology and
Cardiothoracic Surgery, Methodist DeBakey Heart and Vascular Center,
Houston Methodist Hospital, TX, United States
(Iskander) Saint Joseph's Hospital Health Center, Syracuse, NY, United
States
(Bagur, Chu) London Health Sciences Centre, University Campus, ON, Canada
(Sudre) Centre Hospitalier Regional Universitaire de Lille, France
(Ito) Echocardiography Core Laboratory, Mayo Clinic, Rochester, MN, United
States
(Huang, Popma) Medtronic, Mounds View, MN, United States
(Forrest) Department of Internal Medicine (Cardiology), Yale University
School of Medicine, New Haven, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an
alternative to surgery in patients with severe aortic stenosis, but data
are limited on younger, low-risk patients. This analysis compares outcomes
in low-surgical-risk patients aged <75 years receiving TAVR versus
surgery. <br/>METHOD(S): The Evolut Low Risk Trial randomized 1414
low-risk patients to treatment with a supra-annular, self-expanding TAVR
or surgery. We compared rates of all-cause mortality or disabling stroke,
associated clinical outcomes, and bioprosthetic valve performance at 3
years between TAVR and surgery patients aged <75 years. <br/>RESULT(S): In
patients <75 years, 352 were randomized to TAVR and 351 to surgery. Mean
age was 69.1+/-4.0 years (minimum 51 and maximum 74); Society of Thoracic
Surgeons Predicted Risk of Mortality was 1.7+/-0.6%. At 3 years, all-cause
mortality or disabling stroke for TAVR was 5.7% and 8.0% for surgery
(P=0.241). Although there was no difference between TAVR and surgery in
all-cause mortality, the incidence of disabling stroke was lower with TAVR
(0.6%) than surgery (2.9%; P=0.019), while surgery was associated with a
lower incidence of pacemaker implantation (7.1%) compared with TAVR
(21.0%; P<0.001). Valve reintervention rates (TAVR 1.5%, surgery 1.5%,
P=0.962) were low in both groups. Valve performance was significantly
better with TAVR than surgery with lower mean aortic gradients (P<0.001)
and lower rates of severe prosthesis-patient mismatch (P<0.001). Rates of
valve thrombosis and endocarditis were similar between groups. There were
no significant differences in rates of residual >=moderate paravalvular
regurgitation. <br/>CONCLUSION(S): Low-risk patients <75 years treated
with supra-annular, self-expanding TAVR had comparable 3-year all-cause
mortality and lower disabling stroke compared with patients treated with
surgery. There was significantly better valve performance in patients
treated with TAVR.<br/>Copyright &#xa9; 2024 The Authors.

<33>
Accession Number
2032653807
Title
Comparative outcomes of video-assisted thoracic surgery versus open
thoracic surgery in pediatric pulmonary metastasectomy: a systematic
review and meta-analysis.
Source
Pediatric Surgery International. 41(1) (no pagination), 2025. Article
Number: 34. Date of Publication: December 2025.
Author
da Nobrega Oliveira R.E.N.; de Andrade Pontual Peres C.; Oliveira A.C.;
Onyeji P.; Kemczenski F.
Institution
(da Nobrega Oliveira) Department of Thoracic Surgery, Barretos Cancer
Hospital, Street Antenor Duarte Vilela, 1331, Dr. Paulo Prata, SP,
Barretos 14784-400, Brazil
(de Andrade Pontual Peres) University of Pernambuco, Recife, Brazil
(Oliveira) Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
(Onyeji) All Saints University, Goodwill, Dominica
(Kemczenski) University of Joinville's Region, Joinville, Brazil
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
This meta-analysis aimed to compare the outcomes of video-assisted
thoracic surgery (VATS) and open thoracotomy in pediatric patients
undergoing pulmonary metastasectomy for various malignancies. We
systematically searched PubMed, Embase, and Cochrane Library databases for
studies comparing VATS and open thoracotomy in pediatric patients. The
treatment effects for continuous outcomes were compared using mean
differences (MDs), and binary endpoints were evaluated using odds ratios
(ORs), with 95% confidence intervals (CIs). Heterogeneity was assessed
with I² statistics. Statistical analyses were performed using R
software, version 4.4.1. A total of 4 studies involving 1,541 patients
were included. There were no significant differences in overall survival
(OR 0.65; 95% CI 0.36-1.18; p = 0.16) or disease-free survival (DFS) (OR
1.65; 95% CI 0.88-3.10; p = 0.12) between groups. However, VATS was
associated with a significantly reduced length of hospital stay (MD -2.06
days; 95% CI - 2.93 to - 1.20; p < 0.01). This meta-analysis suggests that
VATS significantly reduces hospitalization duration compared to open
thoracotomy, with no significant difference in survival outcomes. Future
prospective studies are needed to validate these findings and optimize
patient selection criteria. International Prospective Register of
Systematic Reviews; No: CRD42024581284; URL:
https://www.crd.york.ac.uk/prospero/.<br/>Copyright &#xa9; The Author(s),
under exclusive licence to Springer-Verlag GmbH Germany, part of Springer
Nature 2024.

<34>
Accession Number
2032638214
Title
The IMproving treatment decisions for Patients with AortiC stenosis
Through Shared Decision Making (IMPACT SDM) Study: study protocol for a
cluster randomized stepped wedge trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 820. Date of
Publication: December 2024.
Author
Sepucha K.; Elmariah S.; Valentine K.D.; Cavender M.A.; Chang Y.;
Devireddy C.M.; Dickert N.W.; Gama K.D.; Knoepke C.E.; Korngold E.;
Kumbhani D.J.; Matlock D.D.; Messenger J.C.; Strong S.; Thourani V.H.;
Nathan A.; Quader N.; Brescia A.A.
Institution
(Sepucha, Valentine, Chang) Division of General Internal Medicine,
Massachusetts General Hospital, Boston, MA, United States
(Sepucha, Valentine) Harvard Medical School, Boston, MA, United States
(Elmariah) Division of Cardiology, University of California San Francisco,
San Francisco, CA, United States
(Cavender) Division of Cardiology, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States
(Devireddy, Dickert) Division of Cardiology, Department of Medicine, Emory
University School of Medicine, Atlanta, United States
(Gama, Messenger) Division of Cardiology, Department of Medicine,
University of Colorado School of Medicine, Aurora, CO, United States
(Knoepke) Division of Cardiology, Adult and Child Center for Outcomes
Research and Delivery Science (ACCORDS), Colorado Program for
Patient-Centered Decisions, University of Colorado School of Medicine,
Aurora, United States
(Korngold) Division of Cardiology, Providence Heart Institute, Portland,
OR, United States
(Kumbhani) Division of Cardiology, UT Southwestern Medical Center, Dallas,
TX, United States
(Matlock) Division of Geriatric Medicine, Department of Medicine,
University of Colorado School of Medicine, Aurora, CO, United States
(Matlock) VA Eastern Colorado Geriatric Research Education and Clinical
Center, Denver, CO, United States
(Strong) Heart Valve Voice-US, Washington, DC, United States
(Thourani) Department of Cardiovascular Surgery, Marcus Valve Center,
Piedmont Heart Institute, Atlanta, GA, United States
(Nathan) Division of Cardiovascular Medicine, University of Pennsylvania,
Philadelphia, PA, United States
(Quader) Cardiovascular Division, Department of Medicine, Washington
University in St. Louis, St. Louis, MO, United States
(Brescia) Division of Cardiothoracic Surgery, Washington University in St.
Louis, St. Louis, MO, United States
Publisher
BioMed Central Ltd
Abstract
Background: The American College of Cardiology, American Heart
Association, and Centers for Medicare and Medicaid Services recommend
shared decision-making (SDM) for patients with severe aortic stenosis
choosing between transcatheter aortic valve replacement (TAVR) and
surgical aortic valve replacement (SAVR). Although tools such as patient
decision aids (DAs) and training in SDM have been shown to improve SDM,
implementation of SDM and DAs is limited. The IMproving treatment
decisions for Patients with AortiC stenosis Through Shared Decision Making
(IMPACT SDM) study aims to (1) determine the effectiveness of the
interventions (a DA and clinician SDM training) in achieving SDM (primary
outcome) and improving the quality of decisions about aortic valve
replacement, (2) determine the reach of the DAs and adoption of training,
and (3) explore potential mechanisms of effectiveness and implementation
at the patient-, clinician-, and clinic-level. <br/>Method(s): The study
is a hybrid type II effectiveness-implementation study using a cluster
randomized batched stepped wedge trial with 8 sites across the USA.
Eligible patients will be surveyed before and after visits with the heart
valve team; clinicians will be surveyed after visits. Reach of DAs and
adoption of training will be tracked. Clinicians will be interviewed
regarding barriers and facilitators to implementation. <br/>Discussion(s):
The IMPACT SDM Study seeks to provide evidence of the ability of the
interventions to improve SDM and decision quality, and also to shed light
on barriers and facilitators to SDM implementation to promote future
implementation efforts. Trial registration: ClinicalTrials.gov
NCT06171737. Registered on December 15, 2023.<br/>Copyright &#xa9; The
Author(s) 2024.

<35>
Accession Number
2036606622
Title
Optimal Strategy for Complete Revascularization in ST-Segment Elevation
Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis.
Source
Journal of the American College of Cardiology. 85(1) (pp 19-38), 2025.
Date of Publication: 07 Jan 2025.
Author
Ueyama H.A.; Akita K.; Kiyohara Y.; Takagi H.; Briasoulis A.; Wiley J.;
Bangalore S.; Mehran R.; Stone G.W.; Kuno T.; Bhatt D.L.
Institution
(Ueyama) Division of Cardiology, Emory University School of Medicine,
Atlanta, GA, United States
(Akita) Division of Cardiology, Department of Medicine, Columbia
University Irving Medical Center, New York, NY, United States
(Kiyohara) Department of Medicine, The University of Tokyo Hospital,
Tokyo, Japan
(Kiyohara) Department of Medicine, Icahn School of Medicine at Mount
Sinai, Mount Sinai Morningside and West, New York, NY, United States
(Takagi) Division of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Briasoulis) Division of Cardiovascular Medicine, University of Iowa, Iowa
City, IA, United States
(Briasoulis) National and Kapodistrian University of Athens Medical
School, Athens, Greece
(Wiley) Section of Cardiology, Department of Medicine, Tulane University
School of Medicine, New Orleans, LA, United States
(Bangalore) Division of Cardiovascular Medicine, New York University
Grossman School of Medicine, New York, NY, United States
(Mehran, Stone, Bhatt) Mount Sinai Fuster Heart Hospital, Icahn School of
Medicine at Mount Sinai, New York, NY, United States
(Kuno) Cardiology Division, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, New York, NY, United States
Publisher
Elsevier Inc.
Abstract
Background: In patients with ST-segment elevation myocardial infarction
(STEMI) and multivessel coronary artery disease, most but not all
randomized trials have reported that complete revascularization (CR)
offers advantages over culprit vessel-only revascularization. In addition,
the optimal timing and assessment methods for CR remain undetermined.
<br/>Objective(s): The purpose of this study was to identify the optimal
revascularization strategy in patients with STEMI and multivessel disease,
using a network meta-analysis of randomized controlled trials.
<br/>Method(s): We searched PUBMED and EMBASE for randomized trials
evaluating revascularization strategies in patients with STEMI and
multivessel disease through July 2024. A network meta-analysis was
performed analyzing CR vs culprit vessel-only revascularization as well as
the timing of CR (immediate CR vs staged CR). Outcomes were also assessed
with 4 CR strategies based on whether revascularization was immediate or
staged and whether it was angiographically guided or functionally guided.
The primary outcome was major adverse cardiovascular events (MACE).
<br/>Result(s): A total of 26 randomized trials that enrolled 15,902
patients were included. The mean weighted duration of follow-up was 25.2
+/- 15.7 months. MACE was reduced with both immediate CR and staged CR
compared with culprit-vessel-only treatment (RR: 0.48; 95% CI: 0.36-0.64
and RR: 0.65; 95% CI: 0.52-0.82, respectively), whether with angiographic
or functional guidance. Immediate CR was associated with reduced MACE
compared with staged CR (RR: 0.74; 95% CI: 0.56-0.97), whether CR was
guided angiographically or functionally (RR: 0.77; 95% CI: 0.61-0.99 and
RR: 0.49; 95% CI: 0.27-0.89, respectively) caused by reductions in MI.
However, when the analysis was restricted to studies that reported both
all MI and nonprocedural MI, the benefit of immediate CR in reducing MI
compared with staged CR was diminished after excluding procedural MI (RR:
0.44; 95% CI: 0.27-0.71 with procedural MI vs RR: 0.65; 95% CI: 0.36-1.16
without procedural MI). <br/>Conclusion(s): Among patients with STEMI and
multivessel disease, outcomes were better with immediate or staged CR
compared with culprit vessel-only treatment, whether with angiographic or
functional guidance.<br/>Copyright &#xa9; 2025 American College of
Cardiology Foundation

<36>
Accession Number
2036052682
Title
Reduction of Coronary Flow Velocity Reserve as the Main Driver of
Prognostically Beneficial Coronary Revascularization.
Source
Journal of the American Society of Echocardiography. 38(1) (pp 24-32),
2025. Date of Publication: January 2025.
Author
Cortigiani L.; Gaibazzi N.; Ciampi Q.; Rigo F.; Tuttolomondo D.; Bovenzi
F.; Gregori D.; Carerj S.; Pepi M.; Pellikka P.A.; Picano E.
Institution
(Cortigiani, Bovenzi) Cardiology Division, San Luca Hospital, Lucca, Italy
(Gaibazzi, Tuttolomondo) Cardiology Department, Parma University Hospital,
Parma, Italy
(Ciampi) Cardiology Division, Fatebenefratelli Hospital, Benevento, Italy
(Rigo) Cardiology Division, Villa Salus Hospital, Mestre, Italy
(Gregori) Biostatistics, Epidemiology and Public Health Unit, Padova
University, Padova, Italy
(Carerj) Divisione di cardiologia, Policlinico Universitario, Universita
di Messina, Messina, Italy
(Pepi) Centro Cardiologico Monzino, IRCCS, Milan, Italy
(Pellikka) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
MN, United States
(Picano) Cardiology Clinic, University Center Serbia, Medical School,
University of Belgrade, Belgrade, Serbia
Publisher
Elsevier Inc.
Abstract
Background: Regional wall motion abnormality (RWMA) can be absent during
stress echocardiography (SE) in patients with chronic coronary syndromes
(CCS) and angiographically significant coronary artery disease (CAD)
despite a reduction of coronary flow velocity reserve (CFVR).
<br/>Objective(s): To assess the value of a physiology-driven approach,
based on CFVR, to coronary revascularization in patients with
physiologically and anatomically significant disease of the left anterior
descending (LAD) coronary artery. <br/>Method(s): In a 3-center,
observational study with retrospective analysis of prospectively acquired
data, 749 patients with CCS, CFVR of the LAD <=2.0, and >=50% diameter
stenosis of the LAD were enrolled. All patients were evaluated with
dipyridamole (0.84 mg/kg in 6') SE. Patients were followed for 6.4 +/- 4.5
years for the outcome of all-cause death. <br/>Result(s): Inducible RWMA
was present in 295 patients (39%). Coronary flow velocity reserve was
lower in patients with inducible RWMA compared to those without (1.51 +/-
0.28 vs 1.65 +/- 0.25; P <.001). Coronary revascularization was performed
in 514 (69%) patients (388 with percutaneous coronary intervention, 126
with coronary artery bypass surgery). Of them, 226 exhibited inducible
RWMA and 288 exhibited isolated reduction of CFVR. During the follow-up,
185 (25%) deaths occurred. The 10-year survival in the entire study
population was 70%. The survival at 10 years was markedly lower in
conservatively treated patients compared to invasively treated patients
(53 vs 76%; P <.0001), with no significant difference between those with
solitary reduction of CFVR and reduction of CFVR accompanied by concurrent
inducible RWMA. Propensity score-weighted all-cause mortality risk was
significantly higher for conservative than for invasive strategy
(propensity score adjusted hazard ratio = 2.12; 95% CI, 1.51-2.96; P
<.0001). <br/>Conclusion(s): In patients with CCS and physiologically and
anatomically significant LAD disease, coronary revascularization driven by
a reduction in CFVR is accompanied by a prognostic benefit independently
of the presence of inducible RWMA.<br/>Copyright &#xa9; 2024

<37>
Accession Number
2035902137
Title
Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of
the SOLVE-TAVI Trial.
Source
Journal of the American College of Cardiology. 85(1) (pp 74-82), 2025.
Date of Publication: 07 Jan 2025.
Author
Feistritzer H.-J.; Kurz T.; Vonthein R.; Schroder L.; Stachel G.; Eitel
I.; Marquetand C.; Saraei R.; Kirchhof E.; Heringlake M.; Abdel-Wahab M.;
Desch S.; Thiele H.
Institution
(Feistritzer, Stachel, Abdel-Wahab, Desch, Thiele) Heart Center Leipzig at
University of Leipzig, Leipzig, Germany
(Kurz, Eitel, Marquetand, Saraei, Heringlake) University Heart Center
Lubeck, Lubeck, Germany
(Kurz, Eitel, Marquetand, Saraei, Heringlake, Desch) German Center for
Cardiovascular Research (DZHK), Partner Site Hamburg-Kiel-Lubeck, Lubeck,
Germany
(Vonthein, Schroder) Institute of Medical Biometry and Statistics, Lubeck,
Germany
(Stachel) Clinic and Policlinic for Cardiology, Leipzig University Clinic,
Leipzig, Germany
(Kirchhof) Helios Health Institute, Leipzig, Germany
Publisher
Elsevier Inc.
Abstract
Background: In the randomized SOLVE-TAVI (compariSon of secOnd-generation
seLf-expandable vs. balloon-expandable Valves and gEneral vs. local
anesthesia in Transcatheter Aortic Valve Implantation) trial comparing
newer-generation self-expanding valves (SEV) and balloon-expandable valves
(BEV), as well as conscious sedation (CS) and general anesthesia (GA),
clinical outcomes were similar both for valve and anesthesia comparison at
30 days and 1 year. Prosthesis durability may affect clinical outcomes
during long-term follow-up. Moreover, the impact of the anesthesia
strategy on long-term clinical outcomes is unknown so far.
<br/>Objective(s): The authors sought to compare clinical outcomes during
5-year follow-up in the randomized SOLVE-TAVI trial. <br/>Method(s): In
the randomized, multicenter, 2 x 2 factorial, open-label SOLVE-TAVI trial,
447 intermediate- to high-risk patients with severe, symptomatic aortic
stenosis were randomly assigned to transfemoral transcatheter aortic valve
replacement (TAVR) using either SEV (Evolut R, Medtronic) or BEV (SAPIEN
3, Edwards Lifesciences) and also to CS vs GA. Patients were followed-up
for 5 years. <br/>Result(s): During 5 years of follow-up, the combined
predefined endpoint of all-cause mortality, stroke, moderate or severe
paravalvular leakage, and permanent pacemaker implantation was similar in
the SEV and BEV groups (67.7% vs 63.4%; HR: 0.89; 95% CI: 0.70-1.13; P =
0.34). Stroke rates at 5 years were lower in the SEV group (2.2% vs 9.6%;
HR: 4.84; 95% CI: 1.65-14.18; P = 0.002). Regarding the anesthesia
comparison, the primary endpoint of all-cause mortality, stroke,
myocardial infarction, and acute kidney injury occurred in 51.4% in the CS
group and 61.3% in the GA group (HR: 0.80; 95% CI: 0.62-1.04; P = 0.09).
All-cause mortality at 5 years was lower for CS (41.5% vs 54.3%; HR: 0.70;
95% CI: 0.53-0.94; P = 0.02). <br/>Conclusion(s): Transfemoral TAVR using
either SEV and BEV as well as CS and GA showed similar clinical outcomes
at 5 years using a combined clinical endpoint.<br/>Copyright &#xa9; 2025
American College of Cardiology Foundation

<38>
Accession Number
2035829849
Title
Drug-Coated Balloon Angioplasty of the Side Branch During Provisional
Stenting: The Multicenter Randomized DCB-BIF Trial.
Source
Journal of the American College of Cardiology. 85(1) (pp 1-15), 2025. Date
of Publication: 07 Jan 2025.
Author
Gao X.; Tian N.; Kan J.; Li P.; Wang M.; Sheiban I.; Figini F.; Deng J.;
Chen X.; Santoso T.; Shin E.-S.; Munawar M.; Wen S.; Wang Z.; Nie S.; Li
Y.; Xu T.; Wang B.; Ye F.; Zhang J.; Shou X.; Chen S.-L.
Institution
(Gao, Tian, Kan, Ye, Zhang, Chen) Nanjing First Hospital, Nanjing Medical
University, Nanjing, China
(Li) Yulin First People's Hospital, Yulin, China
(Wang) West China Hospital, Sichuan University, Chengdu, China
(Sheiban, Figini) Pederzoli Hospital, Peschiera del Garda, Verona, Italy
(Deng) Nanchong Municipal Central Hospital, Nanchong, China
(Chen) Xiamen Heart Center, Xiamen University, Xiamen, China
(Santoso) Medistra Hospital, Medistra University, Jakarta, Indonesia
(Shin) Ulsan University Hospital, University of Ulsan College of Medicine,
Ulsan, South Korea
(Munawar) Binawaluya Cardiac Center, Jakarta, Indonesia
(Wen) Tianjin Fourth Central Hospital, Tianjin, China
(Wang) Qingdao Municipal Hospital, Qingdao, China
(Nie) Beijing Anzhen Hospital, Capital Medical University, Beijing, China
(Li) First Hospital, Harbin Medical University, Harbin, China
(Xu) Xinyang Central Hospital, Xinyang, China
(Wang) School of Medicine, Shantou University, Shantou, China
(Shou) Shaanxi Provincial People's Hospital, Xi'an, China
Publisher
Elsevier Inc.
Abstract
Background: Side branch stenting is often required during provisional
stenting, leading to suboptimal results. Drug-coated balloons (DCB) for
the compromised side branch have emerged as an attractive strategy.
However, the benefit of DCB for coronary bifurcations remains unclear.
<br/>Objective(s): This study aimed to investigate whether DCB, compared
with a noncompliant balloon (NCB), for the pinched side branch improves
the outcomes of provisional stenting in patients with simple, true
coronary bifurcations. <br/>Method(s): In this multicenter, randomized
controlled trial, patients with true coronary bifurcations who had side
branch diameter stenosis of >=70% after main vessel stenting at 22 centers
in China, Indonesia, Italy, and Korea were randomly assigned to either DCB
or NCB intervention. The primary endpoint was major adverse cardiac
events, a composite of cardiac death, target vessel myocardial infarction,
or clinically driven target-lesion revascularization at the 1-year
follow-up. <br/>Result(s): Between September 8, 2020, and June 2, 2023,
784 patients with true coronary bifurcation lesions undergoing main vessel
stenting and having a severely compromised side branch were randomly
assigned to the DCB (n = 391) or NCB (n = 393) group. One-year follow-up
was completed in all patients. The primary endpoint occurred in 28
patients in the DCB group and 49 patients in the NCB group (Kaplan-Meier
rate: 7.2% vs 12.5%; HR: 0.56; 95% CI: 0.35-0.88; P = 0.013), driven by a
reduction in myocardial infarction. There were no significant differences
between groups in procedural success, crossover to a 2-stent approach,
all-cause death, revascularization, or stent thrombosis.
<br/>Conclusion(s): In patients with simple and true coronary bifurcation
lesions undergoing provisional stenting, main vessel stenting with a DCB
for the compromised side branch resulted in a lower 1-year rate of the
composite outcome compared with an NCB intervention for the side branch.
The high rates of periprocedural myocardial infarction, which occurred
early and did not lead to revascularization, are of unclear clinical
significance.<br/>Copyright &#xa9; 2025 American College of Cardiology
Foundation

<39>
Accession Number
2031764386
Title
Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent
Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal
Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109.
Source
Annals of Surgical Oncology. 32(1) (pp 293-301), 2025. Article Number:
e3839. Date of Publication: January 2025.
Author
Matsuda S.; Takeuchi H.; Kato K.; Machida R.; Ito Y.; Tsubosa Y.; Daiko
H.; Koyanagi K.; Ogata T.; Fukuda T.; Fujita T.; Abe T.; Bamba T.;
Watanabe M.; Kawakubo H.; Shibuya Y.; Otsubo D.; Kakisita T.; Hashimoto
T.; Sasaki K.; Kitagawa Y.
Institution
(Matsuda, Kawakubo, Kitagawa) Department of Surgery, Keio University
School of Medicine, Tokyo, Japan
(Takeuchi) Department of Surgery, Hamamatsu University School of Medicine,
Hamamatsu, Japan
(Kato) Department of Head and Neck and Esophageal Medical Oncology,
National Cancer Center Hospital, Tokyo, Japan
(Machida, Hashimoto, Sasaki) Japan Clinical Oncology Group Data Center,
National Cancer Center Hospital, Tokyo, Japan
(Ito) Department of Radiation Oncology, Showa University School of
Medicine, Tokyo, Japan
(Tsubosa) Division of Esophageal Surgery, Shizuoka Cancer Center,
Nagaizumi, Japan
(Daiko) Department of Esophageal Surgery, National Cancer Center Hospital,
Tokyo, Japan
(Koyanagi) Department of Gastroenterological Surgery, Tokai University
School of Medicine, Isehara, Japan
(Ogata) Department of Gastrointestinal Surgery, Kanagawa Cancer Center,
Yokohama, Japan
(Fukuda) Department of Gastrointestinal Surgery, Saitama Cancer Center,
Saitama, Japan
(Fujita) Division of Esophageal Surgery, National Cancer Center Hospital
East, Kashiwa, Japan
(Abe) Department of Gastroenterological Surgery, Aichi Cancer Center,
Nagoya, Japan
(Bamba) Department of Gastroenterological Surgery, Niigata Cancer Center,
Niigata, Japan
(Watanabe) Department of Gastroenterological Surgery, The Cancer Institute
Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
(Shibuya) Department of Gastroenterological Surgery, Kochi Health Science
Center, Kochi, Japan
(Otsubo) Department of Gastroenterological Surgery, Hyogo Cancer Center,
Akashi, Japan
(Kakisita) Department of Surgery, Shikoku Cancer Center, Matsumoto, Japan
(Hashimoto) Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East, Kashiwa, Japan
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Although several studies have investigated whether thoracic
duct (TD) resection improves prognosis, the conclusion remains
controversial. JCOG1109 is a three-arm randomized phase III trial to
confirm the survival advantage of docetaxel, cisplatin, 5-fluorouracil
(DCF), and cisplatin plus 5-fluorouracil (CF) combined with radiotherapy
(CF-RT) over CF as neoadjuvant treatment. The study aimed to evaluate the
survival impact of TD resection and its association with neoadjuvant
treatment and pathological response in patients enrolled in JCOG1109.
<br/>Patients and Methods: Clinicopathological factors, surgical results,
and prognosis were compared between TD preserved and resected groups. The
survival impact of TD resection was also evaluated in the subgroups on the
basis of combinations of preoperative therapy and pathological response.
<br/>Result(s): Between December 2012 and July 2018, 601 patients were
randomized (CF/DCF/CF-RT; 199/202/200) in JCOG1109. Of them, 541 patients
underwent esophagectomy (183/181/177), and TD was resected in 265 patients
(93/91/81). For the entire cohort, TD resection was not a significant
prognostic factor for overall survival in the multivariable analysis (HR
1.20, 95% CI 0.91-1.57). In the subgroup analyses by combinations of
neoadjuvant treatment and pathological response, TD resected group had a
significantly better overall survival compared with TD preserved group in
patients who received DCF and achieved pathological response (HR 0.20, 95%
CI 0.07-0.61). <br/>Conclusion(s): The survival benefit of TD resection
was not demonstrated in patients with surgically resectable esophageal
squamous cell carcinoma enrolled in JCOG1109. The residual tumor burden
after neoadjuvant treatment might be linked to the survival impact of TD
resection.<br/>Copyright &#xa9; Society of Surgical Oncology 2024.

<40>
Accession Number
2036692737
Title
Left atrial strain predicts long-term heart failure outcomes after
ST-elevation myocardial infarction.
Source
International Journal of Cardiology. 422 (no pagination), 2025. Article
Number: 132931. Date of Publication: 01 Mar 2025.
Author
Ricken K.W.L.M.; Lenselink C.; Venema C.S.; van der Horst I.C.C.; van der
Harst P.; Pundziute-Do Prado G.; Voors A.A.; Lipsic E.
Institution
(Ricken, Lenselink, Venema, Pundziute-Do Prado, Voors, Lipsic) Department
of Cardiology, University Medical Center Groningen, Hanzeplein 1,
Groningen 9713 GZ, Netherlands
(van der Horst) Department of Intensive Care Medicine, Maastricht
University Medical Center, Maastricht, Netherlands
(van der Horst) Cardiovascular Research Institute (CARIM), Maastricht
University, Universiteitssingel 50, Maastricht 6229 ER, Netherlands
(van der Harst) Department of Cardiology, University Medical Center
Utrecht, Heidelberglaan 100, Utrecht 3584 CX, Netherlands
Publisher
Elsevier Ireland Ltd
Abstract
Background: Left atrial (LA) strain reflects not only LA function but also
systolic and diastolic left ventricular function. We therefore hypothesize
that LA strain may be a comprehensive predictor of heart failure related
endpoints after ST-elevation myocardial infarction (STEMI). We aim to
assess the impact of LA reservoir strain on the long-term prognosis
following ST-elevation myocardial infarction (STEMI). Method and results:
LA strain was measured in 287 first-time STEMI patients using
two-dimensional speckle tracking echocardiography at hospitalization.
Patients were categorized according to quartiles of LA reservoir strain
for the analysis of population characteristics and assessment of
event-free survival. Predictors of the composite heart failure endpoint of
cardiac death, heart failure hospitalization, and new-onset heart failure
were identified using Cox regression. The study population was 57.8 +/-
11.3 years of age and predominantly male (74.6 %). After a median
follow-up of 8.8 years, 33 (11.5 %) patients reached the composite
endpoint. Mean LA reservoir strain was 27.5 +/- 7.97 %. Patients with
lower LA reservoir strain were older (p = 0.003) and had a lower left
ventricular ejection fraction (LVEF, p < 0.001) at admission. Independent
predictors for the composite endpoint were higher age (HR = 1.07, p =
0.001), lower LVEF (HR = 0.94, p = 0.015), lower diastolic blood pressure
(HR = 0.97, p = 0.034), and lower LA reservoir strain (HR = 0.90, p =
0.003). Adding LA reservoir strain to a clinical risk prediction model
significantly improved its performance (C-statistic 0.838 vs. 0.784, p =
0.003). <br/>Conclusion(s): The LA reservoir strain has incremental value
in the prediction of long-term heart failure outcomes in patients after a
first STEMI.<br/>Copyright &#xa9; 2024

<41>
Accession Number
2032694755
Title
The efficacy of colchicine compared to placebo for preventing ischemic
stroke among individuals with established atherosclerotic cardiovascular
diseases: a systematic review and meta-analysis.
Source
Scandinavian Cardiovascular Journal. 59(1) (no pagination), 2025. Article
Number: 2441112. Date of Publication: 2025.
Author
Zhu S.; Pan W.; Yao Y.; Shi K.
Institution
(Zhu) Department of Neurology, The Second Hospital of Liaocheng Affiliated
to Shandong First Medical University, Linqing, China
(Pan, Shi) Department of Cadre Health Care, Qingdao Municipal Hospital,
Qingdao, China
(Yao) Department of Cardiology, Qingdao Hiser Hospital Affiliated of
Qingdao University (Qingdao Traditional Chinese Medicine Hospital),
Qingdao, China
Publisher
Taylor and Francis Ltd.
Abstract
Background. Colchicine is an anti-inflammatory drug with promising
efficacy for preventing cardiovascular events. We aimed to assess the
pooled effect of colchicine on ischemic stroke among patients with
established atherosclerotic cardiovascular diseases. Methods. PubMed,
Scopus, Web of Science, and the Cochrane Library were systematically
searched from the inception to August 5, 2024. A random-effects
(DerSimonian-Laird) model was used to conduct this meta-analysis. The
inclusion criteria were as follows: (I) being a randomized controlled
trial; and (II) measuring the efficacy of colchicine compared to placebo
for preventing ischemic stroke among those with established
atherosclerotic cardiovascular diseases. Results. We identified 13
eligible clinical trials with 24900 participants. Colchicine significantly
decreased the risk of ischemic stroke (relative risk (RR) 0.85, 95%
confidence interval (CI) (0.72, 0.99), I²=2.92%) among those
with established atherosclerotic cardiovascular diseases. Colchicine was
more effective when used at 0.5 mg/day (RR 0.86, 95% CI (0.75, 0.99)),
prescribed for more than 30 days (RR 0.86, 95% CI (0.75, 1.00)) or for
more than 90 days (RR 0.65, 95% CI (0.46, 0.92)), or administered for
patients with acute coronary syndrome (RR 0.46, 95% CI (0.23, 0.92)). In
addition, colchicine was more effective in studies with a sample size of
more than 500 patients, consistent with sensitivity analysis, which
indicated that the results relied on large-sized clinical trials.
Conclusion. Colchicine may decrease the risk of ischemic stroke among
patients with established atherosclerotic cardiovascular diseases,
particularly after long-term use; however, future studies are needed due
to inconsistencies between existing trials.<br/>Copyright &#xa9; 2024 The
Author(s). Published by Informa UK Limited, trading as Taylor & Francis
Group.

<42>
Accession Number
2036564843
Title
Sarcopenia and risk of postoperative pneumonia: a systematic review and
meta-analysis.
Source
Journal of Nutrition, Health and Aging. 29(3) (no pagination), 2025.
Article Number: 100457. Date of Publication: March 2025.
Author
Shu X.; Song Q.; Huang X.; Tang T.; Huang L.; Zhao Y.; Lin T.; Xu P.; Yu
P.; Yue J.
Institution
(Shu, Song, Huang, Tang, Huang, Zhao, Lin, Yue) Department of Geriatrics,
West China Hospital, Sichuan University, Sichuan, Chengdu, China
(Shu, Song, Huang, Tang, Huang, Zhao, Lin, Yue) Department of National
Clinical Research Center for Geriatrics, West China Hospital, Sichuan
University, Sichuan Province, Chengdu, China
(Xu, Yu) Department of Biomedical Engineering, Sichuan University Library,
Sichuan, Chengdu, China
Publisher
Elsevier B.V.
Abstract
Background: Identifying patients at risk for postoperative pneumonia and
preventing it in advance is crucial for improving the prognoses of
patients undergoing surgery. This review aimed to interpret the predictive
value of sarcopenia on postoperative pneumonia. <br/>Method(s): Science
Citation Index Expanded (SCIE), Embase, Medline, and Cochrane Central
Register of Controlled Trials were searched from inception to August 2nd,
2023 to retrieve eligible studies. The risk of bias was assessed by the
Newcastle-Ottawa Scale (NOS). For each study, we computed the odds ratio
(OR) and 95% confidence interval (CI) for postoperative pneumonia in
patients with and without preoperative sarcopenia, and the I-squared
(I²) test was employed to estimate heterogeneity.
<br/>Result(s): The search identified 6530 studies, and 32 studies
including 114,532 participants were analyzed in this review. In most of
the studies included, the risk of bias was moderate. The most reported
surgical site was the chest and abdomen, followed by the abdomen, chest,
limbs and spine, and head and neck. Overall, patients with preoperative
sarcopenia have a 2.62-fold increased risk of developing postoperative
pneumonia compared to non-sarcopenic patients [OR 2.62 (I² =
67.5%, 95%CI 2.04-3.37). Subgroup analysis focusing on different surgical
sites revealed that sarcopenia has the strongest predictive effect on
postoperative pneumonia following abdominal surgery (OR 4.69,
I² = 0, 95% CI 3.06-7.19). Subgroup analyses targeting
different types of research revealed that sarcopenia has a stronger
predictive effect on postoperative pneumonia in prospective studies (OR
5.84 vs. 2.22). <br/>Conclusion(s): Our research findings indicate that
preoperative sarcopenia significantly increases the risk of postoperative
pneumonia. Future high-quality prospective studies and intervention
studies are needed to validate the relationship between sarcopenia and
postoperative pneumonia and improve patient outcomes.<br/>Copyright &#xa9;
2024 The Authors

<43>
Accession Number
2036547446
Title
Prophylactic ablation during cardiac surgery in patients without atrial
fibrillation: a systematic review and meta-analysis of randomized trials.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 39(6) (no
pagination), 2024. Article Number: ivae195. Date of Publication: 01 Dec
2024.
Author
Visanji M.; Belley-Cote E.P.; Pandey A.; Amit Y.; McClure G.R.; Young J.;
Um K.J.; Oraii A.; Healey J.S.; Whitlock R.P.; McIntyre W.F.
Institution
(Visanji, Belley-Cote, Um, Healey, McIntyre) Department of Medicine,
McMaster University, Hamilton, ON, Canada
(Belley-Cote, McClure, Um, Oraii, Healey, Whitlock, McIntyre) Population
Health Research Institute, Hamilton, ON, Canada
(Pandey) Department of Pharmacology and Toxicology, University of Toronto,
Toronto, ON, Canada
(Amit) Department of Physiology, McGill University, Montreal, QC, Canada
(McClure, Whitlock) Department of Surgery, McMaster University, Hamilton,
ON, Canada
(Young) Health Sciences Library, McMaster University, Hamilton, ON, Canada
Publisher
Oxford University Press
Abstract
OBJECTIVES. Atrial fibrillation is the most common complication of cardiac
surgery and occurs frequently in patients without a history of the
arrhythmia. We conducted a systematic review and meta-analysis of
randomized controlled trials to assess whether prophylactic ablation
during cardiac surgery in patients without a history of atrial
fibrillation prevents atrial fibrillation. METHODS. We searched CENTRAL,
MEDLINE and Embase from inception to August 2024. We included randomized
trials of adults without a history of atrial fibrillation undergoing
cardiac surgery. The intervention of interest was ablation during surgery.
We pooled data using random-effects models. The primary outcome was
new-onset early postoperative atrial fibrillation within 30days following
surgery. The key secondary outcome was incident clinical atrial
fibrillation at follow-up (minimum 6months). We assessed risk of bias
using the Cochrane Collaboration's risk of bias tool v.2 and evidence
quality using Grading of Recommendations, Assessment, Development and
Evaluation (GRADE). RESULTS. We included 7 trials (n=687). The
intervention was pulmonary vein isolation in 6 trials and ganglion plexi
ablation in 1. Patients who received prophylactic ablation were less
likely to have early postoperative atrial fibrillation (21% vs 37%, risk
ratio [RR] 0.5, 95% confidence interval 0.3-0.8, I² = 64%) and
incident clinical atrial fibrillation at longest follow-up (range
6months-2years; 3% vs 10%, RR 0.3, 95% confidence interval 0.2-0.7,
I² = 0%). The quality of evidence was low. CONCLUSIONS.
Prophylactic ablation during cardiac surgery may prevent atrial
fibrillation in patients without a history of the arrhythmia. A definitive
randomized trial is needed to confirm effects and safety.<br/>Copyright
&#xa9; The Author(s) 2024.

<44>
Accession Number
2036536142
Title
Cost-effectiveness of intravascular ultrasound-guided percutaneous
intervention in patients with acute coronary syndromes: a UK perspective.
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 10(8) (pp
677-688), 2024. Date of Publication: 01 Dec 2024.
Author
Sharp A.S.P.; Kinnaird T.; Curzen N.; Ayyub R.; Alfonso J.E.; Mamas M.A.;
Baviere H.V.
Institution
(Sharp, Kinnaird) University Hospital of Wales, Cardiff and Cardiff
University CF103AT, United Kingdom
(Curzen) University Hospital Southampton NHS Foundation Trust, School of
Medicine, University of Southampton, Southampton SO171BJ, United Kingdom
(Ayyub, Alfonso) Deloitte, Brussels 1930, Belgium
(Mamas) Keele Cardiovascular Research Group, Keele University,
Stoke-on-Trent ST55BG, United Kingdom
(Baviere) Chief Medical Office, Health Economic & Outcomes Research,
Amsterdam 1096BC, Netherlands
(Baviere) Erasmus University College, Brussels 1090, Belgium
Publisher
Oxford University Press
Abstract
Background Use of intravascular ultrasound (IVUS) during percutaneous
coronary intervention (PCI) is associated with improved clinical outcomes
over angiography alone. Despite this, the adoption of IVUS in clinical
practice remains low. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . Aims To examine the cost-effectiveness of
IVUS-guided PCI compared to angiography alone in patients with acute
coronary syndromes (ACS). . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . Methods and A 1-year decision tree and
lifetime Markov model were constructed to compare the cost-effectiveness
of IVUS-guided results PCI to angiography alone for two hypothetical adult
populations consisting of 1000 individuals: ST-elevation myocardial
infarction (STEMI) and unstable angina/non-ST-elevation myocardial
infarction (UA/NSTEMI) patients undergoing drug-eluting stent (DES)
implantation. The United Kingdom (UK) healthcare system perspective was
applied using 2019/20 costs. All-cause death, myocardial infarction (MI),
repeat PCI, lifetime costs, life expectancy, and quality-adjusted
life-years (QALYs) were assessed. Over a lifetime horizon, IVUS-guided PCI
was cost-effective compared to angiography alone in both populations,
yielding an incremental cost-effectiveness ratio of 3649 and 5706
per-patient in STEMI and UA/NSTEMI patients, respectively. In the 1-year
time horizon, the model suggested that IVUS was associated with reductions
in mortality, MI, and repeat PCI by 51%, 33%, and 52% in STEMI and by 50%,
29%, and 57% in UA/NSTEMI patients, respectively. Sensitivity analyses
demonstrated the robustness of the model with IVUS being 100%
cost-effective at a willingness to pay threshold of 20 000 per
QALY-gained. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . Conclusions From a UK healthcare perspective, an
IVUS-guided PCI strategy was highly cost-effective over angiography alone
amongst ACS patients undergoing DES implantation due to the medium- and
long-term reduction in repeat PCI, death, and MI.<br/>Copyright &#xa9; The
Author(s) 2023. Published by Oxford University Press on behalf of the
European Society of Cardiology.

<45>
Accession Number
2036505119
Title
Remote ischemic preconditioning and cognitive dysfunction following
coronary artery bypass grafting: A systematic review and meta-analysis of
randomized controlled trials.
Source
Saudi Journal of Anaesthesia. 18(2) (pp 187-193), 2024. Date of
Publication: 2024.
Author
Siburian R.; Fadillah R.; Altobaishat O.; Umar T.P.; Dilawar I.; Nugroho
D.T.
Institution
(Siburian) Research Unit, Jakarta Heart Center, Jakarta, Indonesia
(Fadillah) Department of Medical Profession, Faculty of Medicine,
Universitas Sriwijaya, Palembang, Indonesia
(Altobaishat) Faculty of Medicine, Jordan University of Science and
Technology, Irbid, Jordan
(Umar) UCL Centre for Nanotechnology and Regenerative Medicine, Division
of Surgery and Interventional Science, University College London, London,
United Kingdom
(Dilawar, Nugroho) Division of Cardiothoracic Surgery, Jakarta Heart
Center, Jakarta, Indonesia
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Postoperative cognitive dysfunction (POCD) is a common
neurological issue following cardiopulmonary bypass (CPB)-assisted heart
surgery. Remote ischemic preconditioning (RIPC) increases the tolerance of
vital organs to ischemia/reperfusion injury, leading to reduced brain
injury biomarkers and improved cognitive control. However, the exact
mechanisms underlying RIPC's neuroprotective effects remain unclear. This
systematic review aimed to explore the hypothesis that RIPC lowers
neurocognitive dysfunction in patients undergoing CPB surgery.
<br/>Method(s): All relevant studies were searched in PubMed,
ScienceDirect, EBSCOhost, Google Scholar, Semantic Scholar, Scopus, and
Cochrane Library database. Assessment of study quality was carried out by
two independent reviewers individually using the Cochrane Risk of Bias
(RoB-2) tool. Meta-analysis was performed using a fixed-effect model due
to low heterogeneity among studies, except for those with substantial
heterogeneity. <br/>Result(s): A total of five studies with 1,843
participants were included in the meta-analysis. RIPC was not associated
with reduced incidence of postoperative cognitive dysfunction (five RCTs,
odds ratio [OR: ] 0.79, 95% confidence interval [CI]: 0.56-1.11) nor its
improvement (three RCTs, OR: 0.80, 95% CI: 0.50-1.27). In addition, the
analysis of the effect of RIPC on specific cognitive function tests found
that pooled SMD for RAVLT 1-3 and RAVLT LT were -0.07 (95% CI: -0.25,012)
and -0.04 (95% CI: -0.25-0.12), respectively, and for VFT semantic and
phonetic were -0.15 (95% CI: -0.33-0.04) and 0.11 (95% CI: -0.40-0.62),
respectively. <br/>Conclusion(s): The effect of RIPC on cognitive
performance in CABG patients remained insignificant. Results from previous
studies were unable to justify the use of RIPC as a neuroprotective agent
in CABG patients.<br/>Copyright &#xa9; 2024 Saudi Journal of Anesthesia.

<46>
Accession Number
2031816579
Title
Secondary anti-viral prophylaxis in solid organ transplant recipients for
the prevention of cytomegalovirus relapse: A systematic review and
meta-analysis.
Source
Transplant Infectious Disease. 26(6) (no pagination), 2024. Article
Number: e14393. Date of Publication: December 2024.
Author
Moynan D.; Higgins E.; Passerini M.; Prokop L.J.; Murad M.H.; Razonable
R.R.
Institution
(Moynan) Department of Infectious Diseases, Mater Misericordiae University
Hospital, Dublin, Ireland
(Higgins) Department of Infectious Diseases, University Hospital Galway,
Galway, Ireland
(Passerini) Department of Pathophysiology and Transplantation, University
of Milano, Milan, Italy
(Passerini) Department of Infectious Diseases, ASST FBF SACCO
Fatebenefratelli, Milan, Italy
(Prokop) Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, United States
(Murad) Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, United
States
(Murad, Razonable) Department of Medicine, Division of Public Health,
Infectious Diseases and Occupational Medicine and the William J. von
Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic,
Rochester, MN, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Cytomegalovirus (CMV) is a significant cause of morbidity and
mortality in solid organ transplant recipients (SOTRs). Secondary
prophylaxis (SP) is not routinely recommended by guidelines on the
management of CMV in SOTR but may be considered in certain higher-risk
situations. <br/>Method(s): A comprehensive search of English language
publications up to September 2023 was performed. The primary outcome was
CMV relapse, defined as the recurrence of DNAemia or disease. Secondary
outcomes included graft loss, mortality, and hematological toxicity.
Meta-analysis used the random-effects model. The study protocol is
registered in PROSPERO (no. CRD42022357028). <br/>Result(s): Six
retrospective comparative studies were included. A total of 520/727 (72%)
of SOTR received SP with valganciclovir. The meta-analysis did not
demonstrate a significant difference in CMV relapse (odds ratio [OR] 1.15,
95% confidence interval [CI] 0.79-2.63). Heterogeneity between the studies
was low (I² = 0%, p = 0.57). SP was significantly associated
with a reduction in mortality (OR 0.2, 95% CI 0.07-0.54) but not graft
loss (OR 0.67, 0.17-2.63). There was no significant difference in CMV
relapse among kidney-specific SOTR (OR 1.38, 95% CI 0.65-2.96).
<br/>Conclusion(s): Evidence from six nonrandomized studies is limited and
cannot support a recommendation for or against routine SP in SOTR treated
for CMV infection. Awaiting prospective-controlled trials, the decision
about SP should depend on individualized risk-profile assessments by
experienced clinicians. (Figure presented.).<br/>Copyright &#xa9; 2024 The
Author(s). Transplant Infectious Disease published by Wiley Periodicals
LLC.

<47>
Accession Number
2029068341
Title
Perioperative Pain Management for Thoracic Surgery: A Multi-Layered
Approach.
Source
Seminars in Cardiothoracic and Vascular Anesthesia. 28(4) (pp 215-229),
2024. Date of Publication: December 2024.
Author
Tong L.; Solla C.; Staack J.B.; May K.; Tran B.
Institution
(Tong, Tran) Virginia Commonwealth University, Richmond, VA, United States
(Solla, Staack, May) University of Tennessee, Knoxville, TN, United States
Publisher
SAGE Publications Inc.
Abstract
Cardiothoracic surgeries frequently pose unique challenges in the
management of perioperative acute pain that require a multifaceted and
personalized approach in order to optimize patient outcomes. This article
discusses various analgesic strategies including regional anesthesia
techniques such as thoracic epidurals, erector spinae plane blocks, and
serratus anterior plane blocks and underscores the significance of
perioperative multimodal medications, while providing nuanced
recommendations for their use. This article further attempts to provide
evidence for the efficacy of the different modalities and compares the
effectiveness of the choice of analgesia. The roles of Acute Pain Services
(APS) and Transitional Pain Services (TPS) in mitigating opioid dependence
and chronic postsurgical pain are also discussed. Precision medicine is
also presented as a potential way to offer a patient tailored analgesic
strategy. Supported by various randomized controlled trials and
meta-analyses, the article concludes that an integrated, patient-specific
approach encompassing regional anesthesia and multimodal medications,
while also utilizing the services of the Acute Pain Service can help to
enhance pain management outcomes in cardiothoracic surgery.<br/>Copyright
&#xa9; The Author(s) 2024.

<48>
Accession Number
2035271826
Title
Prevention of pulmonary embolism through the prism of Systematic reviews
and meta-analyses.
Source
Salus. 28(3) (pp 34-39), 2024. Date of Publication: September-December
2024.
Author
Baysekeev T.A.; Derkembaeva Z.S.; Choi E.D.; Kydyrbaev A.K.; Zholborsov
A.A.; Kaliev Z.Y.; Jaxymbaev N.B.; Turkmenov A.A.
Institution
(Baysekeev, Derkembaeva, Kydyrbaev, Zholborsov, Turkmenov) Akhunbaev
Kyrgyz State Medical Academy, Bishkek, Kyrgyztan
(Choi) Royal Metropolitan University, Bishkek, Kyrgyztan
(Kaliev) National Hospital of the Ministry of Health of the Kyrgyz
Republic, Bishkek, Kyrgyztan
(Jaxymbaev) Kyrgyz State Medical Institute of post-graduate training and
continuous education named S. B. Daniyarov, Bishkek, Kyrgyztan
Publisher
Revista Salus
Abstract
Introduction: The prevention of pulmonary embolism is a subject of ongoing
debate, with significant ambiguity and controversy surrounding current
methods. <br/>Objective(s): The purpose of this study was to review the
modern world literature, focusing exclusively on scientific articles,
systematic reviews and meta-analyses published between 2020 and 2023, to
assess the effectiveness of various pulmonary embolism prevention
strategies. <br/>Method(s): A comprehensive literature search was
conducted using leading databases such as Google Scholar, Cochrane
Library, EMBASE, EmCare, MEDLINE, EBSCOhost, Web of Science, Ovid Medline,
and PubMed. The search strategy was guided by the PRISMA. <br/>Result(s):
The analysis revealed substantial variability and ambiguity in the
effectiveness of pharmacological and mechanical methods for PE prevention.
Pharmacological interventions like low molecular weight heparin were
effective in certain contexts but inconsistent overall. Mechanical
methods, such as intermittent pneumatic compression and venous cava
filters, showed mixed results across different patient populations.
<br/>Conclusion(s): The combined use of pharmacological and mechanical
methods sometimes improved outcomes, but the overall evidence was weak and
often biased. It is necessary to conduct a larger number of studies, such
as randomized controlled trials, with minimizing the level of
methodological bias on the mentioned set of means of preventing pulmonary
embolism. This should be done in order to eliminate the controversial and
ambiguous nature of the means of preventing pulmonary embolism in the
research environment.<br/>Copyright &#xa9; 2024, Revista Salus. All rights
reserved.

<49>
Accession Number
2036495110
Title
In stable CAD and aortic stenosis, adding routine PCI to TAVI reduced MACE
but increased bleeding at 2 y.
Source
Annals of Internal Medicine. 177(12) (pp JC139), 2024. Date of
Publication: December 2024.
Author
Lader E.
Institution
(Lader) Health Alliance Hospital, Kingston, NY, United States
Publisher
American College of Physicians

<50>
Accession Number
2036443505
Title
Fasting vs. no fasting prior to catheterization laboratory procedures: the
SCOFF trial.
Source
European Heart Journal. 45(47) (pp 4990-4998), 2024. Date of Publication:
14 Dec 2024.
Author
Ferreira D.; Hardy J.; Meere W.; Butel-Simoes L.; Sritharan S.; Ray M.;
French M.; McGee M.; O'Connor S.; Whitehead N.; Turner S.; Healey P.;
Davies A.; Morris G.; Jackson N.; Barlow M.; Ford T.; Leask S.; Oldmeadow
C.; Attia J.; Sverdlov A.; Collins N.; Boyle A.; Wilsmore B.
Institution
(Ferreira, Hardy, Butel-Simoes, Sritharan, Ray, French, Turner, Davies,
Morris, Jackson, Barlow, Sverdlov, Collins, Boyle, Wilsmore)
Cardiovascular Department, John Hunter Hospital, Lookout Road, New Lambton
Heights, Newcastle, NSW 2305, Australia
(Ferreira, Attia, Sverdlov, Collins, Boyle, Wilsmore) School of Medicine
and Public Health, Newcastle University, University Drive, Callaghan,
Newcastle, NSW 2308, Australia
(Ferreira, Leask, Oldmeadow, Attia, Sverdlov, Collins, Boyle) Hunter
Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton
Heights, Newcastle, NSW 2305, Australia
(Meere) Department of Cardiology, Gosford Hospital, Gosford, Australia
(McGee, O'Connor, Ford) Department of Medicine, Tamworth Rural Referral
Hospital, Tamworth, NSW, Australia
(Whitehead) Department of Cardiology, Calvary Mater Hospital, Newcastle,
NSW, Australia
(Healey) Department of Anaesthesia, John Hunter Hospital, Newcastle, NSW,
Australia
Publisher
Oxford University Press
Abstract
Background and Aims: Current guidelines recommend 6 h of solid food and 2
h of clear liquid fasting for patients undergoing cardiac procedures with
conscious sedation. There are no data to support this practice, and
previous single-centre studies support the safety of removing fasting
requirements. The objective of this study was to determine the
non-inferiority of a no-fasting strategy to fasting prior to cardiac
catheterization procedures which require conscious sedation.
<br/>Method(s): This is a multicentre, investigator-initiated,
non-inferiority, randomized trial conducted in Australia with a
prospective open-label, blinded endpoint design. Patients referred for
coronary angiography, percutaneous coronary intervention, or cardiac
implantable electronic device (CIED)-related procedures were enrolled.
Patients were randomized 1:1 to fasting as normal (6 h solid food and 2 h
clear liquid) or no-fasting requirements (encouraged to have regular meals
but not mandated to do so). Recruitment occurred from 2022 to 2023. The
primary outcome was a composite of aspiration pneumonia, hypotension,
hyperglycaemia, and hypoglycaemia assessed with a Bayesian approach.
Secondary outcomes included patient satisfaction score, new ventilation
requirement (non-invasive and invasive), new intensive care unit
admission, 30-day readmission, 30-day mortality, 30-day pneumonia.
<br/>Result(s): A total of 716 patients were randomized with 358 in each
group. Those in the fasting arm had significantly longer solid food
fasting (13.2 vs. 3.0 h, Bayes factor >100, indicating extreme evidence of
difference) and clear liquid fasting times (7.0 vs. 2.4 h, Bayes factor
>100). The primary composite outcome occurred in 19.1% of patients in the
fasting arm and 12.0% of patients in the no-fasting arm. The estimate of
the mean posterior difference in proportions with credibility interval
(CI) in the primary composite outcome was -5.2% (95% CI -9.6 to -.9),
favouring no fasting. This result confirms the non-inferiority (posterior
probability >99.5%) and superiority (posterior probability 99.1%) of no
fasting for the primary composite outcome. The no-fasting arm had improved
patient satisfaction scores with a posterior mean difference of 4.02
points (95% CI 3.36-4.67, Bayes factor >100). Secondary outcome events
were observed to be similar. <br/>Conclusion(s): In patients undergoing
cardiac catheterization and CIED-related procedures, no fasting was
non-inferior and superior to fasting for the primary composite outcome of
aspiration pneumonia, hypotension, hyperglycaemia, and hypoglycaemia.
Patient satisfaction scores were significantly better with no fasting.
This supports removing fasting requirements for patients undergoing
cardiac catheterization laboratory procedures that require conscious
sedation.<br/>Copyright &#xa9; 2024 The Author(s). Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved.

<51>
Accession Number
2036654185
Title
Systematic Review of Surgical Success, Complications, Revision Rates,
Radiation Dosage, and Operative Time of 3D-Navigated versus Non-Navigated
Spinal Procedures.
Source
World Neurosurgery. 194 (no pagination), 2025. Article Number: 123550.
Date of Publication: February 2025.
Author
Suri I.; Ezzat B.; Suthakaran S.; Arroyave Villada J.S.; Kwon D.; Martin
L.; Hu J.; Yaeger K.; Carr M.
Institution
(Suri, Ezzat, Suthakaran, Arroyave Villada, Kwon, Martin) Icahn School of
Medicine at Mount Sinai, New York, NY, United States
(Suri, Ezzat, Arroyave Villada, Carr) Department of Neurosurgery at Mount
Sinai, New York, NY, United States
(Suri, Hu, Yaeger) Illuminant Surgical, Los Angeles, CA, United States
(Yaeger) Department of Neurosurgery, Houston Methodist, Houston, TX,
United States
Publisher
Elsevier Inc.
Abstract
Objective: Three-dimensional (3D) navigation offers real-time guidance in
surgery. However, there is limited and inconsistent data regarding the
usability, safety, and efficacy. To address gaps in knowledge about 3D
navigation in spinal surgery, we conducted a comprehensive review of
success rates, complications, revisions, radiation exposure, and operative
time associated with Federal and Drug Administration-approved 3D surgical
navigation tools. <br/>Method(s): This study adhered to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines and
used a protocol registered on International Prospective Registration of
Systematic Reviews (CRD42023404554). Ovid MEDLINE, Embase, and Cochrane
Central Register of Controlled Trials databases were searched using
relevant keywords for 3D surgical navigation and spinal procedures from
1946 to March 02, 2023. Two independent reviewers assessed the studies
using inclusion/exclusion criteria and risk of bias tools. Statistical
analyses included one-way analysis of variance, weighted-mean difference,
and unpaired t-tests with Welch's correction for associations and
comparisons between groups, respectively. <br/>Result(s): Of the total
11,324 studies identified and 7198 screened, 62 studies totaling 3170
adult patients were included in this comprehensive review. Complication
and surgical success rates have remained constant since 2004, with overall
rates of 5.5% and 94.0%, respectively. When segmented by spinal region,
complication rates may be moderately positively correlated with frequency
of cervical and thoracic procedures (r = 0.25, P = 0.68). The most
commonly reported complication was pedicle screw malposition or breach. A
subset of 20 studies, totaling 1554 patients, compared the performance of
3D navigation to two-dimensional fluoroscopy or freehand navigation. There
was a significant difference of 6.53% between surgical success rates of
the 3D-navigated and control groups (P = 0.03). However, there was no
significant difference in radiation exposure or operative time.
<br/>Conclusion(s): The 3D navigation in spinal procedures has higher
surgical success rates than two-dimensional fluoroscopy and freehand
navigation. Included studies exhibited varying limitations, including no
patient follow-up (n = 1), less than 10 patients (n = 6), various types of
spinal disorders (n = 1), and varying comorbidities among participants (n
= 2). Improving 3D navigation tools remains imperative to decrease
operative time and radiation exposure.<br/>Copyright &#xa9; 2024 The
Authors

<52>
Accession Number
2032551058
Title
A profile of the impella 5.5 for the clinical management of cardiogenic
shock and a review of the current indications for use and future
directions.
Source
Expert Review of Medical Devices. 21(12) (pp 1087-1099), 2024. Date of
Publication: 2024.
Author
Hershenhouse K.S.; Ferrell B.E.; Glezer E.; Wu J.; Goldstein D.
Institution
(Hershenhouse, Ferrell, Glezer, Wu, Goldstein) Department of
Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert
Einstein College of Medicine, Bronx, NY, United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: The Impella 5.5 device is a surgically inserted,
trans-valvular, microaxial flow device capable of providing 5.5 L/min of
continuous, antegrade flow from the left ventricle (LV) to the aorta. The
ability of the Impella 5.5 to fully pressure and volume unload the
dysfunctional LV while allowing for mobilization and rehabilitation has
rapidly expanded its use. Clinical use scenarios include escalation of
support for acute myocardial infarction cardiogenic shock (AMICS),
transition from extracorporeal membrane oxygenation to mobile support,
bridge to transplantation or durable MCS in acute decompensated heart
failure, or perioperative use in post-cardiotomy cardiogenic shock (PCCS).
Areas covered: This review provides a profile of the Impella 5.5 device,
summarizes the current literature surrounding clinical applications,
reviews active and upcoming clinical trials, and projects future
applications for the device through an expert review. Expert opinion: The
development of the Impella 5.5 has allowed for monitoring of left-heart
recovery, optimizing right ventricular function, and rehabilitating
patients to meet bridging endpoints. The 2018 heart transplant allocation
system modifications have expanded the use of temporary mechanical
circulatory support (tMCS) on the transplant waitlist, increasing the
number of patients transplanted on support. With increased safety and
durability, an expanding frontier is used in perioperative support for
PCCS in high-risk cardiac surgery.<br/>Copyright &#xa9; 2024 Informa UK
Limited, trading as Taylor & Francis Group.

<53>
Accession Number
2036599436
Title
Feasibility of Alerting Systems and Family Care Partner Support for
Postoperative Delirium Prevention.
Source
Journal of Neurosurgical Anesthesiology. (no pagination), 2024. Article
Number: ANA.0000000000001016. Date of Publication: 2024.
Author
Vlisides P.E.; Runstadler N.; Martinez S.; Ragheb J.W.; Mentz G.; Leis A.;
Schoettinger A.; Hickey K.; McKinney A.; Brooks J.; Zierau M.; Norcott A.;
Mody L.; Inouye S.K.; Avidan M.S.; Min L.
Institution
(Vlisides, Runstadler, Martinez, Mentz, McKinney) Department of
Anesthesiology, Michigan Medicine, Ann Arbor, MI, United States
(Vlisides) Center for Consciousness Science, University of Michigan
Medical School, Ann Arbor, MI, United States
(Ragheb, Norcott) Department of Anesthesiology, University of Miami
Miller, School of Medicine, Miami, FL, United States
(Leis) Department of Epidemiology, School of Public Health, University of
Michigan, Ann Arbor, MI, United States
(Schoettinger) Department of Social Work, University of Michigan, United
States
(Hickey) Department of Nursing, Michigan Medicine, Ann Arbor, MI, United
States
(Brooks) Department of Orthopaedic Surgery, Michigan Medicine, Ann Arbor,
MI, United States
(Zierau) College of Health Professions, University of Detroit Mercy,
Detroit, MI, United States
(Norcott, Mody, Min) Department of Internal Medicine, Division of
Geriatric and Palliative Medicine, Michigan Medicine, Ann Arbor, MI,
United States
(Inouye) Aging Brain Center, Hinda and Arthur Marcus Institute for Aging
Research, Hebrew SeniorLife, Boston, MA, United States
(Inouye) Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, United States
(Avidan) Department of Anesthesiology, Washington University School of
Medicine, St. Louis, MO, United States
(Min) Geriatric Research Education and Clinical Care, Veterans Affairs
Arbor Healthcare System, Ann Arbor, MI, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The objective of this study was to determine whether
postoperative pager alerts to the Hospital Elder Life Program (HELP), a
delirium prevention service, would accelerate program enrollment for older
surgical patients. This study also tested feasibility of family care
partner interventions for delirium prevention. <br/>Method(s): This
single-center, pilot clinical trial factorially randomized 57 non-cardiac
surgical patients >= 70 years of age to 4 arms: (1) standard care, (2)
pager alerts to accelerate HELP enrollment, (3) family care partner-based
delirium prevention interventions, or (4) a combined arm with both HELP
and family interventions. The primary clinical outcome was delirium
(assessed through the Confusion Assessment Method). <br/>Result(s): In the
pager alerting arms, 13/24 (54%) participants were enrolled by HELP on
postoperative day 1 compared with 0/26 (0%, P < 0.001) in the non-alerting
arms. Median [interquartile range] time spent in delirium prevention
protocols was significantly longer in pager alerting arms than in
non-alerting arms (39 [5 to 75] min vs. 0 [0 to 0] min; P < 0.001). Family
care partners spent 18 [11 to 25)] hours at the bedside over the first 3
postoperative days. There was no significant difference in delirium
occurrence in participants randomized to pager alert arms compared with
non-alerting arms (odds ratio, 1.02, 95% CI, 0.97-1.07; P = 0.390).
Similarly, there was no significant difference in delirium occurrence in
family intervention arms compared with nonintervention arms (odds ratio,
0.97; 95% CI 0.93-10.02; P = 0.270). <br/>Conclusion(s): Pager alerts
significantly reduced time to HELP enrollment, albeit without reducing
delirium incidence in this pilot study. Family care partners spent
substantial time at the bedside during the study period.<br/>Copyright
&#xa9; 2024 Wolters Kluwer Health, Inc. All rights reserved.

<54>
Accession Number
2034641870
Title
Effects of Serratus Anterior Plane Block on Early Recovery from
Thoracoscopic Lung Resection: A Randomized, Blinded, Placebo-controlled
Trial.
Source
Anesthesiology. 141(6) (pp 1065-1074), 2024. Date of Publication: 01 Dec
2024.
Author
Jackson J.C.; Tan K.S.; Pedoto A.; Park B.J.; Rusch V.W.; Jones D.R.;
Zhang H.; Desiderio D.; Fischer G.W.; Amar D.
Institution
(Jackson, Tan, Pedoto, Zhang, Desiderio, Fischer, Amar) Department of
Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer
Center, New York, NY, United States
(Jackson, Pedoto, Desiderio, Fischer, Amar) Department of Anesthesiology,
Weill Cornell Medical College, New York, NY, United States
(Park, Rusch, Jones) Thoracic Service, Department of Surgery, Memorial
Sloan Kettering Cancer Center, New York, NY, United States
(Park, Rusch, Jones) Department of Surgery, Weill Cornell Medical College,
New York, NY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The efficacy of serratus anterior plane block for treatment of
pain after minimally invasive thoracic surgery remains unclear. This trial
assesses the impact of serratus anterior plane block on postoperative
opioid consumption and on measures of early recovery after thoracoscopic
lung resection. <br/>Method(s): Patients undergoing minimally invasive
anatomic lung resection at a single center were randomized to undergo
serratus anterior plane block with 40 ml injectate containing bupivacaine
0.25%, clonidine 100 mug, and dexamethasone 4 mg (serratus anterior plane
block group) or sham block with 40 ml normal saline (placebo group) at the
conclusion of surgery. The primary outcome was cumulative intravenous
morphine equivalents during the first 24 h postoperatively. Secondary
outcomes were intravenous morphine equivalents, pain scores at rest and
with cough, inspiratory volume on incentive spirometry, incidence of
nausea or vomiting during the first 48 h postoperatively, Quality of
Recovery-15 score on postoperative day 7, and length of stay.
<br/>Result(s): Using the protocol-specified intention-to-treat analysis,
the median (interquartile range) intravenous morphine equivalents was 10.6
(5.0 to 27.1) mg in serratus anterior plane block patients (n = 46) versus
18.8 (9.9 to 29.6) mg in placebo patients (n = 46; 32% reduction; ratio,
0.68 [95% CI, 0.44 to 1.06]; P = 0.085). Of the secondary outcomes, only
the composite pain with cough scores differed significantly in the
serratus anterior plane block group by a coefficient of -0.41 (95% CI,
-0.81 to -0.01; P = 0.044). A sensitivity as-treated analysis reported
median (interquartile range) intravenous morphine equivalents of 10.0 (5.0
to 27.2) mg in serratus anterior plane block patients (n = 44) versus 19.9
(10.4 to 29.0) mg in placebo patients (n = 48; 36% reduction; ratio, 0.64
[95% CI, 0.41 to 1.00]; P = 0.048). <br/>Conclusion(s): The
protocol-specified intention-to-treat analysis demonstrated that serratus
anterior plane block did not result in a significant reduction in opioid
consumption when added to a multimodal analgesic regimen after
thoracoscopic anatomic lung resection. The sensitivity as-treated analysis
showed a significant and modest clinical reduction in the primary outcome
that warrants further investigation.<br/>Copyright &#xa9; 2024 American
Society of Anesthesiologists. All Rights Reserved.

<55>
Accession Number
644926618
Title
Protective effect of sevoflurane on myocardial ischemia-reperfusion
injury: a systematic review and meta-analysis.
Source
International journal of surgery (London, England). 110(11) (pp
7311-7330), 2024. Date of Publication: 01 Nov 2024.
Author
Nasiri-Valikboni A.; Rashid M.; Azimi A.; Zarei H.; Yousefifard M.
Institution
(Nasiri-Valikboni, Azimi, Zarei, Yousefifard) Physiology Research Center,
Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Rashid) Student Research Committee, Babol University of Medical Sciences,
Babol, Iran, Islamic Republic of
Abstract
BACKGROUND: Myocardial ischemia-reperfusion (I/R) injury significantly
impacts recovery in both cardiac and noncardiac surgeries, potentially
leading to severe cardiac dysfunction. Sevoflurane, a volatile anesthetic,
is reputed for its protective effects against myocardial I/R injury,
although evidence remains inconclusive. This systematic review and
meta-analysis aim to clarify the cardioprotective efficacy of sevoflurane.
<br/>METHOD(S): The systematic search of databases including Medline,
Embase, Scopus, and Web of Science, was supplemented with a manual search
to retrieve studies using rat or mouse models of myocardial I/R injury,
comparing sevoflurane pretreatment (>=24 h before I/R), preconditioning
(within 24 h before I/R), or postconditioning (after I/R) against
nontreated controls. The outcomes were cardiac function, myocardial
infarct size, apoptosis, inflammation, oxidative stress, and cardiac
biomarkers. Using the random effects model, standardized mean differences
(SMD) were pooled to perform meta-analyses. <br/>RESULT(S): Fifty-one
studies, encompassing 8189 subjects, were included in the meta-analysis.
Pretreatment with Sevoflurane significantly reduced infarct size.
Sevoflurane preconditioning exhibited positive effects on left ventricular
parameters and ejection fraction, and reduced infarct size, apoptosis, and
oxidative stress. Postconditioning with Sevoflurane demonstrated
improvements in cardiac function, including enhanced left ventricular
parameters and reduced infarct size, apoptosis, inflammation, oxidative
stress, and cardiac biomarkers. <br/>CONCLUSION(S): Sevoflurane
demonstrates a significant protective effect against myocardial I/R injury
in animal models. These findings support the potential clinical utility of
sevoflurane as an anesthetic choice in preventing and managing myocardial
I/R injury during surgeries.<br/>Copyright &#xa9; 2024 The Author(s).
Published by Wolters Kluwer Health, Inc.

<56>
Accession Number
644614060
Title
Stellate ganglion block for visceral pain in elderly patients undergoing
video-assisted thoracoscopic lung cancer surgery: a randomized, controlled
trial.
Source
International journal of surgery (London, England). 110(11) (pp
6996-7002), 2024. Date of Publication: 01 Nov 2024.
Author
Xiang X.-B.; Wu Y.-Y.; Fang Z.; Tang X.; Wu Y.-L.; Zhou J.; Cheng X.-Q.
Institution
(Xiang, Tang, Wu, Zhou) Department of Anesthesiology, Zhejiang Cancer
Hospital and Hangzhou Institute of Medicine (HIM), Chinese Academy of
Sciences, Hangzhou, Zhejiang, China
(Wu, Fang, Cheng) Department of Anesthesiology, First Affiliated Hospital
of Anhui Medical University and Key Laboratory of Anesthesiology and
Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical
University, Hefei, China
Abstract
BACKGROUND: Visceral pain occurs commonly following thoracic surgery, but
an effective method to relieve visceral pain in thoracic surgery remains
controversial. The authors test the effect of stellate ganglion blocks
(SGB) on perioperative visceral pain following video-assisted
thoracoscopic surgery (VATS). <br/>METHOD(S): A prospective, randomized,
controlled trial enrolled 77 elderly patients undergoing VATS. Patients
were randomized to SGB followed by modified intercostal nerve block (Group
S, n =37); or modified intercostal nerve block only (Group C, n =40).
Remifentanil 0.02-0.2 mug.kg -1 .min -1 was titrated to keep pain
threshold index values between 40 and 65 and maintain mean arterial
pressure or heart rate values around 20% of baseline values.
Patient-controlled intravenous analgesia with sufentanil was used in the
postoperative period. The co-primary outcomes were the perioperative
cumulative opioid consumption and pain scores on movement at 24 h after
surgery. <br/>RESULT(S): Compared with the control group, SGB greatly
reduced the intraoperative remifentanil consumption [300.00
(235.00-450.00)mug versus 710.00 (500.00-915.00)mug; P <0.01], with no
difference in cumulative sufentanil consumption to 48 h postsurgery. There
was a statistically significant difference in pain scores on movement at
24 h between groups [4.00 (3.00-4.00) versus 4.00 (3.25-5.00); P =0.01].
Further exploratory analyses showed a significant difference in intrachest
pain on movement at 24 h [3.00 (2.00-3.00) versus 3.00 (2.25-4.00); P
=0.01]. No significant difference was observed in nausea/vomiting, time to
pass flatus, and postoperative length of stay. <br/>CONCLUSION(S):
Preoperative SGB for elderly patients could effectively blunt
intraoperative visceral stress and reduce postoperative visceral pain
extending 24 h after VATS. This initial finding deserves further
investigation.<br/>Copyright &#xa9; 2024 The Author(s). Published by
Wolters Kluwer Health, Inc.

<57>
Accession Number
2032639559
Title
The Utility of Coronary Revascularization to Reduce Ventricular
Arrhythmias in Coronary Artery Disease Patients: A Systematic Review.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2024.
Date of Publication: 2024.
Author
Junarta J.; Siddiqui M.U.; Abaza E.; Zhang P.; Patel A.; Park D.S.; Aizer
A.; Razzouk L.; Rao S.V.
Institution
(Junarta, Park, Aizer, Razzouk, Rao) Leon H. Charney Division of
Cardiology, New York University Langone Health, New York, NY, United
States
(Siddiqui) Jefferson Heart Institute, Thomas Jefferson University
Hospitals, Philadelphia, PA, United States
(Abaza, Zhang) Department of Internal Medicine, New York University
Langone Health, New York, NY, United States
(Patel) Department of Internal Medicine, Thomas Jefferson University
Hospitals, Philadelphia, PA, United States
Publisher
John Wiley and Sons Inc
Abstract
Ventricular arrhythmias (VA) are a major cause of morbidity and mortality
in patients with coronary artery disease (CAD). Current guidelines
recommend revascularization of significant CAD to improve survival in
patients with ventricular fibrillation (VF), polymorphic ventricular
tachycardia (VT), or those who are post-cardiac arrest. However,
revascularization is not recommended for CAD patients with suspected
scar-mediated monomorphic VT. There is a paucity of data detailing the
utility of revascularization in reducing VA in CAD patients who do not
present with acute coronary syndrome (ACS) and are not immediately
post-cardiac arrest, which is the focus of this review. Medline, Scopus,
and the Cochrane Central Register of Controlled Trials were systematically
searched to identify relevant studies addressing this question. Studies
that included patients presenting with ACS or those who were immediately
post-cardiac arrest at the time of revascularization were excluded. In
total, five studies comprising 2663 patients were reviewed.<br/>Copyright
&#xa9; 2024 Wiley Periodicals LLC.

<58>
Accession Number
2036477005
Title
Use of Intraoperative Hemostatic Checklists for Blood Management in
Patients Undergoing Cardiac Surgery: A Scoping Review.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Irabor B.; Kothari A.; Hong J.; Chiang B.; Kent D.; Duhamel T.A.; Lawal
M.; El-Diasty M.; Arora R.C.
Institution
(Irabor, Lawal) Cumming School of Medicine, University of Calgary,
Calgary, Canada
(Kothari, Arora) Max Rady College of Medicine, University of Manitoba,
Manitoba, Canada
(Hong) Department of Surgery, Section of Cardiac Surgery, Max Rady College
of Medicine, University of Manitoba, Manitoba, Canada
(El-Diasty, Arora) Division of Cardiac Surgery, Harrington Heart and
Vascular Institute, University Hospitals Cleveland Medical Center,
Cleveland, OH, United States
(Arora) Department of Surgery, Case Western Reserve University, Cleveland,
OH, United States
(Chiang) University of Calgary's Libraries and Cultural Resources,
Calgary, Canada
(Kent, Duhamel) Institute of Cardiovascular Sciences, St. Boniface
Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada
(Duhamel) Faculty of Kinesiology and Recreation Management, University of
Manitoba, Winnipeg, MB, Canada
Publisher
W.B. Saunders
Abstract
Background: Using intraoperative hemostatic checklists may improve rates
of surgical re-exploration and utilization of allogenic blood products in
patients undergoing cardiac surgery. In this review, the authors explore
the current evidence describing the impact of using intraoperative
hemostatic checklists on reducing rates of surgical bleeding and
perioperative blood product transfusion in this group of patients.
<br/>Method(s): Following Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines, electronic information was obtained via
sources that included Scopus, MEDLINE, EMBASE, and the Cochrane Library.
Specifically, randomized controlled and observational studies reporting on
hemostatic checklists in cardiac surgery were assessed for the following
inclusion criteria: adult patients undergoing cardiac surgery, use of an
intraoperative hemostatic checklist, a comparative study design, and full
text available in the English language. All conference abstracts,
editorials, and other reviews were excluded. <br/>Result(s): A total of
3,022 articles were retrieved. Four articles, with 19,946 patients, were
ultimately included in this review. These studies showed a significant
reduction in bleeding re-exploration rates after implementing an
intraoperative hemostatic checklist. In addition, three studies showed
lower cost per patient, less blood product transfusion, and reduced
intensive care unit stay after using checklists. <br/>Conclusion(s): These
findings suggest that using intraoperative hemostatic checklists may
reduce surgical re-exploration rates and improve blood product utilization
after cardiac surgery. Large multicenter studies are needed to endorse the
utilization of these checklists in routine clinical
practice.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<59>
Accession Number
2036593191
Title
Comparative safety between transdiaphragmatic and subxiphoid mediastinal
access modality in patients undergoing hybrid Convergent atrial
fibrillation ablation: A systematic review and meta-analysis.
Source
European Journal of Arrhythmia and Electrophysiology. 10(Supplement 1) (pp
82-83), 2024. Date of Publication: 2024.
Author
Urgesi E.U.; Mukhtar I.M.; Ahmed O.A.; Behr E.B.; Momin A.M.; Kaba R.A.K.
Institution
(Urgesi, Mukhtar, Ahmed, Momin, Kaba) Department of Cardiology, Ashford
and St Peter's NHS Foundation Trust, London, United Kingdom
(Ahmed, Behr, Momin, Kaba) Cardiovascular Clinical Academic Group,
Molecular and Clinical Sciences Institute, St George's University of
London and St George's University Hospitals NHS Foundation Trust, London,
United Kingdom
(Kaba) Centre for Biomedical Sciences, Biological Sciences, Royal
Holloway, University of London, London, United Kingdom
Publisher
Touch Medical Media
Abstract
Introduction: Hybrid ablation has become a well-established, efficacious
approach for the treatment of resistant varieties of atrial fibrillation
(AF), with the convergent procedure (CP) emerging as the least invasive
form of such therapy. In recent years, growing concerns regarding the
safety profile of the transabdominal, transdiaphragmatic (TD) CP approach
led to the development of an alternative, and even less invasive,
technique that achieves epicardial access via a subxiphoid (Sub-X) means
of entry. We aimed to perform a review of the available evidence and
compare the safety profiles between TD and Sub-X epicardial components of
the hybrid CP. <br/>Method(s): We performed a comprehensive online search
of PubMed for cohort, case-control, or RCT studies investigating adult
patients undergoing the CP via either TD or Sub-X approach, excluding any
concomitant cardiac surgery, patients affected by valvular-AF or
hypertrophic cardiomyopathy. Safety was defined as 30-day operative
mortality and major procedural complication rates. Results are presented
as absolute rates and 95% confidence intervals (CIs), employing
appropriate meta-analysis tools for transformations, risk of biases and
controls for family-wise error rates. <br/>Result(s): Of 12,717 screened
articles, 954 patients (293 Sub-X, 661 TD) from 14 (13 cohort, 1 RCT)
studies met our study criteria. No study was found to be at high risk of
bias. Rates of overall major complications (10.4% versus 7.2%), 30-day
operative mortality (1.7% versus 0.7%), atrio-oesophageal fistula (AOF:
0.9% versus 0%), cardiac tamponade (1.7% versus 1.0%), stroke (1.2% versus
0%), major bleeding (1.4% versus 0.3%), and incisional abdominal wall
hernia (1.5% versus 0.3%) were all higher in the TD group. Pericardial
effusions were more common in the Sub-X group (1.7% versus 0.6%). Here,
most major complications (16/22) were reported by the study with the
earliest recruitment period (2009-2020) - lower overall major
complications were noted in the remaining studies (4.4% versus 10.1%).
Meta-analysis showed an overall incidence of major complications of 12.3%
(CI: 7.9-17.5; p<0.001) and 5.4% (CI: 0.9-12.7; p:0.003) in the TD and
Sub-X groups, respectively. Mortality was significant in the TD (0.9%; CI:
0.02-2.4; p: 0.025) but not in the Sub-X group (0.3%; CI: 0-1.7; p:0.259).
In the TD group, AOF represented the leading cause of death, in 6/11
events. Stroke/TIA (1.1%; CI: 0.3-2.3; p<0.001), major bleeding (0.8%; CI:
0.04-1.8; p:0.014) and tamponades/effusions (1.7%; CI: 0.6-3.2; p<0.001)
were all found to be significant in the TD group. Stroke/TIA (0.5%; CI:
0-2.1; p: 0.118) and major bleeding (0.1%; CI: 0-1.2; p: 0.555) were not
significant in the Sub-X group - although tamponades/effusions (2.1%; CI:
0.4-4.7; p: 0.002) was. No significant publication bias or small study
effect were noted. <br/>Conclusion(s): Major complications following the
Sub-X CP were found to be less common compared to the TD technique, with a
clear trend favouring the Sub-X CP observed for nearly all point
estimates. Indeed, major complications were found to be twice as common
via meta-analysis in the TD group and seldomly statistically significant
in the Sub-X group. Our data supports the anatomical advantage of the
Sub-X CP over the TD approach, thus advocating for its implementation as
the mainstay of hybrid Convergent therapy in patients undergoing ablation
for the more complex forms of AF.(Image Presented)<br/>Copyright &#xa9;
(2024), (Touch Medical Media). All Rights Reserved.

<60>
Accession Number
2036676526
Title
Midterm survival, clinical, and hemodynamic outcomes of a novel mechanical
mitral valve prosthesis.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2024.
Date of Publication: 2024.
Author
Ruel M.; Chu M.W.A.; Graeve A.; Gerdisch M.W.; Damiano R.J.; Smith R.L.;
Keeling W.B.; Wait M.A.; Hagberg R.C.; Quinn R.D.; Sethi G.K.; Floridia
R.; Barreiro C.J.; Pruitt A.L.; Accola K.D.; Dagenais F.; Markowitz A.H.;
Ye J.; Sekela M.E.; Tsuda R.Y.; Duncan D.A.; Swistel D.G.; Harville L.E.;
DeRose J.J.; Lehr E.J.; Alexander J.H.; Puskas J.D.
Institution
(Ruel) Division of Cardiac Surgery, University of Ottawa Heart Institute,
Ottawa, ON, Canada
(Chu) Division of Cardiac Surgery, London Health Sciences Centre, Western
University, London, ON, Canada
(Graeve) Cardiothoracic Division, MultiCare Health System, Tacoma, Wash,
United States
(Gerdisch) Department of Cardiovascular and Thoracic Surgery, Franciscan
St Francis Health, Indianapolis, Ind, United States
(Damiano) Department of Surgery, Washington University SL, St. Louis, Mo,
United States
(Smith) Robotic Cardiac Surgery, The Heart Hospital Baylor Plano, Plano,
Tex, United States
(Keeling) Division of Cardiothoracic Surgery, Emory University Hospital
Midtown, Atlanta, GA, United States
(Wait) Department of Cardiovascular and Thoracic Surgery, UT Southwestern
Medical Center, Dallas, Tex, United States
(Hagberg) Department of Cardiac Surgery, Hartford Hospital, Hartford,
Conn, United States
(Quinn) Department of Cardiac Services, Maine Medical Center, Portland,
Maine, United States
(Sethi) Division of Cardiothoracic Surgery, University of Arizona, Tucson
Heart Center, Tucson, Ariz, United States
(Floridia) Department of Cardiovascular and Thoracic Surgery, Loma Linda
University Medical Center, Loma Linda, Calif, United States
(Barreiro) Sentara Health Research Center, Sentara Norfolk General
Hospital, Norfolk, Va, United States
(Pruitt) Cardiovascular and Thoracic Surgery, St Joseph Mercy Hospital,
Ann Arbor, Mich, United States
(Accola) Cardiovascular Surgery, Florida Hospital, Orlando, Fla, United
States
(Dagenais) Department of Cardiac Surgery, Institut universitaire de
cardiologie et de pneumologie de Quebec, Quebec City, QC, Canada
(Markowitz) Heart & Vascular Institute, University Hospitals-Cleveland,
Cleveland, Ohio, United States
(Ye) Division of Cardiovascular Surgery, St Paul's and Vancouver General
Hospital, Vancouver, BC, Canada
(Sekela) Division of Cardiothoracic Surgery, University of Kentucky,
Lexington, Ky, United States
(Tsuda) Department of Cardiology, Southern Arizona VA Medical Center,
Tucson, Ariz, United States
(Duncan) Cardiovascular and Thoracic Surgery, Novant Clinical Research
Institute, Winston-Salem, NC, United States
(Swistel) Department of Cardiac Surgery, NYU Langone Hospitals, New York,
NY, United States
(Harville) Department of Surgery, University of Oklahoma Health Sciences
Center, Oklahoma City, Okla, United States
(DeRose) Division of Cardiothoracic Surgery, Montefiore Medical Center,
Bronx, NY, United States
(Lehr) Cardiac Surgery, Swedish Medical Center, Seattle, Wash, United
States
(Alexander) Division of Cardiology, Duke Clinical Research Institute, Duke
University, Durham, NC, United States
(Puskas) Division of Cardiothoracic Surgery, Mount Sinai Saint Luke's, New
York, NY, United States
Publisher
Elsevier Inc.
Abstract
Objective: To evaluate the midterm survival, clinical, and hemodynamic
outcomes of the On-X mechanical mitral valve, based on the 5-year results
of the Prospective Randomized On-X Anticoagulation Clinical Trial
(PROACT). <br/>Method(s): PROACT Mitral was a multicenter study evaluating
401 patients who underwent mitral valve replacement (MVR) with either
Standard or Conform-X On-X mitral valves, comparing low-dose and
standard-dose warfarin. Here we report prespecified secondary outcomes of
survival, New York Heart Association (NYHA) functional classification, and
valve hemodynamics as assessed by core lab-adjudicated echocardiography at
1, 3, and 5 years in the pooled population. <br/>Result(s): Actuarial
survival was 99.7% at 1 year, 95.1% at 3 years, and 92.4% at 5 years, with
no significant difference between the Standard and Conform-X cuffs.
Hemodynamic analysis revealed a mean transvalvular pressure gradient (MG)
of 4.6 +/- 2.0 mm Hg at 1 year, with no interaction between valve size and
patient body surface area. MG values were consistent over time. Quality of
life improved with 96.6% of patients in NYHA class I or II at the latest
available follow-up of 3 or 5 years. There were no significant differences
in survival, clinical, or hemodynamic outcomes between valve sizes.
<br/>Conclusion(s): The On-X mechanical mitral valve demonstrated
favorable survival, stable hemodynamics, and enhanced quality of life up
to 5 years postimplantation. Derived from high-quality, rigorous
randomized trial data, these findings can guide decision making in young
patients requiring MVR.<br/>Copyright &#xa9; 2024 The American Association
for Thoracic Surgery

<61>
Accession Number
2036653042
Title
Development of and recovery from acute kidney injury after cardiac
surgery: Randomized phase 2 trial of the hepatocyte growth factor mimetic
ANG-3777.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2024.
Date of Publication: 2024.
Author
Ayad S.S.; Beaver T.; Corteville D.; Swaminathan M.; Pearl R.G.; Aslam S.;
Csomor P.A.; Alperovich G.; Neylan J.
Institution
(Ayad) Outcomes Research Department, Anesthesiology Institute, Cleveland
Clinic, Cleveland, Ohio, United States
(Beaver) Division of Thoracic and Cardiovascular Surgery, Department of
Surgery, University of Florida, Gainesville, Fla, United States
(Corteville) Department of Cardiology, Sands-Constellation Heart
Institute, Rochester Regional Health, Rochester, NY, United States
(Swaminathan) Department of Anesthesiology, Atrium Health Wake Forest
Baptist, Wake Forest University School of Medicine, Winston-Salem, NC,
United States
(Pearl) Department of Anesthesiology, Perioperative, and Pain Medicine,
Stanford University School of Medicine, Stanford, Calif, United States
(Aslam, Neylan) Angion Biomedica, Uniondale, NY, United States
(Csomor) CSL Vifor, Glattbrugg, Switzerland
(Alperovich) CSL Vifor, Madrid, Spain
Publisher
Elsevier Inc.
Abstract
Objectives: To investigate the safety and efficacy of ANG-3777, a
hepatocyte growth factor mimetic, in mitigating the risk of acute kidney
injury (AKI) in patients undergoing cardiac surgery with cardiopulmonary
bypass. <br/>Method(s): In this double-blind placebo-controlled study
(Guard Against Renal Damage [GUARD]), patients were randomized to receive
intravenous ANG-3777 2 mg/kg or placebo once daily for 4 days. The primary
end point was severity of AKI, measured by mean area under the
concentration-time curve on percent increase in serum creatinine from days
2 to 6. Secondary end points included the proportions of patients who
developed major adverse kidney events by day 30 or 90 and the percentage
of patients diagnosed with AKI through day 5. <br/>Result(s): In total,
259 patients received study treatment (ANG-3777, n = 129; placebo, n =
130). Through day 6, there was no significant difference in least-squares
mean change in serum creatinine between ANG-3777 and placebo (1.1%; 95%
confidence interval, -6.2 to 8.4; P = .77), or in proportions of patients
who developed major adverse kidney events by day 30 (18.6% vs 16.2%; P =
.60) or day 90 (14.7% vs 21.5%; P = .16). Similar proportions of patients
were diagnosed with AKI through day 5 (ANG-3777, 47.3%; placebo, 48.5%);
however, exploratory analysis revealed more patients diagnosed with AKI
postoperatively showed signs of recovery after treatment with ANG-3777
than placebo. Overall, ANG-3777 was well tolerated, with similar
incidences of treatment-emergent adverse events between treatment arms.
<br/>Conclusion(s): Findings from this study do not support the efficacy
of ANG-3777 in preventing the development of AKI after cardiopulmonary
bypass.<br/>Copyright &#xa9; 2024 The Authors

<62>
Accession Number
2036653034
Title
Outcomes of Endovascular Repair Confined to the Ascending Thoracic Aorta:
A Systematic Review and Meta-Analysis.
Source
European Journal of Vascular and Endovascular Surgery. (no pagination),
2024. Date of Publication: 2024.
Author
de Kort J.F.; Mandigers T.J.; Bissacco D.; Domanin M.; Piffaretti G.;
Twine C.P.; Wanhainen A.; van Herwaarden J.A.; Trimarchi S.; de Vincentiis
C.
Institution
(de Kort, Mandigers, Domanin, Trimarchi) Cardio Thoracic Vascular
Department, Section of Vascular Surgery, Fondazione IRCCS Ca Granda
Ospedale Maggiore Policlinico, Milan, Italy
(de Kort, Mandigers, van Herwaarden) Department of Vascular Surgery,
University Medical Centre Utrecht, Utrecht, Netherlands
(Bissacco, Domanin, Trimarchi) Department of Clinical Sciences and
Community Health, Universita degli Studi di Milano, Milan, Italy
(Piffaretti) Department of Medicine and Surgery, Vascular Surgery,
University of Insubria School of Medicine, Varese University Hospital,
Varese, Italy
(Twine) Southmead Hospital, North Bristol NHS Trust, and University of
Bristol Medical School, Bristol, United Kingdom
(Wanhainen) Section of Vascular Surgery, Department of Surgical Sciences,
Uppsala University, Uppsala, Sweden
(Wanhainen) Department of Surgical and Peri-operative Sciences, Surgery,
Umea University, Umea, Sweden
(de Vincentiis) Cardiac Surgery Unit, Cardiac Surgery Division, Department
of Cardiovascular Disease E. Malan, IRCCS Policlinico S. Donato, Milan,
Italy
Publisher
W.B. Saunders Ltd
Abstract
Objective: High risk, inoperable patients with ascending aortic disease
are increasingly managed with thoracic endovascular aortic repair (TEVAR).
The aim of this study was to assess the available literature on TEVAR
confined to the ascending aorta (a-TEVAR), describing study and patient
characteristics, procedural and stent graft details, and outcomes. Data
sources: This was a systematic review and meta-analysis. MEDLINE, Web of
Science, and Scopus were systematically searched for eligible studies
reporting on outcomes after a-TEVAR (PROSPERO ID: CRD42023440826).
Eligible studies reported outcomes after a-TEVAR without adjunctive
supra-aortic vessel treatment. Review Methods: The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was
followed. The ROBINS-I and Joanna Briggs Institute Critical Appraisal
Checklist were used as quality assessment tools. A Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) evidence
certainty analysis was performed for the main outcomes. The main outcome
was death. A proportional meta-analysis was performed with a mean and 95%
confidence interval (CI) for the main outcomes. All articles were included
up to 1 January 2024. <br/>Result(s): Ninety four studies were included
(19 cohort studies, 75 case reports or series), reporting on 259 patients
(57.8% male). The mean age was 69.1 (95% CI 65.0 - 73.1) years and mean
follow up 19.6 (95% CI 14.5 - 24.6) months. The most common comorbidity
was prior cardiac or thoracic surgery (n = 191). The most frequent
indications for a-TEVAR (52.1% urgent a-TEVAR) were type A aortic
dissection (43.6%) and pseudoaneurysm (38.6%). The most commonly deployed
stent grafts were Gore (44.5%), Cook (23.5%), and Medtronic (17.0%). The
in hospital mortality rate was 7.3% (95% CI 4.7 - 11.2%), 30 day mortality
rate 7.7% (95% CI 5.1 - 11.6%), and overall mortality rate 17.0% (95% CI
12.9 - 22.0%) during follow up. GRADE showed very low evidence certainty
for all outcomes. Eighty eight complications were reported and there was a
re-operation rate of 13.1% (95% CI 9.5 - 17.8%). In hospital and 30 day
mortality rates for type A dissection were 12.4% (95% CI 7.5 - 19.7%) (n =
14) and 13.3% (95% CI 8.2 - 20.8%) (n = 15), respectively, and for
pseudoaneurysm 4.0% (95% CI 1.6 - 9.8%) (n = 4) and 4.0% (95% CI 1.6 -
9.8) (n = 4), respectively. <br/>Conclusion(s): Despite heterogeneous
literature and very low GRADE evidence certainty, a-TEVAR seems
technically feasible in high risk patients. In addition, there is need for
a consensus on when and how to use a-TEVAR and a need for a specific
endograft for use in the ascending aorta.<br/>Copyright &#xa9; European
Society for Vascular Surgery

<63>
Accession Number
2032056959
Title
Virtual Reality for Postoperative Pain Management: A Review of Current
Evidence.
Source
Current Pain and Headache Reports. 28(12) (pp 1307-1319), 2024. Date of
Publication: December 2024.
Author
Malik A.; Elshazly T.; Pokuri K.; Apai C.; Rothkrug A.; Hasoon J.; Chung
M.; Ye Z.; Bhayani S.; Kaye A.D.; Liu H.; Lang M.; Yong R.J.; Donjow A.R.;
Varrassi G.; Robinson C.L.
Institution
(Malik) Department of Physical Medicine and Rehabilitation, The University
of Texas Health Science Center at Houston, McGovern Medical School, 1333
Moursund Street, Houston, TX 77030, United States
(Elshazly) Department of Anesthesiology, Case Western Reserve University,
University Hospitals, Cleveland, OH, United States
(Pokuri) Department of Anesthesiology and Perioperative Medicine, Tufts
Medicine, Boston, MA, United States
(Apai) Department of Anesthesiology and Perioperative Medicine, Rutgers
Health, New Jersey Medical School, Newark, NJ, United States
(Rothkrug) Department of Anesthesiology, Division of Pain Management, The
University of North Carolina at Chapel Hill, Chapel Hill, NC, United
States
(Hasoon) Department of Anesthesia and Pain Medicine, UTHealth McGovern
Medical School, Houston, TX, United States
(Chung) Department of Pain Medicine, Division of Anesthesia, Critical Care
and Pain Medicine, The University of Texas MD Anderson Cancer Center,
Houston, TX, United States
(Ye) Department of Orthopedics, Wuhan Union Hospital, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan, China
(Bhayani) Pain Management Department in the Anesthesiology Institute,
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
(Kaye) Department of Anesthesiology, Louisiana State University Health
Sciences Center Shreveport, Shreveport, LA, United States
(Liu) Department of Anesthesiology and Critical Care, Hospital of the
University of Pennsylvania, Philadelphia, PA, United States
(Lang) Department of Radiology, Harvard Medical School, Massachusetts
General Hospital, Boston, MA, United States
(Yong, Robinson) Department of Anesthesiology, Perioperative, and Pain
Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston,
MA, United States
(Donjow) Massachusetts Institute of Technology, Cambridge, MA, United
States
(Varrassi) Deaprtment of Research, Paolo Procacci Foundation, Rome, Italy
Publisher
Springer
Abstract
Purpose of Review: With the ongoing opioid crisis, there is a continued
need to develop multimodal pain management strategies inclusive of
non-pharmacological treatments. Virtual reality (VR) offers a non-invasive
treatment approach for the management of acute and chronic pain including
postoperative pain. The aim of this review is to describe the use of VR
and its effect on pain-related outcome measures compared to routine care
in various types of surgical procedures. Recent Findings: Severe
postoperative pain is associated with an increased risk of medical
complications and may lead to the development of chronic pain. VR-based
interventions are a form of distraction therapy that attenuates pain
perception and have been shown to reduce activity in central
pain-processing regions. In patients undergoing cardiac surgery, VR may
reduce postoperative pain and improve physiological parameters such as
heart rate and blood pressure. VR technology was found to have a high
satisfaction rate in patients undergoing laparoscopic abdominal surgeries.
Three-dimensional (3D) VR interventions may be useful for postoperative
pain control in patients undergoing head and neck surgery. VR technology
has revealed mixed results for postoperative pain control following
orthopedic procedures although it has beneficial effects on functional
outcomes during postoperative rehabilitation. In the pediatric population,
VR is notable for its applicability in postoperative pain control and
anxiety. <br/>Summary: VR technology is a novel, non-pharmacologic adjunct
in the management of postoperative pain. Current studies are limited
regarding therapy adaptations for the elderly population. High-quality
randomized controlled trials are needed to establish the clinical
effectiveness of VR-based therapies in the postoperative
setting.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<64>
Accession Number
2032746768
Title
A Randomized Controlled Trial on the Efficacy of 20% Human Albumin in
Reducing Pleural Effusion After Cardiopulmonary Bypass.
Source
Journal of Clinical Medicine. 13(24) (no pagination), 2024. Article
Number: 7693. Date of Publication: December 2024.
Author
Setlers K.; Aispure K.; Zolovs M.; Zvaigzne L.; Sabelnikovs O.; Stradins
P.; Strike E.
Institution
(Setlers, Strike) Department of Cardiovascular Anesthesia and Intensive
Care, Pauls Stradins Clinical University Hospital, LV, Riga 1002, Latvia
(Setlers, Sabelnikovs, Strike) Department of Anesthesiology, Riga Stradins
University, LV, Riga 1007, Latvia
(Aispure) Faculty of Medicine, Riga Stradins University, LV, Riga 1007,
Latvia
(Zolovs) Statistics Unit, Riga Stradins University, LV, Riga 1007, Latvia
(Zolovs) Institute of Life Sciences and Technology, Daugavpils University,
LV, Daugavpils 5401, Latvia
(Zvaigzne) Institute of Radiology, Pauls Stradins Clinical University
Hospital, LV, Riga 1002, Latvia
(Sabelnikovs) Department of Intensive Care, Pauls Stradins Clinical
University Hospital, LV, Riga 1002, Latvia
(Stradins) Department of Cardiac Surgery, Pauls Stradins Clinical
University Hospital, LV, Riga 1002, Latvia
(Stradins) Department of Surgery, Riga Stradins University, LV, Riga 1007,
Latvia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Cardiopulmonary bypass can lead to hemodilution,
causing a fluid shift to the interstitial space. Albumin helps counteract
the intravascular fluid movement to the extravascular space and reduces
the risk of complications associated with fluid imbalance. Our main
objective was to evaluate the effectiveness of albumin addition in the
cardiopulmonary bypass priming solution compared to standard priming,
focusing on its role in reducing pleural effusion development.
<br/>Method(s): This was a single-center randomized controlled trial
conducted at a tertiary care hospital specializing in cardiology and
cardiac surgery. It involved 70 individuals scheduled for elective
open-heart surgery. All cases were randomly assigned into two groups of 35
patients. The study group replaced 100 mL of standard CPB priming solution
with 100 mL of 20% human albumin. We measured serum albumin levels before
and after the surgery, 6 and 12 h after, and calculated colloid oncotic
pressure. Thorax CT scans were performed on the first postoperative day to
measure and calculate pleural effusion volume. <br/>Result(s): Albumin
addition to cardiopulmonary bypass priming solution led to a significant
reduction in pleural effusion development after CPB. An albumin level <35
g/L after the surgery showed a significant increase in pleural effusion
development, and 100 mL of 20% albumin was sufficient to maintain serum
albumin levels > 35 g/L. <br/>Conclusion(s): Our study suggests a link
between postoperative hypoalbuminemia and the early development of pleural
effusion after CPB, as well as the possible benefits of adding 100 mL of
20% albumin compared to standard crystalloid CPB priming to minimize
postoperative pleural effusion development.<br/>Copyright &#xa9; 2024 by
the authors.

<65>
Accession Number
2032778819
Title
Sex-based Disparities in Morbidity and Mortality Following Coronary Artery
Bypass Grafting: an Updated Systematic Review and Meta-analysis.
Source
SN Comprehensive Clinical Medicine. 7(1) (no pagination), 2024. Article
Number: 8. Date of Publication: December 2024.
Author
Sebastian S.A.; Vaja H.; Shah Y.; Chitagi P.
Institution
(Sebastian) Department of Internal Medicine, Azeezia Medical College,
Kerala, Kollam, India
(Vaja) Department of Internal Medicine, Byramjee Jeejeebhoy Medical
College & Civil Hospital, Gujarat, Ahmedabad, India
(Shah, Chitagi) Department of Internal Medicine, Trinity Health Oakland/
Wayne State University, Pontiac, MI, United States
(Sebastian) AirdrieCanada
Publisher
Springer Nature
Abstract
Sex is suggested to play a role in influencing outcomes after coronary
artery bypass grafting (CABG). However, the evidence regarding its impact
on long-term mortality and other clinical outcomes remains inconclusive.
Our study aims to comprehensively analyze and elucidate sex differences in
morbidity and mortality among individuals undergoing CABG. A systematic
search was performed of the following databases MEDLINE (via PubMed),
Google Scholar, the Cochrane Library, and ScienceDirect to identify
studies on sex differences in post-CABG outcomes from January 2010 to
April 2024. Statistical analysis was performed using RevMan 5.4, applying
an inverse variance random effects model to pool hazard ratio (HR) and
odds ratio (OR) for primary and secondary outcomes. The study protocol is
registered with PROSPERO (CRD42024516859). The final analysis comprised 35
studies involving 14,740,743 participants, with 34.4% being females. The
average age was 67.2 years for females and 63.7 years for males. Upon
pooled analysis, no statistically significant differences were observed in
the composite outcome of major adverse cardiovascular events (MACE) (HR:
1.03, 95% CI: 0.89 to 1.19, p = 0.69). However, there was a significant
increase in the risk of all-cause mortality in females, with a reported HR
of 1.14 (95% CI: 1.09 to 1.19, p < 0.00001). Similarly, females showed a
statistically significant higher risk of short-term mortality
(in-hospital/30-day mortality) with an OR of 1.73 (95% CI: 1.61 to 1.86, p
< 0.00001) and postoperative stroke with an OR of 1.28 (95% CI: 1.15 to
1.43, p < 0.00001), respectively. In contrast, the incidence of myocardial
infarction (MI) (OR: 1.13, 95% CI: 0.97 to 1.32, p = 0.12), cardiovascular
mortality (OR: 1.67, 95% CI: 0.84 to 3.32, p = 0.14), and repeat
revascularization (OR: 1.42, 95% CI: 0.30 to 6.68, p = 0.66) did not show
statistically significant differences between females and males. In
conclusion, females undergoing CABG exhibited an increased risk of
all-cause mortality, short-term mortality, and postoperative stroke,
underscoring the need for focused efforts to understand and mitigate this
sex-based disparity.<br/>Copyright &#xa9; The Author(s), under exclusive
licence to Springer Nature Switzerland AG 2024.

<66>
Accession Number
2032714008
Title
Evaluating air leakage from staple line reinforcements in anatomical
pulmonary resection (AIRSTOP): a prospective randomized controlled trial
protocol.
Source
General Thoracic and Cardiovascular Surgery. (no pagination), 2024. Date
of Publication: 2024.
Author
Yusa J.; Tanaka K.; Takahashi K.; Shiko Y.; Sugawara T.; Yoshino I.;
Suzuki H.
Institution
(Yusa, Tanaka, Yoshino, Suzuki) Department of General Thoracic Surgery,
Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chiba
260-8670, Japan
(Takahashi, Shiko) Biostatistics Section, Clinical Research Center, Chiba
University Hospital, Chiba, Japan
(Shiko) Department of Biostatistics, Graduate School of Medicine, Saitama
Medical University, Saitama, Japan
(Sugawara) Clinical Research Center, Chiba University Graduate School of
Medicine, Chiba, Japan
(Yoshino) Department of Thoracic Surgery, International University Health
and Welfare School of Medicine, Narita, Japan
Publisher
Springer
Abstract
Background: Air leakage during pulmonary resection is a major complication
in thoracic surgery. It frequently occurs at sites of adhesion dissection,
due to lung manipulation, and along the staple lines of automatic suturing
devices, particularly in cases of pulmonary fragility such as those of
emphysema and interstitial pneumonia. Persistent postoperative air leakage
prolongs chest tube indwelling and extends hospitalization time. Staplers
with absorbable tissue reinforcements have been introduced for pulmonary
resection to prevent intraoperative stapler-related air leakage. This
phase II prospective, open-label, randomized, parallel-group trial aims to
validate the efficacy of staplers with or without absorbable tissue
reinforcements in controlling stapler-related air leakage during
anatomical pulmonary resections. <br/>Method(s): Overall, 120 patients
will be randomized into two groups: one that will undergo conventional
anatomical pulmonary resection and the other in which staplers with
absorbable tissue reinforcements will be used. The primary endpoint will
be intraoperative stapler-related air leakage. Data will be analyzed
between 2024 and 2025. <br/>Discussion(s): This trial will validate the
effectiveness and safety of staple line reinforcements in controlling
intraoperative air leakage during anatomical pulmonary resections,
potentially leading to optimized strategies for patients with conditions
such as emphysema and interstitial pneumonia. Trial registration: This
trial has been registered with the Japan Registry of Clinical Trials
1032220620
(https://jrct.niph.go.jp/latest-detail/jRCTs031230224).<br/>Copyright
&#xa9; The Author(s) 2024.

<67>
Accession Number
2032711614
Title
Prognostic models for prediction of perioperative allogeneic red blood
cell transfusion in adult cardiac surgery: A systematic review and
meta-analysis.
Source
Transfusion. (no pagination), 2024. Date of Publication: 2024.
Author
Van den Eynde R.; Vrancken A.; Foubert R.; Tuand K.; Vandendriessche T.;
Schrijvers A.; Verbrugghe P.; Devos T.; Van Calster B.; Rex S.
Institution
(Van den Eynde, Vrancken, Foubert, Schrijvers, Rex) Department of
Cardiovascular Sciences, Unit Anesthesiology and Algology, Biomedical
Sciences Group, University of Leuven (KU Leuven), Leuven, Belgium
(Tuand, Vandendriessche) KU Leuven Libraries - 2Bergen - Learning Centre
Desire Collen, Leuven, Belgium
(Verbrugghe) Department of Cardiovascular Sciences, Unit Cardiac surgery,
Biomedical Sciences Group, University of Leuven (KU Leuven), Leuven,
Belgium
(Devos) Department of Hematology, University Hospitals Leuven, and
Department of Microbiology and Immunology, Laboratory of Molecular
Immunology (Rega Institute), University of Leuven (KU Leuven), Leuven,
Belgium
(Van Calster) Department of Development and Regeneration, Unit Woman and
Child, University of Leuven (KU Leuven), Leuven, Belgium
Publisher
John Wiley and Sons Inc
Abstract
Objectives: Identifying cardiac surgical patients at risk of requiring red
blood cell (RBC) transfusion is crucial for optimizing their outcome. We
critically appraised prognostic models preoperatively predicting
perioperative exposure to RBC transfusion in adult cardiac surgery and
summarized model performance. <br/>Method(s): Design: Systematic review
and meta-analysis. Study eligibility criteria: Studies developing and/or
externally validating models preoperatively predicting perioperative RBC
transfusion in adult cardiac surgery. Information sources MEDLINE, CENTRAL
& CDSR, Embase, Transfusion Evidence Library, Web of Science, Scopus,
ClinicalTrials.gov, and WHO ICTRP. Risk of bias and applicability: Quality
of reporting was assessed with the Transparent Reporting of studies on
prediction models for Individual Prognosis or Diagnosis adherence form,
and risk of bias and applicability with the Prediction model Risk of Bias
ASsessment Tool. Synthesis methods: Random-effects meta-analyses of
concordance-statistics and total observed:expected ratios for models
externally validated >=5 times. <br/>Result(s): Nine model development,
and 27 external validation studies were included. The average TRIPOD
adherence score was 66.4% (range 44.1%-85.2%). All studies but 1 were
rated high risk of bias. For TRUST and TRACK, the only models externally
validated >=5 times, summary c-statistics were 0.74 (95% CI: 0.65-0.84; 6
contributing studies) and 0.72 (95% CI: 0.68-0.75; 5 contributing studies)
respectively, and summary total observed:expected ratios were 0.86 (95%
CI: 0.71-1.05; 5 contributing studies) and 0.94 (95% CI: 0.74-1.19; 5
contributing studies), respectively. Considerable heterogeneity was
observed in all meta-analyses. <br/>Discussion(s): Future high quality
external validation and model updating studies which strictly adhere to
reporting guidelines, are warranted.<br/>Copyright &#xa9; 2024 The
Author(s). Transfusion published by Wiley Periodicals LLC on behalf of
AABB.

<68>
Accession Number
2032057083
Title
Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents
in the Randomised BIO-RESORT Trial at 3 Years.
Source
PharmacoEconomics - Open. (no pagination), 2024. Date of Publication:
2024.
Author
Ploumen E.H.; Wolcherink M.J.O.; Buiten R.A.; Pinxterhuis T.H.; Doggen
C.J.M.; Schotborgh C.E.; Danse P.W.; Scholte M.; van Houwelingen K.G.;
Zocca P.; Pouwels X.G.L.V.; von Birgelen C.
Institution
(Ploumen, Buiten, Pinxterhuis, van Houwelingen, Zocca, von Birgelen)
Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente,
Koningsplein 1, Enschede 7512 KZ, Netherlands
(Ploumen, Wolcherink, Pinxterhuis, Doggen, Pouwels, von Birgelen)
Department of Health Technology and Services Research, Faculty of
Behavioural, Management and Social Sciences, Technical Medical Centre,
University of Twente, Enschede, Netherlands
(Schotborgh) Department of Cardiology, Haga Hospital, The Hague,
Netherlands
(Danse) Department of Cardiology, Rijnstate Hospital, Arnhem, Netherlands
(Scholte) Department of Cardiology, Albert Schweitzer Hospital, Dordrecht,
Netherlands
Publisher
Adis
Abstract
Background and Objective: Evidence on health economic outcomes for
percutaneous coronary intervention (PCI) comparing different contemporary
drug-eluting stents (DES) with each other is scarce, as most previous
randomised DES trials did not assess such aspects. This prespecified
health economic evaluation of the Comparison of Biodegradable Polymer and
Durable Polymer Drug-Eluting Stents in an All Comers Population
(BIO-RESORT) trial aimed to compare at 3-year follow-up both health
effects and costs of PCI with one of three new-generation drug-eluting
stents (DES) in patients with obstructive coronary artery disease.
<br/>Method(s): The randomised BIO-RESORT trial assessed in 3514 patients
the ultrathin-strut biodegradable polymer Orsiro sirolimus-eluting stent
(SES) and very-thin-strut Synergy everolimus-eluting (EES) stent versus
the thin-strut durable polymer Resolute Integrity zotarolimus-eluting
stent (ZES). In the current analysis, we used the perspective of a health
insurer in the Netherlands. The main endpoints were quality-adjusted life
years (QALYs), and costs for each treatment strategy. Bootstrapping with
5000 resamples was performed to capture the uncertainty of results.
<br/>Result(s): Mean QALYs for each stent group were 2.566 for the SES,
2.551 for the EES, and 2.550 for the ZES. Mean costs per strategy were
14,670 for the SES, 14,946 for the EES, and 15,069 for the ZES. The SES
had the highest probability of being cost-effective for every
willingness-to-pay threshold up to 100,000 per QALY. Furthermore, in 79%
of modelling scenarios, the SES was more effective and cheaper than ZES.
<br/>Conclusion(s): At 3-year follow-up, PCI with the SES had the highest
probability of being cost-effective due to greater effectiveness and lower
costs compared with the ZES and EES. These findings suggest that, due to
the overall high volume of coronary stenting in clinical practice, use of
this SES could result in substantial cost savings, complemented by slight
additional health benefits.<br/>Copyright &#xa9; The Author(s) 2024.

<69>
Accession Number
646098147
Title
Left atrial appendage occlusion in patients with atrial fibrillation and
intracerebral haemorrhage associated with cerebral amyloid angiopathy: a
multicentre observational study and pooled analysis of published studies.
Source
Journal of neurology, neurosurgery, and psychiatry. (no pagination),
2024. Date of Publication: 18 Dec 2024.
Author
Thiankhaw K.; Best J.; Srivastava S.; Prachee I.; Agarwal S.; Tan S.;
Calvert P.A.; Chughtai A.; Ang R.; Segal O.R.; Werring D.J.
Institution
(Thiankhaw, Best, Srivastava, Werring) Stroke Research Centre, Department
of Brain Repair and Rehabilitation, UCL Queen Square Institute of
Neurology, London, United Kingdom
(Thiankhaw) Department of Internal Medicine, Chiang Mai University, Chiang
Mai, Thailand
(Prachee, Ang, Segal) Department of Cardiac Electrophysiology, Saint
Bartholomew's Hospital Barts Heart Centre, London, United Kingdom
(Agarwal, Tan) Department of Stroke Medicine, Clinical Neurosciences,
Addenbrooke's Hospital, Cambridge, United Kingdom
(Calvert, Chughtai) Department of Cardiology, Royal Papworth Hospital,
Cambridge, United Kingdom
(Calvert) University of Cambridge, Cambridge, United Kingdom
Abstract
BACKGROUND: Cerebral amyloid angiopathy (CAA) is a common cause of
intracerebral haemorrhage (ICH) with a high recurrence risk. Left atrial
appendage occlusion (LAAO) is a method for ischaemic stroke prevention in
patients with atrial fibrillation (AF), potentially reducing the risk of
intracranial bleeding in CAA-associated ICH. We aimed to determine the
outcomes of patients with AF with CAA-associated ICH undergoing LAAO.
<br/>METHOD(S): We conducted a multicentre study of patients with
CAA-associated ICH who underwent LAAO for stroke prevention. We pooled our
findings with data from a systematic review of relevant published studies
of LAAO for AF in ICH survivors reporting CAA diagnosis. <br/>RESULT(S):
We included data from two published studies (n=65) with CAA-specific data
and our cohort study (n=37), providing a total of 102 participants (mean
age 76.2+/-8.0 years, 74.6% male) with CAA-related symptomatic ICH and AF
treated with LAAO. The median follow-up period was 9.4 months (IQR
4.2-20.6). Postprocedural antithrombotic regimens varied between single
(73.0%) or dual antiplatelet therapy (16.2%), or direct oral anticoagulant
(DOAC) (10.8%), with a median duration of 42 days (IQR 35-74).
Postprocedural complications were uncommon, but included transient
arrhythmias (2.1%) and non-life-threatening tamponade (2.1%). Pooled
incidence rates of ischaemic stroke and ICH during follow-up were 5.16
(95% CI 1.36 to 17.48) and 2.73 (95% CI 0.41 to 13.94) per 100 patient
years, respectively. <br/>CONCLUSION(S): LAAO followed by short-term
antithrombotic therapy might be a safe and effective ischaemic stroke
preventive strategy in people with CAA-associated ICH and AF. However,
randomised controlled trials are needed to determine how LAAO compares
with long-term DOAC in this population. PROSPERO REGISTRATION NUMBER:
CRD42023415354.<br/>Copyright &#xa9; Author(s) (or their employer(s))
2024. No commercial re-use. See rights and permissions. Published by BMJ.

<70>
Accession Number
646096293
Title
Bacterial air contamination and the protective effect of coverage for
sterile surgical goods: A randomized controlled trial.
Source
American journal of infection control. (no pagination), 2024. Date of
Publication: 16 Dec 2024.
Author
Wistrand C.; Soderquist B.; Friberg O.; Sundqvist A.-S.
Institution
(Wistrand) University Health Care Research Centre, Faculty of Medicine and
Health, Orebro University, Sweden; Department of Cardiothoracic and
Vascular Surgery, Orebro University Hospital, Sweden
(Soderquist) School of Medical Sciences, Faculty of Medicine and Health,
Orebro University, Sweden; Department of Laboratory Medicine, Faculty of
Medicine and Health, Orebro University, Sweden
(Friberg) Department of Cardiothoracic and Vascular Surgery, Orebro
University Hospital, Sweden; School of Medical Sciences, Faculty of
Medicine and Health, Orebro University, Sweden
(Sundqvist) University Health Care Research Centre, Faculty of Medicine
and Health, Orebro University, Sweden
Abstract
BACKGROUND: There is limited knowledge regarding how long prepared sterile
goods can wait before becoming contaminated. We investigated whether
surgical goods could be prepared the day before surgery and kept sterile
overnight in the operating room, if protected by sterile covers.
<br/>METHOD(S): Sterile surgical goods for open-heart surgeries (n=70)
were randomized to preparation on the morning of the operation or on the
previous evening. Exposure time was the total time between preparation and
use. Primary outcome was bacterial growth reported as colony forming units
(cfu), isolated on 840 agar plates. The protocol was registered with
ClinicalTrials.gov (NCT05597072). <br/>RESULT(S): When the agar plates
were protected with sterile covers, exposure time had no impact
(intervention group: 7 cfu, control group: 17 cfu). Without protection,
longer exposure time was associated with more cfu (p=0.016). A total of
499 cfu were isolated, displaying 59 different types of bacteria including
13 resistant Staphylococcus epidermidis, 6 (46%) of which were multidrug
resistant. <br/>CONCLUSION(S): Sterile goods could wait in the operating
room for at least 15 hours before use without increased risk of bacterial
air contamination, if protected with sterile covers. However, if the goods
were not covered, bacterial air contamination occurred over
time.<br/>Copyright &#xa9; 2024. Published by Elsevier Inc.

<71>
Accession Number
2036621765
Title
EE839 New Finding on the Cost-Effectiveness of Robotic-Assisted Lobectomy
for Non-Small Cell Lung Cancer.
Source
Value in Health. Conference: ISPOR Europe 2024. Barcelona Spain. 27(12
Supplement) (pp S220), 2024. Date of Publication: December 2024.
Author
Xu Y.; Cheng L.
Institution
(Xu, Cheng) Intuitive Surgical, Sunnyvale, CA, United States
Publisher
Elsevier Ltd
Abstract
Objectives: The objective of this study was to evaluate the long-term
cost-effectiveness of robotic-assisted lobectomy (RAL) compared to
video-assisted thoracoscopy (VATS) for adults with non-small-cell lung
cancer (NSCLC) from the perspective of UK healthcare system, and provide
new findings to the published health technology appraisal. <br/>Method(s):
Leveraged from the appraisal on robotic-assisted thoracic surgery
conducted by Health Technology Wales, we developed a partition survival
model in TreeAge by using 5-year survival data reported by Kneuertz et al
2020, which is the only RCT compared RAL, VATS and open thoracotomy and
reported long-term oncological outcomes. Health utility data were from
published literature and RAVAL trial that compared RAL and VATS from
postoperative to 1-year. Cost data from the Wales HTA including
perioperative cost, long-term health state costs and amortized capital and
maintenance cost were retained and inflated to 2024 currency. Primary
outcome was the incremental cost-effectiveness ratios (ICERs). Scenarios
of applying alternative survival data and exploratory 10-year time horizon
were examined. <br/>Result(s): Compared to VATS, RAL gained 0.5 more
quality-adjusted life-year (QALY) at an additional cost of 2,793 over the
5-year time horizon, thus yielded an ICER of 5,586 per QALY from the UK
healthcare system perspective. The exploratory scenarios of applying
10-year survival data derived from the Kneuertz study, and using pooled
hazard ratios beyond 1-year, had further brought down the ICER to 4,913
and 4,902 per QALY, respectively. <br/>Conclusion(s): We found RAL to be
cost-effective at conventional willingness-to-pay threshold when compared
to VATS for NSCLC from the UK healthcare system perspective, and the ICERs
in various scenarios were all well below what the Wales HTA had found. The
study emphasized that as long as RAL could demonstrate favorable survival
and quality-of-life over VATS, it would be a cost-effective approach for
NSCLC treatment in the long-term.<br/>Copyright &#xa9; 2024

<72>
[Use Link to view the full text]
Accession Number
2036328268
Title
ASCVD Risk Refinement with NT-proBNP for Statin Allocation among Low- and
Intermediate-Risk Individuals.
Source
Circulation. 150(25) (pp 2070-2072), 2024. Date of Publication: 17 Dec
2024.
Author
Pavlovic J.; Kavousi M.; Ikram M.K.; Ikram M.A.; Bos D.; Leening M.J.G.
Institution
(Pavlovic, Kavousi, Ikram, Ikram, Bos, Leening) Department of
Epidemiology, Erasmus Medical Center-University Medical Center Rotterdam,
Netherlands
(Ikram) Department of Neurology, Erasmus Medical Center-University Medical
Center Rotterdam, Netherlands
(Bos, Leening) Department of Radiology and Nuclear Medicine, Erasmus
Medical Center-University Medical Center Rotterdam, Netherlands
(Leening) Department of Cardiology, Erasmus Medical Center-University
Medical Center Rotterdam, Netherlands
(Bos) Department of Neuroscience, Katholieke Universiteit Leuven, Belgium
(Bos) Department of Clinical Epidemiology, Harvard Tseng-Hsi Chan School
of Public Health, Boston, MA, United States
Publisher
Lippincott Williams and Wilkins

<73>
Accession Number
2035254989
Title
Intraoperative Use of Sodium Bicarbonate Ringer's Solution Instead of
Sodium Lactate Ringer's Solution to Reduce Endothelial Glycocalyx
Degradation and Improve Postoperative Recovery During Cardiopulmonary
Bypass Cardiac Surgery: A Single-Center Prospective Cohort Study.
Source
Drug Design, Development and Therapy. 18 (pp 5881-5893), 2024. Date of
Publication: 2024.
Author
Shi Y.; Tao Y.; Xu B.; Wang X.; Xie Y.; Zhang M.
Institution
(Shi, Tao, Xu, Wang, Xie, Zhang) Department of Anesthesiology, The First
Affiliated Hospital of USTC, Division of Life Sciences and Medicine,
University of Science and Technology of China, Anhui, Hefei 230001, China
(Shi) Department of Anesthesiology, Wannan Medical College, Anhui, Wuhu
241000, China
Publisher
Dove Medical Press Ltd
Abstract
Objective: To investigate the effect of sodium bicarbonate Ringer's
solution (BRS) on the degradation of endothelial glycocalyx components in
patients undergoing cardiopulmonary bypass (CPB) during cardiac surgery,
and to evaluate its impact on endothelial glycocalyx preservation and
postoperative recovery. <br/>Patients and Methods: A total of eight
patients scheduled for elective CPB heart surgery were included and
randomly divided into two groups: the sodium lactate Ringer's solution
(LRS) group and the BRS group. ELISA was used to measure plasma
concentrations of syndecan-1, matrix metalloproteinase-9 (MMP-9), matrix
metalloproteinase-3 (MMP-3), IL-6, IL-8, TNF-alpha, and TGF-beta at
predefined time points: T0 (before induction of anesthesia), T3
(immediately after weaning from CPB), T5 and T6 (24 and 72 hours
postoperatively). Serum creatinine concentrations were measured within 48
hours postoperatively. The incidence of postoperative delirium (POD) was
assessed three days after surgery. Postoperative mechanical ventilation
time, duration of stay in the intensive care unit and hospital stay were
also documented. <br/>Result(s): The BRS group had significantly lower
plasma concentrations of syndecan-1 at T3 (7.98 [7.43, 8.92] ng/mL vs 9.54
[8.4, 10.73] ng/mL, P < 0.001) and T5 (4.20 [3.31, 4.96] ng/mL vs 5.40
[3.95, 6.55] ng/mL, P = 0.001) in comparison with the LRS group (P<0.01).
Syndecan-1 levels in both groups were similar at T6 (3.18 [2.88, 3.5]ng/mL
vs 3.12 [2.77, 3.45] ng/mL, P > 0.05). Additionally, MMP-9, MMP-3, IL-6
and IL-8 were significantly lower at T3 and T5 in the BRS group (P<0.05
and P<0.01, respectively). However, no significant differences were
observed between the two groups in the incidence of acute kidney injury
(AKI) or POD (P > 0.05). <br/>Conclusion(s): BRS has the potential to
reduce glycocalyx degradation in patients undergoing heart valve surgery
with CPB. However, both groups demonstrated similar post-postoperative
clinical outcomes, including the rates of AKI and POD.<br/>Copyright
&#xa9; 2024 Shi et al.

<74>
Accession Number
2036454089
Title
Role of physiological ischemia training in suppressing ventricular
remodeling and ventricular arrhythmia in patients after myocardial
infarction: a randomized controlled trial.
Source
American Journal of Translational Research. 16(11) (pp 7176-7185), 2024.
Date of Publication: 2024.
Author
Chen W.; Wang L.; Zheng J.; Wu Y.; You H.; Qiao Z.
Institution
(Chen, Wang, Zheng, Wu, You) Department of Cardiology, Suzhou Ninth
People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University,
Jiangsu, Suzhou 215200, China
(Qiao) Department of Gastroenterology, Suzhou Ninth People's Hospital,
Suzhou Ninth Hospital Affiliated to Soochow University, Jiangsu, Suzhou
215200, China
Publisher
E-Century Publishing Corporation
Abstract
Objectives: The randomized controlled study explored whether physiological
ischemia training (PIT) can inhibit ventricular remodeling and reduce
ventricular arrhythmias in the early period of acute myocardial infarction
(AMI). <br/>Method(s): AMI patients with hypotension or bradycardia were
randomly divided into PIT (n = 21) and control (n = 20) groups. Meanwhile,
patients with normal blood pressure (BP) and heart rate (HR) were randomly
divided into PIT+angiotensin-converting enzyme inhibitor (ACEI) and/or
beta-blocker (AB) (n = 30) and AB (n = 30) groups. PIT was performed in
the PIT and PIT+AB groups. Finally, indicators of
renin-angiotensin-aldosterone system (RAAS) activity, ventricular
remodeling, cardiac function, vascular neovascularization, and ventricular
arrhythmias were compared among the groups after 3 months of intervention.
<br/>Result(s): Indicators of RAAS activity, ventricular remodeling, left
ventricular ejection fraction (LVEF) and QT dispersion (QTd) were improved
in the PIT, PIT+AB and AB groups after 3 months of intervention (P <
0.05). Improvements in the indicators of RAAS activity, ventricular
remodeling, LVEF and QTd in the PIT+AB group were superior to those in the
AB group by the end of training (P < 0.05). The levels of vascular
endothelial growth factor (VEGF) and nitric oxide (NO) in circulating
blood were higher significantly in the PIT and PIT+AB groups after 3
months of intervention (P < 0.05). The Lown classification in the PIT+AB
group decreased more than in other groups, and there was a significant
difference compared with the control group (P < 0.05). Diastolic BP
increased to some extent during PIT, whereas systolic BP or HR showed no
significant effects. <br/>Conclusion(s): These findings suggest that PIT
can effectively inhibit early ventricular remodeling, thereby reducing the
risk of ventricular arrhythmias after myocardial infarction, and patients
can further benefit from a combination of PIT and ACEIs/angiotensin
receptor blockers and beta-blockers.<br/>Copyright &#xa9; 2024 E-Century
Publishing Corporation. All rights reserved.

<75>
Accession Number
2035055705
Title
Exeporfinium chloride (XF-73) nasal gel significantly reduces
Staphylococcus aureus nasal carriage in cardiac surgery patients
throughout surgery and the early recovery period: Results from a
randomized placebo-controlled Phase 2 study.
Source
Infection Control and Hospital Epidemiology. 45(11) (pp 1355-1357), 2024.
Date of Publication: 01 Nov 2024.
Author
Mangino J.E.; Firstenberg M.S.; Rhys-Williams W.; Lees J.P.; Dane A.; Love
W.G.; Gonzalez Moreno J.; Martina Y.; Barker D.
Institution
(Mangino) Division of Infection Diseases, Department of Internal Medicine,
The Ohio State University, Columbus, OH, United States
(Firstenberg) Department of Surgery, Maui Memorial Medical Center, Maui,
HI, United States
(Rhys-Williams, Love, Barker) Destiny Pharma Plc, Brighton, United Kingdom
(Dane) Danestat Consulting Ltd., Macclesfield, United Kingdom
(Lees, Gonzalez Moreno, Martina) Formerly at Destiny Pharma Plc, Brighton,
United Kingdom
Publisher
Cambridge University Press
Abstract
Staphylococcus aureus nasal carriers were randomized (1:1) to XF-73 or
placebo nasal gel, administered 5x over ~24hrs pre-cardiac surgery. S.
aureus burden rapidly decreased after 2 doses (-2.2log<inf>10</inf>
CFU/mL; placebo -0.01log<inf>10</inf> CFU/mL) and was maintained to 6 days
post-surgery. Among XF-73 patients, 46.5% received post-operative
anti-staphylococcal antibiotics versus 70% in placebo (P =
0.045).<br/>Copyright &#xa9; Destiny Pharma Limited, 2024.

<76>
[Use Link to view the full text]
Accession Number
2034137896
Title
The Use of Immunomodulators, Biologic Therapies, and Small Molecules in
Patients with Inflammatory Bowel Disease and Solid Organ Transplant.
Source
Journal of Clinical Gastroenterology. 59(1) (pp 24-35), 2024. Date of
Publication: 14 Aug 2024.
Author
Ghusn W.; Mourad F.H.; Francis F.F.; Pasha S.; Farraye F.A.; Hashash J.G.
Institution
(Ghusn) Division of Gastroenterology and Hepatology, Mayo Clinic, MN,
United States
(Ghusn) Department of Internal Medicine, Boston Medical Center, MA, United
States
(Mourad) Division of Gastroenterology and Hepatology, Department of
Internal Medicine, American University of Beirut, Beirut, Lebanon
(Francis) Division of Gastroenterology, Hepatology, and Nutrition,
University of Pittsburgh, Medical Center, PA, United States
(Pasha) Division of Gastroenterology and Hepatology, Mayo Clinic, AZ,
United States
(Farraye, Hashash) Division of Gastroenterology and Hepatology, Mayo
Clinic, FL, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Patients with inflammatory bowel diseases (IBDs) may require solid organ
transplants (SOTs) for multiple reasons, making its prevalence slightly
higher than the general population. Although immunosuppression used in SOT
may help control IBD-related inflammation, many patients still require
additional immunosuppressive medications. We aim to assess the
effectiveness and safety of the combination of SOT-related
immunosuppression and IBD medications in patients with liver, kidney, or
heart transplantation. We conducted a clinical review using PubMed,
Scopus, MEDLINE, Embase, and Google Scholar databases for our search. We
included data from systematic reviews, meta-analyses, case series, and
case reports to assess the safety, effectiveness, and side effect profile
of immunomodulators, biologic therapies, and small molecules in patients
with SOT. Our review encompassed 25 liver, 6 kidney, and 1 heart
transplant studies involving patients with IBD. Common liver transplant
immunosuppressants included tacrolimus, mycophenolate mofetil,
cyclosporine, and steroids. Anti-TNF agents, widely used in all SOT types,
showed no significant safety issues, though infections and malignancies
were noted. Patients with liver transplant on tacrolimus responded well to
anti-integrins and ustekinumab without major complications. For kidney
transplants, cyclosporine and tacrolimus were prevalent, and their
combination with anti-TNF or ustekinumab was generally safe, with rare
reports of malignancy or infection. Hence, the use of anti-TNF,
anti-integrin agents, and ustekinumab appears to be safe in patients with
SOT, regardless of their transplant related immunosuppression. More
studies are needed in patients with kidney and heart transplants and in
patients treated with small molecules for their IBD.<br/>Copyright &#xa9;
2024 Wolters Kluwer Health, Inc. All rights reserved.

<77>
Accession Number
2032623449
Title
A Meta-Analysis of Mitral Surgery in Patients Undergoing Surgery for
Anomalous Left Coronary Artery: When to Perform Repair?.
Source
Pediatric Cardiology. (no pagination), 2024. Date of Publication: 2024.
Author
Brancaccio G.; Chinali M.; Dionisi S.; Trezzi M.; Esposito C.; Iacobelli
R.; Miraldi F.; Labriola V.; Alessia R.; Francesco B.; D'Inzeo V.; Perri
G.; Butera G.; Galletti L.
Institution
(Brancaccio, Trezzi, Labriola, Alessia, Francesco, D'Inzeo, Perri,
Galletti) Pediatric Cardiac Surgery Unit, Bambino Gesu Children's
Hospital, IRCCS, Rome, Italy
(Chinali, Esposito, Iacobelli, Butera) Pediatric Cardiology Unit, Bambino
Gesu Children's Hospital, IRCCS, Rome, Italy
(Dionisi, Miraldi) Department of Cardiac Surgery, University "La Sapienza"
of Rome, Rome, Italy
(Labriola, Francesco) Department of Cardiac Surgery, University of "Tor
Vergata", Rome, Italy
Publisher
Springer
Abstract
The present study is the first meta-analysis comparing long-term outcomes
in patients undergoing correction for anomalous left coronary artery
(ALCAPA) regarding concomitant mitral valve surgery. A systematic
literature review was conducted to identify all relevant studies with
comparative data on mitral valve surgery performed during surgery for
ALCAPA correction. Predefined primary end points included mortality and
mitral valve (re)operation. Echocardiographic outcomes were assessed when
available (including severity of mitral regurgitation). Fifty-three
relevant retrospective studies with comparative data for ALCAPA patients
with concomitant mitral valve surgery were identified from the existing
literature. The study population included 3,851 patients, of whom 55% were
girls. The mean age at surgery was 6 months [0-99 months]. The mean
follow-up after surgery was 22.7 years [6.3-37.2]. Among patients with
available echocardiographic data at the time of ALCAPA correction, 283 had
no mitral regurgitation (13%), 642 had mild mitral regurgitation (30%),
756 had moderate mitral regurgitation (36%), and 437 had severe mitral
regurgitation (21%). A subgroup of patients who underwent mitral valve
surgery (yMVS; n = 753; 19.5% of the total population) was identified. A
total of 228 patients died during follow-up (5.9%), with no differences
among patients who underwent vs those who did not undergo mitral valve
concomitant surgery at baseline (p = ns). Among the 1,536 patients with
available follow-up echocardiographic data, 519 had no mitral
regurgitation (34%), 663 had mild mitral regurgitation (43%), 268 had
moderate mitral regurgitation (17%), and 86 had severe mitral
regurgitation (6%). Overall, during follow-up, 91 patients underwent
mitral valve surgery (first MVS for 20 pts and reintervention for 71 pts,
representing a 10% reintervention rate). In regression analysis, we found
no association between the mean age at first surgery and the need for
reoperation (p = 0.458). Mitral valve surgery is performed in about 20% of
patients undergoing ALCAPA correction. Indications for MVS vary among
centers, although the severity of MV regurgitation was the most common
criterion (more than 50% of the yMVS group). Of yMVS patients,
approximately 10% underwent a second MVS during follow-up, regardless of
age at first surgery. Overall, long-term mortality in these patients is
over 5%, with no evident impact related to concomitant MV
surgery.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<78>
Accession Number
2032635170
Title
Albuminuria Prevalence in Fontan Patients: A Systematic Review and
Meta-Analysis.
Source
Pediatric Cardiology. (no pagination), 2024. Article Number: n71. Date of
Publication: 2024.
Author
Van Belle H.; Van den Eynde J.; Cieplucha A.; Ladouceur M.; Martinod K.;
Pierard S.; Coats L.; Jansen K.; Opotowsky A.; Van Craenenbroeck A.H.;
Budts W.; Van De Bruaene A.
Institution
(Van Belle, Van den Eynde, Cieplucha, Martinod, Budts, Van De Bruaene)
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
(Budts, Van De Bruaene) Division of Structural and Congenital Cardiology,
University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium
(Cieplucha) Department of Cardiology, Poznan University of Medical
Sciences, Poznan, Poland
(Ladouceur) Departement of Cardiology, University Hospital of Geneva,
Geneva, Switzerland
(Pierard) Department of Cardiology, Cliniques Universitaires Saint-Luc,
Brussels, Belgium
(Coats, Jansen) Adult Congenital Heart Unit, Freeman Hospital, Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United
Kingdom
(Coats, Jansen) Population Health Sciences Institute, Newcastle
University, Newcastle Upon Tyne, United Kingdom
(Opotowsky) Department of Pediatrics, Heart Institute, Cincinnati
Children's Hospital, University of Cincinnati College of Medicine,
Cincinnati, OH, United States
(Van Craenenbroeck) Department of Microbiology, Immunology and
Transplantation, Nephrology and Kidney Transplantation Research Group, KU
Leuven, Leuven, Belgium
(Van Craenenbroeck) Department of Nephrology and Kidney Transplantation,
University Hospitals Leuven, Leuven, Belgium
Publisher
Springer
Abstract
Patients with a Fontan circulation are at risk for chronic kidney disease
(CKD), which is defined as persistently reduced glomerular filtration rate
(GFR) <60ml/min/1.73² or elevated marker of kidney injury such
as urinary albumin-to-creatinine ratio (UACR) >30mg/g. We determined the
prevalence of albuminuria in patients with a Fontan circulation. The
MEDLINE, EMBASE, Trip, and Cochrane databases were searched for studies
reporting the prevalence of albuminuria in Fontan patients. Case reports,
reviews, and univentricular patients pre-Fontan completion or post-heart
transplantation were excluded. Studies were assessed for potential
confounders and measurement, patient selection, intervention, and
reporting biases, reported in a table. After systematic review, the pooled
prevalence of albuminuria was calculated using the quality effects model
for meta-analysis. Secondary outcomes were the clinical determinants of
albuminuria. Thirteen studies were included in the systematic review, of
which 11 were included in the meta-analysis (6 prospective, sample size
per study 25-195 patients, 873 patients in total). The pooled prevalence
of albuminuria was 28.4% (95% confidence interval 23.5-33.5%). GFR was
mostly preserved in these patients. Albuminuria was associated with
elevated systemic venous pressure in 5 studies. Other associations were
inconclusive. The main limitations of our study are the predominantly
retrospective and cross-sectional nature of the included studies with
small sample sizes and heterogeneous study populations. Our findings show
albuminuria is more prevalent than reduced GFR in patients with a Fontan
circulation, implicating the potential value of UACR in addition to GFR
when screening for CKD in these patients.<br/>Copyright &#xa9; The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature 2024.

<79>
Accession Number
2036536136
Title
European Society of Cardiology quality indicators for the care and
outcomes of adults undergoing transcatheter aortic valve implantation.
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 10(8) (pp
723-736), 2024. Date of Publication: 01 Dec 2024.
Author
Ali N.; Aktaa S.; Younsi T.; Beska B.; Batra G.; Blackman D.J.; James S.;
Ludman P.; Mamas M.A.; Abdel-Wahab M.; Borregaard B.; Iung B.; Joner M.;
Kunadian V.; Modine T.; Neylon A.; Petronio A.S.; Pibarot P.; Popescu
B.A.; Sabate M.; Stortecky S.; Teles R.C.; Treede H.; Gale C.P.
Institution
(Ali, Aktaa, Younsi, Blackman, Gale) Department of Cardiology, Leeds
Teaching Hospitals NHS Trust, Leeds, United Kingdom
(Aktaa, Gale) Leeds Institute for Cardiovascular and Metabolic Medicine,
University of Leeds, Leeds, United Kingdom
(Beska) Translational and Clinical Research Institute, Newcastle
University, Newcastle upon Tyne, United Kingdom
(Beska, Kunadian) Cardiothoracic Centre, Freeman Hospital, Newcastle upon
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
(Batra, James) Department of Medical Sciences, Uppsala Clinical Research
Center, Uppsala University, Uppsala, Sweden
(Ludman) Institute of Cardiovascular Sciences, University of Birmingham,
Birmingham, United Kingdom
(Mamas) Keele Cardiovascular Research Group, Keele University, Keele,
United Kingdom
(Abdel-Wahab) Heart Center Leipzig, University of Leipzig, Leipzig,
Germany
(Borregaard) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Borregaard) Department of Clinical Research, University of Southern
Denmark, Odense, Denmark
(Iung) Cardiology Department, Bichat Hospital, AP-HP, Universite
Paris-Cite, Paris, France
(Joner) Deutsches Herzzentrum Munchen, Technische Universitat Munchen,
Munich, Germany
(Joner) DZHK (German Centre for Cardiovascular Research), Partner Site
Munich Heart Alliance, Munich, Germany
(Modine) Hopital Cardiologique du Haut-Leveque, Bordeaux, France
(Neylon) Saolta University Health Care Group, University Hospital Galway,
National University of Ireland, Galway, Ireland
(Petronio) Cardiac Catheterization Laboratory, Cardiothoracic and Vascular
Department, Pisa University Hospital, Pisa 56100, Italy
(Pibarot) Institut Universitaire de Cardiologie et de Pneumologie de
Quebec, Quebec Heart and Lung Institute, Universite Laval, Quebec City,
QC, Canada
(Popescu) University of Medicine and Pharmacy Carol Davila, Bucharest,
Romania
(Sabate) Interventional Cardiology Department, Cardiovascular Institute,
Hospital Clinic, IDIBAPS, Barcelona, Spain
(Stortecky) Department of Cardiology, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
(Teles) CHLO, Nova Medical School, Hospital de Santa Cruz, CEDOC, Lisbon,
Portugal
(Treede) Department of Cardiovascular Surgery, University Medical Center
Mainz, Mainz, Germany
(Gale) Leeds Institute for Data Analytics, Leeds Institute of
Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United
Kingdom
Publisher
Oxford University Press
Abstract
Aims To develop a suite of quality indicators (QIs) for the evaluation of
the care and outcomes for adults undergoing transcatheter aortic valve
implantation (TAVI). Methods and We followed the European Society of
Cardiology (ESC) methodology for the development of QIs. Key domains were
results identified by constructing a conceptual framework for the delivery
of TAVI care. A list of candidate QIs was developed by conducting a
systematic review of the literature. A modified Delphi method was then
used to select the final set of QIs. Finally, we mapped the QIs to the
EuroHeart (European Unified Registries on Heart Care Evaluation and
Randomized Trials) data standards for TAVI to ascertain the extent to
which the EuroHeart TAVI registry captures information to calculate the
QIs. We formed an international group of experts in quality improvement
and TAVI, including representatives from the European Association of
Percutaneous Cardiovascular Interventions, the European Association of
Cardiovascular Imaging, and the Association of Cardiovascular Nursing and
Allied Professions. In total, 27 QIs were selected across 8 domains of
TAVI care, comprising 22 main (81%) and 5 secondary (19%) QIs. Of these,
19/27 (70%) are now being utilized in the EuroHeart TAVI registry.
Conclusion We present the 2023 ESC QIs for TAVI, developed using a
standard methodology and in collaboration with ESC Associations. The
EuroHeart TAVI registry allows calculation of the majority of the QIs,
which may be used for benchmarking care and quality improvement
initiatives.<br/>Copyright &#xa9; The Author(s) 2024. Published by Oxford
University Press on behalf of the European Society of Cardiology.

<80>
Accession Number
2032702198
Title
Characterizing the antibody response to amustaline/glutathione
pathogen-reduced red blood cells.
Source
Transfusion. (no pagination), 2024. Date of Publication: 2024.
Author
Karim C.; Panigrahi A.; Pearl R.G.; Sodha N.R.; Beaver T.M.; Pelletier
J.P.R.; Nuttall G.A.; Reece T.B.; Erickson A.; Hedrick T.; Liu K.; Bentow
S.; Corash L.; Mufti N.; Varrone J.; Benjamin R.J.
Institution
(Karim, Erickson, Hedrick, Liu, Bentow, Corash, Mufti, Varrone, Benjamin)
Cerus Corporation, Concord, CA, United States
(Panigrahi, Pearl) Stanford University, Stanford, CA, United States
(Sodha) Rhode Island Hospital, Providence, RI, United States
(Beaver, Pelletier) University of Florida, Gainesville, FL, United States
(Nuttall) Mayo Clinic, Rochester, MN, United States
(Reece) University of Colorado Hospital, Denver, CO, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: The clinical significance of natural and treatment-emergent
antibodies specific for amustaline/glutathione pathogen-reduced red blood
cells (PRRBCs) is not known. Study Design and Methods: A Phase 3,
randomized clinical trial of PRRBCs (ReCePI) compared PRRBCs with
conventional RBCs in cardiac or thoracic-aorta surgery. Subjects
transfused during and for 7 days after surgery were screened for
PRRBC-specific antibodies at baseline, 28 and 75 days post-surgery.
Subjects with treatment-emergent antibodies were assessed for evidence of
hemolysis. Cryopreserved subject RBC samples were assayed by flow
cytometry for circulating PRRBCs using an acridine-specific (2S197-2M1)
monoclonal antibody, and for human IgG-coated RBCs. RBC-surface acridine
density was quantitated using a commercial calibrated phycoerythrin
(PE)-bead panel. <br/>Result(s): Five of 159 (3.1%) PRRBC and zero of 162
conventional RBC recipients developed treatment-emergent PRRBC-specific
IgG, low titer antibodies detected 26-80 days post-surgery after exposure
to 1-3 PRRBC units, without clinical evidence of hemolysis. DAT and eluate
were weak (w+) positive and PRRBC-specific in one subject. A monocyte
monolayer assay (MMA) was non-reactive in the three subjects with an
interpretable result. Flow cytometry demonstrated circulating PRRBCs in
all five subjects expressing surface acridine concentrations at the limit
of detection (approximately 150-301 PE molecules/RBC) compared with
freshly transfused PRRBCs (approximately 7500 PE molecules/RBC). In some
samples, loss of surface acridine expression could not be distinguished
from clearance of the PRRBCs. <br/>Discussion(s): Treatment-emergent
PRRBC-specific antibodies with the characteristics of nonclinically
significant antibodies were detected in five subjects transfused with
PRRBCs. Flow cytometry demonstrated persistent circulating PRRBCs with
minimal surface acridine expression. (www.ClinicalTrials.gov Identifier
NCT03459287).<br/>Copyright &#xa9; 2024 The Author(s). Transfusion
published by Wiley Periodicals LLC on behalf of AABB.

<81>
Accession Number
2032700925
Title
Efficacy of liposomal as compared to standard bupivacaine for intercostal
nerve blocks in patients undergoing minimally invasive thoracic surgery: a
systematic review and meta-analysis.
Source
Minimally Invasive Therapy and Allied Technologies. (no pagination),
2024. Date of Publication: 2024.
Author
Chen R.; Wang Z.
Institution
(Chen, Wang) Department of Anesthesia, Shengzhou People's Hospital
(Shengzhou Branch of the First Affiliated Hospital of Zhejiang University
School of Medicine, the Shengzhou Hospital of Shaoxing University),
Shaoxing, China
Publisher
Taylor and Francis Ltd.
Abstract
Background: This review aimed to provide evidence on the efficacy of
liposomal bupivacaine as compared to standard bupivacaine for intercostal
nerve blocks (ICB) in patients undergoing minimally invasive thoracic
surgery. <br/>Method(s): Randomized controlled trials (RCTs) and
comparative observational studies published on the databases of PubMed,
CENTRAL, Web of Science, and Embase up to June 20, 2024, were included.
Total opioid consumption in morphine equivalents, pain scores, and length
of hospital stay (LOS) were compared. <br/>Result(s): Two RCTs and eight
observational studies were included. Eight hundred and four patients
received liposomal bupivacaine while 631 patients received standard
bupivacaine in the included studies. The meta-analysis showed that the use
of liposomal bupivacaine for ICB did not reduce opioid consumption as
compared to standard bupivacaine at 24 h, 48 h, and for the total duration
of hospitalization. Pain scores were also not significantly different
between the two groups at 24 h and 48 h. Meta-analysis showed that there
was no difference in the LOS between intervention and control groups.
Subgroup analysis based on study design also generated similar results.
<br/>Conclusion(s): Mostly low-quality evidence shows that liposomal
bupivacaine does not offer additional benefits over standard bupivacaine
when used for ICB in patients undergoing minimally invasive thoracic
surgery.<br/>Copyright &#xa9; 2024 Society of Medical Innovation and
Technology.

<82>
Accession Number
2032696733
Title
Randomized Trial of Pulsatile and Nonpulsatile Flow in Cyanotic and
Acyanotic Congenital Heart Surgery.
Source
World Journal for Pediatric and Congenital Heart Surgery. (no
pagination), 2024. Date of Publication: 2024.
Author
Patel K.; Lin T.K.; Clark J.B.; Ceneviva G.D.; Imundo J.R.; Spear D.;
Kunselman A.R.; Thomas N.J.; Myers J.L.; Undar A.
Institution
(Patel, Lin, Clark, Ceneviva, Imundo, Spear, Kunselman, Thomas, Myers,
Undar) Penn State Hershey Pediatric Cardiovascular Research Center, Penn
State College of Medicine, Hershey, PA, United States
(Patel, Clark, Imundo, Myers, Undar) Division of Pediatric Cardiology,
Department of Pediatrics, Penn State College of Medicine, Hershey, PA,
United States
(Patel, Clark, Myers, Undar) Department of Surgery, Penn State College of
Medicine, Hershey, PA, United States
(Lin) Division of Pediatric Critical Care Medicine, Department of
Pediatrics, University of Virginia Children's Hospital, Charlottesville,
VA, United States
(Ceneviva, Spear, Thomas) Division of Pediatric Critical Care Medicine,
Department of Pediatrics, Penn State College of Medicine, Hershey, PA,
United States
(Kunselman, Thomas) Department of Public Health Sciences, Penn State
College of Medicine, Hershey, PA, United States
(Undar) Department of Biomedical Engineering, College of Engineering, The
Pennsylvania State University, University Park, PA, United States
Publisher
SAGE Publications Inc.
Abstract
Background: The study objective was to determine the impact of
cardiopulmonary bypass perfusion modalities on cerebral hemodynamics and
clinical outcomes in congenital cardiac surgery patients stratified by
acyanotic versus cyanotic heart disease. <br/>Method(s): A total of 159
pediatric (age <18 years) cardiac surgery patients were prospectively
randomized to pulsatile or nonpulsatile cardiopulmonary bypass and
stratified by type of congenital heart disease: acyanotic versus cyanotic.
Intraoperative cerebral gaseous microemboli counts and middle cerebral
artery pulsatility index were assessed. Organ injury was quantified by
Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score at 24, 48, and 72 h
postoperatively. Additional outcomes included Pediatric Risk of
Mortality-3 score, vasoactive-inotropic score, duration of mechanical
ventilation, intensive care and hospital length of stay, and 180-day
mortality. Heterogenous variance linear models (ie, ANOVA and mixed
models) and chi² tests were used to compare groups for
continuous and categorical variables, respectively. <br/>Result(s): Within
congenital heart disease subgroups, patients randomized to nonpulsatile
versus pulsatile bypass had similar preoperative and operative
characteristics. While the intraoperative pulsatility index was higher in
the pulsatile subset of both acyanotic and cyanotic groups (P <.05),
regional cerebral oxygen saturation, mean arterial pressure, and gaseous
microemboli counts were similar. Postoperative PELOD-2 scores decreased at
similar rates in the acyanotic and cyanotic subgroups regardless of the
perfusion modality utilized. There were also no significant between-group
differences in the additional postoperative outcomes by perfusion modality
in either acyanotic or cyanotic groups. <br/>Conclusion(s): Despite
patients undergoing pulsatile cardiopulmonary bypass experiencing a more
physiologic pulsatility index in both acyanotic and cyanotic groups, no
significant differences in cerebral hemodynamics or clinical outcomes were
appreciated.<br/>Copyright &#xa9; The Author(s) 2024.

<83>
Accession Number
646075332
Title
Identifying potential predictors of surgical site infection risk following
cardiac surgery: a scoping review.
Source
The Journal of hospital infection. (no pagination), 2024. Date of
Publication: 14 Dec 2024.
Author
Charlwood K.V.; Jackson J.; Vaja R.; Rogers L.J.; Dawson S.; Moawad K.R.;
Brown J.; Trevis J.; Vokshi I.; Layton G.R.; Magboo R.; Tanner J.; Rochon
M.; Murphy G.J.; Whiting P.
Institution
(Charlwood, Jackson, Dawson, Whiting) Population Health Sciences, Bristol
Medical School, University of Bristol, Bristol, United Kingdom
(Vaja) Royal Brompton Hospital, National Heart and Lung Institute,
Imperial College London, London, United Kingdom
(Rogers) Bristol Heart Institute, University Hospitals Bristol & Weston
NHS Foundation Trust, Bristol, United Kingdom
(Moawad) University Hospital Southampton Trust, Southampton, United
Kingdom
(Brown) Royal Victoria Hospital, Belfast, United Kingdom
(Trevis) Freeman Hospital, Newcastle-Upon-Tyne, United Kingdom
(Vokshi) Heart and Lung Centre, New Cross Hospital, Wolverhampton, United
Kingdom
(Layton) University of Leicester, Leicester, United Kingdom
(Magboo) Barts Heart Centre, Barts Health NHS Trust, St Bartholomew's
Hospital, London, United Kingdom
(Tanner) School of Health Sciences, University of Nottingham, Nottingham,
United Kingdom
(Rochon) Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
(Murphy) Leicester NIHR Biomedical Research Centre Cardiovascular,
University of Leicester, Leicester, United Kingdom
Abstract
OBJECTIVES: This scoping review was undertaken to identify risk
predictions models and preoperative predictors of surgical site infection
(SSI) in adult cardiac surgery. A particular focus was on the
identification of novel predictors that could underpin the future
development of a risk prediction model to identify individuals at
high-risk of SSI, and therefore guide a national SSI prevention strategy.
<br/>METHOD(S): A scoping review to systematically identify and map out
existing research evidence on preoperative predictors of SSI was conducted
in two stages. Stage 1 reviewed prediction modelling studies of SSI in
cardiac surgery. Stage 2 identified primary studies and systematic reviews
of novel cardiac SSI predictors. <br/>RESULT(S): The search identified
7887 unique records; 7154 studies were excluded at abstract screening and
733 studies selected for full-text assessment. Twenty-nine were included
for Stage 1 and reported the development (n = 14), validation (n = 13), or
both the development and validation (n = 2) of 52 SSI risk prediction
models including 67 different preoperative predictors. The remaining 703
studies were re-assessed for Stage 2; 49 studies met the inclusion
criteria, and 56 novel preoperative predictors not yet assessed in models
were identified. <br/>CONCLUSION(S): This review identified 123
preoperative predictors of SSI risk following cardiac surgery, 56 of which
have not been previously included in the development of cardiac SSI
prediction models. These candidate predictors will be a valuable resource
in the future development of risk prediction scores and may be relevant to
SSI risk prediction in other surgical specialities.<br/>Copyright &#xa9;
2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

<84>
Accession Number
646071084
Title
Preoperative inspiratory muscle training improves lung function prior to
elective heart valve surgery and reduces postoperative lung function
impairment and pulmonary complications: a randomised trial.
Source
Journal of physiotherapy. (no pagination), 2024. Date of Publication: 14
Dec 2024.
Author
Yu P.; Luo Z.; Wang Y.; Lin S.; Qin D.; Jones A.Y.; He J.
Institution
(Yu, Luo) Rehabilitation Medicine Centre, West China Hospital, Sichuan
University, Sichuan, China
(Wang) Cardiovascular Surgery Research Laboratory, West China Hospital,
Sichuan University, China
(Lin) Department of Rehabilitation, Fuwai Central China Cardiovascular
Hospital, Zhengzhou, China
(Qin) Department of Rehabilitation Medicine, Tianjin Chest Hospital,
Tianjin, China
(Jones) School of Health and Rehabilitation Sciences, University of
Queensland, Brisbane, Australia
(He) National Clinical Research Centre for Geriatrics, West China
Hospital, Sichuan University, Chengdu, China; Med-X Centre for
Manufacturing, Sichuan University, Chengdu, China
Abstract
QUESTION: What is the effect of 3 days of preoperative inspiratory muscle
training (IMT) on lung function prior to heart valve surgery and on
postoperative lung function and pulmonary complications compared with sham
and no IMT? DESIGN: A three-arm, multicentre, randomised controlled trial
with concealed allocation, intention-to-treat analysis and blinded
assessment of some outcomes. PARTICIPANTS: This study included 228 adults
scheduled for heart valve surgery. INTERVENTIONS: The IMT group received 3
days of IMT at 30% maximal inspiratory pressure, the sham IMT group
received the same but at 10% maximal inspiratory pressure and the control
group received no IMT. OUTCOME MEASURES: Spirometric measures, maximal
inspiratory pressure and maximum voluntary ventilation were measured at
hospital admission, the day before surgery and at discharge. The incidence
of postoperative pulmonary complications (primary outcome) and adverse
events were recorded. <br/>RESULT(S): A total of 215 participants
completed surgery as planned and all participants were followed up until
discharge. Spirometric measures, maximal inspiratory pressure and maximum
voluntary ventilation improved in all groups between admission and the day
before surgery, but more so in the IMT group. At discharge, these measures
had deteriorated in all groups, but less so in the IMT group. Preoperative
IMT reduced the total number of participants experiencing a pulmonary
complication in the IMT group compared with the sham IMT group (ARR -0.18,
95% CI -0.33 to -0.03) and compared with the control group (ARR -0.21, 95%
CI -0.35 to -0.05). Very few adverse events occurred in all three groups.
<br/>CONCLUSION(S): Preoperative IMT improved lung function prior to
surgery and at hospital discharge and reduced postoperative pulmonary
complications in adults undergoing elective heart valve surgery.
REGISTRATION: ChiCTR2100054869.<br/>Copyright &#xa9; 2024. Published by
Elsevier B.V.

<85>
Accession Number
646071016
Title
Systematic Review of the Comparative Studies of Image-guided Thermal
Ablation, Stereotactic Radiosurgery, and Sublobar Resection for Treatment
of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.
Source
Seminars in thoracic and cardiovascular surgery. (no pagination), 2024.
Date of Publication: 13 Dec 2024.
Author
Pennathur A.; Lanuti M.; Merritt R.E.; Wolf A.; Keshavarz H.; Loo B.W.;
Suh R.D.; Mak R.H.; Brunelli A.; Criner G.J.; Mazzone P.J.; Walsh G.;
Liptay M.; Eileen Wafford Q.; Murthy S.; Blair Marshall M.; Tong B.;
Pettiford B.; Rocco G.; Luketich J.; Schuchert M.J.; Varghese T.K.;
D'Amico T.A.; Swanson S.J.
Institution
(Pennathur, Luketich, Schuchert) Department of Cardiothoracic Surgery,
University of Pittsburgh School of Medicine, University of Pittsburgh
Medical Center, UPMC Hillman Cancer Center. Pittsburgh, PA, United States
(Lanuti) Division of Thoracic Surgery, Massachusetts General Hospital,
Boston, MA, United States
(Merritt) Division of Thoracic Surgery, Ohio State University-Wexner
Medical Center, Columbus, OH, United States
(Wolf) Department of Thoracic Surgery, The Icahn School of Medicine at
Mount Sinai and Mount Sinai Hospital, New York, NY
(Keshavarz, Eileen Wafford) American Association for Thoracic Surgery,
Beverly, MA, United States
(Loo) Department of Radiation Oncology & Stanford Cancer Institute,
Stanford University School of Medicine, Stanford, CA, United States
(Suh) Department of Radiological Sciences, UCLA Medical Center, David
Geffen School of Medicine at UCLA, Los Angeles, CA, United States
(Mak) Department of Radiation Oncology, Brigham and Women's Hospital and
Dana-Farber Cancer Institute, Boston, MA, United States
(Brunelli) Department of Thoracic Surgery, St. James's University
Hospital, Leeds, United Kingdom
(Criner) Department of Thoracic Medicine and Surgery, Lewis Katz School of
Medicine at Temple University, Philadelphia, PA, United States
(Mazzone) Respiratory Institute, Cleveland Clinic, Cleveland, OH, United
States
(Walsh) Department of Thoracic Surgery, University of Texas M.D. Anderson
Cancer Center, Houston, TX, United States
(Liptay) Department of Cardiovascular and Thoracic Surgery, Rush
University Medical Center, Chicago, IL, United States
(Murthy) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Columbus, OH, United States
(Blair Marshall) Sarasota Memorial Hospital, Sarasota, FL, Puerto Rico
(Tong) Department of Thoracic Surgery, Duke University Hospital, Durham,
NC, United States
(Pettiford) Section of Cardiothoracic Surgery, Ochsner Health System, New
Orleans, LA, United States
(Rocco) Thoracic Service, Department of Surgery, Memorial Sloan Kettering
Cancer Center, New York, NY
(Varghese) Division of Cardiothoracic Surgery, University of Utah,
Huntsman Cancer Center, Salt Lake City, UT, United States
(D'Amico) Department of Surgery, Duke Cancer Institute, Durham, NC, United
States
(Swanson) Division of Thoracic Surgery, Harvard Medical School and Brigham
and Women's Hospital, Boston, MA, United States
Abstract
The Clinical Practice Standards Committee of the American Association for
Thoracic Surgery assembled an expert panel and conducted a systematic
review of the literature detailing studies directly comparing treatment
options for high-risk patients with stage I non-small cell lung cancer
(NSCLC). A systematic search was performed to identify publications
comparing outcomes following image-guided thermal ablation (IGTA),
stereotactic ablative radiotherapy (SABR), and sublobar resection-the main
treatment options applicable to high-risk patients with stage I NSCLC.
There were no publications detailing completed randomized controlled
trials comparing these treatment options. Several retrospective studies
with comparisons were identified, some of which used large,
population-based registries. The findings in 18 of these studies are
summarized in this Expert Review article. Registry studies comparing IGTA
with SABR in propensity-score matched patients with stage I NSCLC found no
difference in overall survival. The use of thermal ablation was less
frequent and had wider variation depending on geographic region as
compared with SABR, however. Studies yielding high-quality data comparing
SABR with sublobar resection have been limited. When comparing sublobar
resection with IGTA, sublobar resection was associated with superior
primary tumor control and overall survival in the retrospective cohort
studies. Retrospective comparative studies are difficult to assess due to
the inherent biases or treatment selection and the definitions of
loco-regional control. Prospective randomized trials are needed to fully
evaluate the outcomes of treatment options applicable to high-risk
patients with early-stage lung cancer.<br/>Copyright &#xa9; 2024.
Published by Elsevier Inc.

<86>
Accession Number
646068846
Title
Can amino acid interventions prevent acute kidney injury in cardiac
surgery? A meta-analysis and systematic review.
Source
Nephrology, dialysis, transplantation : official publication of the
European Dialysis and Transplant Association - European Renal Association.
(no pagination), 2024. Date of Publication: 04 Dec 2024.
Author
Tinica G.; Brinza C.; Popa C.; Covic A.; Voroneanu L.; Kanbay M.; Burlacu
A.
Institution
(Covic, Tinica, Brinza, Popa, Covic, Voroneanu, Burlacu) Faculty of
Medicine, University of Medicine and Pharmacy "Grigore T Popa, Iasi,
Romania
(Covic, Covic, Voroneanu) Nephrology Clinic, Dialysis, Renal Transplant
Center -"C.I. Parhon" University Hospital, Iasi, Romania
(Tinica, Burlacu) Institute of Cardiovascular Diseases "Prof. Dr George
I.M. Georgescu, Iasi, Romania
(Kanbay) Department of Internal Medicine, Division of Nephrology, Koc
University School of Medicine, Istanbul, Turkey
(Kanbay) Department of Medicine, Koc University School of Medicine,
Istanbul, Turkey